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ABSTRACT 
 
 
Over 80 million adults in the United States have hypertension, one of the leading risk 
factors for cardiovascular disease (CVD) and stroke. Sodium and potassium intake are essential 
dietary components, but excess sodium intake and insufficient potassium intake are established 
risk factors for hypertension and CVD. To improve and target interventions to reduce the burden 
of hypertension and CVD, it is critical to identify factors that influence sodium and potassium 
intake. The overarching goal of this dissertation is to provide insight into the genetics of sodium 
and potassium intake with high-quality measurement as well as the role of gene-by-sodium 
interactions underlying blood pressure variation in multiethnic populations.  
Aim 1 of the dissertation focuses on the identification of genomic regions associated with 
sodium intake, potassium intake, and sodium-to-potassium ratio in multiethnic populations. 
Using genome-wide genetic data imputed to the 1000 Genomes Project reference panel in five 
cohorts with European ancestry (N=7,363), one cohort with Asian ancestry (n=2,475), and one 
cohort with African Ancestry (n=1,246), we performed a genome-wide association study 
(GWAS) meta-analysis.  We found a significant genetic locus, rs71639080, near the Fc fragment 
of IgG receptor genes (FCGR2B-FCGR2C- FCGR3A) on chromosome 1 from the meta-analysis 
of 24-hour urinary sodium excretion with a significance threshold of P < 5 X 10-8. Additionally, 
two genetic loci, rs77958157 on chromosome 5 and rs148459019 on chromosome 6, were 
significantly associated with sodium-to-potassium ratio. In Aim 2, we used sequence-kernel 
association methods to investigate gene-level associations from Aim 1 using both common and 
 x 
rare genetic variants. In addition, we evaluated whether the gene-level associations were 
modified by demographic factors (age ≥ 65 years, sex, and college education) and found 
significant interactions in the regions of genes TAPSAR1, CTC-228N24.1, RP11-433C9.2, and 
RP11-483H11.1 in a European American cohort. In Aim 3, we identified 12 genome-wide 
significant genetic loci (P < 5 X 10-8) through meta-analysis of a genome-wide gene-by-sodium 
intake interaction study on blood pressure measures using multiethnic cohort studies (N=6,020). 
One of the identified gene regions includes NKAIN2 (chromosome 6), which is associated with 
the regulation of sodium and potassium ion transporting within or between cells. 
Much research still remains to replicate and understand these initial findings in larger 
multiethnic populations to provide more insight into the underlying genetic variations and 
mechanisms by which these genomic regions are influencing the regulation of sodium and 
potassium intake, as well as blood pressure levels.  
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CHAPTER I: Introduction 
 
1.1 Introduction 
Sodium intake is an essential dietary component, but excess sodium intake is an 
established risk factor for hypertension and cardiovascular disease [1-4]. In 2010, about 1.7 
million, or 9.5%, of all deaths from cardiovascular causes were attributed to high sodium intake 
globally [5]. Potassium intake, however, is beneficial for controlling blood pressure [6, 7]. 
Recently, it was found that the ability to predict an increased risk of cardiovascular diseases 
(CVD) is stronger when using sodium-to-potassium intake ratio than using sodium or potassium 
alone [8, 9]. Thus, identifying factors that influence sodium intake, potassium intake, and 
sodium-to-potassium intake ratio is important and could be a basis for interventions to reduce the 
burden of hypertension and cardiovascular disease. A previous study in Korean participants 
showed that genetic factors contribute to variability in sodium intake (heritability = 34%) [5, 10-
12]. However, there has been limited investigation into the specific genetic variants that 
influence sodium and potassium intake, and their role in blood pressure variation. Identifying 
predictors of sodium and potassium intake will allow better identification of individuals that are 
at high risk of excess sodium and low potassium intake, which is important for improved 
prevention of high blood pressure.  
Sodium consumption is known to be disproportionately high among men, older people, 
and people with low education [13-15]. Potassium intake is also reported to be high among men 
and older people, but low among people with low education [16, 17]. Since the associations 
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between genes and sodium/potassium intake may differ as a function of environmental 
conditions, investigating potential gene-environment interactions with age, sex, and education on 
sodium and potassium intake is also critical. Additionally, examining the role of interactions 
between sodium intake and genomic factors in the explaining interindividual variation in blood 
pressure may provide additional insight into which subgroups of the population are particularly 
susceptible and may require more personalized intervention.  In the section below, the 
overarching research aims of this dissertation are described. These aims address the need to 
identify genes and gene-environment interactions underlying sodium and potassium intake, and 
the relationship between sodium intake and blood pressure variation.  
 
1.2 Research Aims 
In this dissertation, we take advantage of high-quality measurements of sodium and 
potassium intake as well as genome-wide single nucleotide polymorphism (SNP) data from 
multiethnic epidemiologic studies to identify the genomic regions and genetic variants associated 
with sodium intake, potassium intake, and sodium-to-potassium intake ratio. We then investigate 
their interactions with factors underlying differences in sodium and potassium intake (age, sex, 
and education level), and their role in blood pressure variation.  In Figure 1, we illustrate the 
overall conceptual model used to motivate and organize the findings across the three main aims 
of the dissertation.  
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Figure 1 Conceptual model for the proposed study describing the associations between genetic 
factors, sodium intake, potassium intake, sodium-to-potassium ratio, and blood pressure 
  
 
 
 
4 
Specifically, the three aims of this dissertation are: 
Aim 1: Identify genetic factors associated with sodium intake, potassium intake, and sodium-to-
potassium intake ratio by conducting a meta-analysis of genome-wide association studies 
(GWAS) in multi-ancestry cohorts. 
Hypothesis 1: Single nucleotide polymorphism (SNP) markers predict variation in sodium intake, 
potassium intake, and sodium-to-potassium ratio. 
 
Aim 2: Test gene-level associations from Aim 1 and gene-by-demographic factor (age, sex, and 
education level) interactions on sodium intake, potassium intake, and sodium-to-potassium 
intake ratio in multi-ancestry cohorts. 
Hypothesis 2: The genetic variants in a region and gene-by-demographic factor (age, sex, and 
education level) interactions explain significant variation in sodium intake, potassium intake, 
and sodium-to-potassium ratio. 
 
Aim 3: Evaluate gene-by-sodium intake interactions underlying blood pressure variation in 
multi-ancestry cohorts. 
Hypothesis 3: Significant interactions between sodium intake and SNP markers across the 
genome explain blood pressure variation in multi-ancestry cohorts. 
 
In the next section, we provide the background and significance underlying these aims.  
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1.3 Background and significance 
Importance of sodium intake, potassium intake, and sodium-to-potassium intake ratio in 
blood pressure, hypertension, and cardiovascular diseases 
On average, increments of 2.11 mm Hg in systolic blood pressure (SBP) and 0.78 mg Hg 
in diastolic blood pressure (DBP) are associated with each 1g sodium intake increment [12]. The 
average daily sodium intake for Americans is 3,608 mg per day from the National Health and 
Nutrition Examination Survey (NHANES) in 2014, which is much higher than the recommended 
levels by the American Heart Association (1,500mg/day) [18]. Potassium intake, however, is 
beneficial for controlling blood pressure [6, 7]. Each 1.72 g potassium intake increment is on 
average associated with decrement of 2.42 mm Hg in SBP and 1.57 mm Hg in DBP [19]. The 
average daily potassium intake for Americans is 2,155 mg per day from the NHANES in 2014, 
which is much lower than the recommended levels by the American Heart Association 
(4,700mg/day) [18]. Researchers have found that the ability to predict an increased risk of CVD 
is stronger when using sodium-to-potassium intake ratio than using sodium or potassium alone in 
prediction models [8, 9]. Since American consumption of sodium exceeds recommended levels 
while they fall short on their potassium intake by the American Heart Association (1500mg/day), 
investigating the underlying genetic factors and gene-environment interactions associated with 
sodium and potassium intake may allow a better understanding some of the molecular 
mechanisms driving dietary behavior and may provide potential intervention and prevention 
opportunities. 
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Gold standard of sodium and potassium intake measurement 
Population and individual sodium and potassium intake are typically measured in one of 
two ways: 1) self-reported dietary intake data (i.e., dietary recalls, food records, food frequency 
questionnaires) and 2) urine biomarkers (i.e., 24-hour urine sample, half-day urine sample, and 
spot urine sample). Generally, 24-hour urinary excretion is regarded as the gold standard for 
intake assessment of sodium and potassium, and is more accurate than self-reported dietary 
intake data [20-22]. The 24-hour urinary excretion method does not allow electrolyte loss other 
than via the kidney. When comparing estimates of sodium intake from duplicate food portions 
(with sodium content measured by flame photometry) and 24-hour urinary sodium excretion, the 
sodium in the urine sample was only 5% on average lower than intake assessed by duplicate food 
portions [23]. However, intake measured by dietary records was much lower than the urinary 
estimates [23]. In another study, the difference between 24-hour urinary sodium excretion and 
sodium from duplicate food portions was 14% [24]. The remaining sodium is excreted through 
sweat and feces, which is a small portion under normal conditions. Regarding potassium intake, 
the level of potassium in 24-hour urine samples was 13.6% on average lower than intake 
assessed by duplicate food portions [23]. This is the scientific evidence that demonstrates that 
urinary sodium and potassium excretion is a gold standard for measuring sodium and potassium 
intake. 
Collecting 24-hour urinary samples is, however, very challenging compared to using a 
dietary record. Thus, sodium excretions from half-day and spot urine samples are measured, and 
they have acceptable correlation coefficients with measures from 24-hour urine samples [11, 25, 
26]. The Pearson product-moment correlation coefficient (r) between the measured and the 
estimated 24-h sodium excretion using simple volume-time linear extrapolation on half-day urine 
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samples was 0.837 in the Healthy Twin Study, Korea [11]. The correlation between the 
measured and the estimated 24-h sodium excretion and spot urine samples were previously 
reported as 0.53 - 0.82 [25, 26]. 
  
Genetics of sodium and potassium intake 
There is a large amount of variability in sodium intake within and across populations, and 
many factors influence the level of sodium and potassium intake, including sex, age, socio-
economic status, dietary habits, area of residence, and cultural factors [5, 10, 27]. Using the 
Healthy Twin Study, a twin-family cohort in Korea, I previously evaluated the null hypothesis 
that genetic factors do not play role in sodium intake level [11]. In the Healthy Twin Study, the 
intra-class correlation coefficients (ICCs) of 24-hour sodium excretion between family pairs 
were highest among the monozygotic twin pairs (0.47) and lowest among first-degree relative 
pairs (siblings combined with dizygotic twins: 0.09; parent-offspring: 0.07). Genetic versus 
environmental contributions were then estimated in terms of heritability (h2), adjusting for 
associated factors (heritability: 34%). In this dissertation, we extend this research to identify 
genomic regions and genetic variants associated with sodium and potassium intake using a 
genome-wide association meta-analysis in five epidemiologic cohorts. 
To our knowledge there has only been one GWAS for sodium and potassium 
concentration level (mEq/dl) measured from spot urine sample with limited sample size 
(N=3,095) in Japan that found one significant SNP but failed to replicate it in a replication set 
[9].  While research in this area has been limited, other studies have identified genes related to 
salt sensitivity, a measure of how individual blood pressure responds to salt intake [28, 29], and 
salt taste, ability to detect salt [30, 31]. 
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Gene-environment interaction in sodium and potassium intake 
Individual sodium and potassium intake has a wide range of individual variability [32, 
33]. The determinants of sodium and potassium intake have not been fully defined but 
physiological phenotypes, physical characteristics, developmental factors, cultural factors, 
genetic factors, and environmental factors as well as interactions among them have been reported 
to influence individual sodium and potassium intake [16, 27, 34]. Thus, the associations between 
genes and sodium/potassium intake may differ as a function of environmental and other 
conditions. While there has been no study that investigates gene-environment interaction in 
sodium and potassium intake, to our knowledge, other studies have found gene-sodium intake 
interactions that affect blood pressure [35, 36]. 
 
Gene-by-sodium/potassium intake interaction influencing blood pressure 
Blood pressure measures including SBP and DBP are heterogeneous traits because they 
are influenced by both genetic and environmental factors. GWAS have identified numerous 
SNPs that are associated with SBP and DBP, but the identified genetic loci explain only a small 
portion of trait variability (~2%) even though heritability is relatively high (~40-50%) [37-43]. 
Thus, identifying environmental factors that could modify the genetic effects of blood pressure is 
important and being actively researched [44-46]. High sodium intake and low potassium intake 
are strong and independent risk factors for high blood pressure, and the level of sodium and 
potassium intake has a large variation on both the individual and population level [32, 47, 48].  
Thus, research on whether and how individual sodium and potassium intake modifies the 
genetics of blood pressure is important for identifying susceptible genetic groups in populations 
that are disproportionately affected by sodium and potassium intake. However, few studies have 
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been conducted to evaluate the gene-by-sodium intake or gene-by-potassium intake interactions 
on blood pressure traits, especially using large-scale epidemiologic cohort data. 
Studies using animal and human subjects have focused on the identification of genes that 
are involved in blood pressure responses to sodium intake mostly via genetic alterations in 
tubular sodium reabsorption [49]. Changwei et al conducted analyses of gene-by-sodium intake 
and gene-by-potassium intake interactions on blood pressure traits including SBP, DBP, mean 
arterial pressure (MAP), and pulse pressure (PP) and found multiple novel loci from GWAS and 
gene-based analysis in a Chinese population [50, 51]. A recent study in a Korean population 
found 6 loci near significant SNPs that had significant interactions with sodium intake, 
potassium intake, or their ratio on hypertension [52]. However, more studies of gene-by-
sodium or potassium intake interactions on blood pressure traits in multiethnic populations are 
needed to better understand the mechanisms of blood pressure regulation by dynamic 
interrelationships among genes, sodium intake, and potassium intake across ancestry groups. 
This dissertation will help to provide additional insight into the genes that may interact with 
an individual’s sodium intake to influence their blood pressure.  
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CHAPTER II: Genome-wide meta-analysis of sodium intake, potassium intake, and their 
ratio in multiethnic cohorts 
 
2.1 Introduction  
Sodium and potassium are essential dietary components, but excess sodium intake [2, 53] 
and low potassium intake [6, 7] are established risk factors for hypertension and cardiovascular 
disease (CVD). In 2010, about 1.7 million, or 9.5%, of all worldwide deaths from cardiovascular 
causes were attributed to high sodium intake [5]. Although sodium and potassium intake are 
well-known modifiable and targeted dietary factors in CVD prevention, American daily 
consumption of sodium is 2.2 times the recommended maximum 1500mg/day, while daily 
consumption of potassium is 2,000mg/day below the recommended minimum of 4,700mg/day 
[54]. Recently, the sodium-to-potassium ratio has been considered a more important risk factor 
for hypertension than sodium and potassium levels alone [55, 56]. Thus, identifying the factors 
associated with maintaining an optimal sodium-to-potassium ratio could provide a basis for 
interventions to reduce the burden of hypertension and CVD [8, 9, 57]. Since sodium and 
potassium intake are related to eating behavior, which is a complex trait, many factors influence 
the level of consumption, including sex, age, socio-economic status, dietary habits, area of 
residence, and cultural factors [5, 10, 58, 59]. A previous study of 2,209 Koreans in a twin-
family study showed that genetic factors also contribute to variability in sodium intake 
(heritability = 30-35%) [11]. The intra-class correlation coefficients of 24-hour urinary sodium 
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excretion were the highest among monozygotic twin pairs (0.47) and the lowest among first-
degree relative pairs (siblings combined with dizygotic twins: 0.09). 
However, there has been limited investigation into the specific genetic variants that 
influence sodium and potassium intake, as well as their ratio. To our knowledge, there has only 
been one genome-wide association study (GWAS) for sodium and potassium concentration 
(mEq/dl) measured from spot urine samples in a Japanese population (N=3,095 for discovery 
sample, and N=5,716 for replication sample), which found one genome-wide significant locus 
but failed to replicate the genetic variant [9]. While research in this area has been limited, other 
studies have identified genes related to salt sensitivity, a measure of blood pressure 
responsiveness to salt intake [28, 29], salt taste, the ability to detect salt [30, 31].  
To better understand the genetic architecture of sodium and potassium intake and their 
ratio, we conducted a GWAS meta-analysis using the rich combination of high-quality 
measurement of sodium and potassium intake and genotype data from seven cohorts comprising 
over 11,000 participants of European (GENOA, PREVEND, FHS, HyperGEN and HAPI heart), 
African American (HyperGEN), and Asian (HTS) ancestry (Appendix 1). Since there is a wide 
range of sodium and potassium intake across different cultures, the current study includes 
multiethnic populations to help us better understand and generalize our findings about the 
genetics of sodium and potassium intake across ancestry groups. 
 
2.2 Methods 
Aim 1 included the following European Ancestry cohorts in the discovery sample 
(N=7,363): Genetic Epidemiology Network of Arteriopathy (GENOA) [60], Prevention of REnal 
and Vascular ENd-stage Disease(PREVEND) [61], Hypertension Genetic Epidemiology 
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Network (HyperGEN) study European American (EA) [60], Heredity and Phenotype 
Intervention (HAPI) Heart Study [62], and the Framingham Heart Study (FHS) [63, 64]. The 
replication sample (N=3,721) included: HyperGEN African American (AA) [60], and Healthy 
Twin Study - Korea (HTS) [65]. The descriptions and acknowledgements for participating 
cohorts are described in Appendix 1. Each of these cohorts has high-quality measurements of 
sodium and potassium intake from urinary samples, enabling us to initiate an international 
collaboration of multiethnic genome-wide meta-analysis of sodium and potassium intake and 
their ratio. A brief description of each cohort is included below: 
GENOA is a community-based study that aims to identify genes influencing blood 
pressure from Rochester, MN and Jackson, MS. It is a part of the NHLBI-sponsored Family 
Blood Pressure Program (FBPP) [66]. Sibships with at least two adults with clinically diagnosed 
essential hypertension before age 60 were recruited, and all siblings in the sibship were invited to 
participate [60]. Twenty-four hour urinary sodium and potassium excretion levels were collected 
from the participants [67]. 
PREVEND is an ongoing, community-based, and prospective cohort study initiated in 
1997 in the Netherlands [61]. The PREVEND study was designed to investigate the predictive 
value of urinary albumin excretion for renal and cardiovascular disease progression [61]. 
Twenty-four-hour urinary sodium and potassium excretion levels were collected from the 
participants [68]. 
HyperGEN is part of the NHLBI-sponsored Family Blood Pressure Program (FBPP) 
[66]. Participants were recruited from multi-center (Framingham, MA; Minneapolis, MN; Salt 
Lake City, UT; Forsyth County, NC; and Birmingham, AL) to investigate the genetics of 
hypertension [66]. Individuals with onset of hypertension before age 60 and at least one 
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additional hypertensive sibling who could be enrolled in the study were recruited into the 
HyperGEN study [69]. Twenty-four-hour urinary sodium and potassium excretion levels of 
participants were estimated using sodium and potassium excretion levels from overnight urine 
samples. 
In the HAPI Heart study, relatively healthy individuals and their family members who 
were 20 years old or older were recruited from the Amish community in Pennsylvania to 
investigate the response to short-term environmental exposures related to CVD [62]. Usual daily 
sodium and potassium levels were measured from the first-morning single spot urine specimen 
of participants [70]. 
The Framingham Offspring Study is a community-based longitudinal study examining 
CVD risk in the offspring of the original cohort participants of Framingham Heart Study (FHS) 
and their spouses [63, 64]. The analysis in this study was conducted using the data from the FHS 
investigators participating in the SNP Health Association Resource (SHARe) project and 
downloaded from the NIH Database of Genotypes and Phenotypes (dbGaP). 24-hour urinary 
sodium and potassium excretion were measured in Offspring Exam 9 and Omni 1 Exam 4. 
The Healthy Twin Study, Korea is an ongoing community-based cohort study that has 
been running since 2005 [65]. Healthy Korean adult twins and their first-degree adult family 
members were recruited. Half-day and spot urine samples were collected from all participants 
[11]. Sodium and potassium excretion levels of participants were measured either from half-day 
urine samples (≥ 8 hours) or spot urine samples. 
Measurements of sodium and potassium intake 
Urinary sodium and potassium excretion were quantified as continuous variables 
(mmol/day) from urine collections in each cohort. Sodium excretion from a 24-hour urinary 
 
 
 
14 
sample is the gold standard for the assessment of sodium intake [20-22], as its validity is much 
higher than that from self-reported dietary methods, such as 24-hour recalls, dietary records, or 
Food Frequency Questionnaires (FFQ) [20-22, 71]. The validity of urinary sodium excretions 
from half-day/overnight or spot urine samples is lower than that of urinary sodium excretions 
from 24-hour urine samples, but is still higher than that of self-reported dietary methods [22].  
The correlation coefficient (r) between the measured 24-h sodium excretion (from the 24-hour 
urine sample) and the estimated 24-h sodium excretion (using simple volume-time linear 
extrapolation on the half-day urine samples) was 0.837 in Healthy Twin Study, Korea [11]. The r 
between the measured and the estimated 24-h sodium excretion and spot urine samples was 
previously reported as 0.53 - 0.82 [25, 26]. The measurement of the source of urinary sodium 
and potassium excretion in each cohort is described in the study population section and in Table 
1 and Table 2. If the duration of the sample was less than 24 hours, established formulas were 
applied to estimate 24-hour sodium and potassium excretions; simple volume-time linear 
extrapolation was used for half-day urine samples (HyperGEN and HTS), and the Kawasaki 
formula for spot urine samples (HAPI Heart) [11, 25].  
Genotyping 
Genotypes for each cohort were obtained using either Affymetrix or Illumina genotyping 
arrays (Table 3). Each cohort performed internal quality control (QC) assessments of initial 
genotype data including excluding individuals with poor genotype call rate (i.e., <95%) and 
checking for relatedness across individuals. Quality checks for single nucleotide polymorphisms 
(SNPs) included exclusion of SNPs with poor call rate (i.e., <95%), SNPs with Hardy-Weinberg 
disequilibrium P<10-4, SNPs with high duplicate discordance rates, and monomorphic SNPs. 
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Imputation was performed using the 1000 Genomes Project Phase I Integrated Release Version 3 
[March 2012] cosmopolitan reference panel in each cohort. 
Since allele frequency differences in samples due to systemic ancestry differences can 
lead to false associations in GWASs, we adjusted for population stratification in each cohort 
using principal components (PCs) in the analysis [72]. In GENOA, the first 4 PCs were included 
in the model and were calculated using common SNPs shared by Affymetrix (Genome-Wide 
Human SNP Array 6.0) and Illumina (Human 1M-Duo, 660-Quad, or 610-Quad), with 
imputation quality (R2) greater than or equal to 0.8 using unrelated individuals (570 individuals 
from 1,509 subjects). 
Statistical analysis 
Genome-wide association study 
To identify the genetic loci that influence sodium intake, potassium intake, and their ratio 
across the genome, associations between each SNP and these traits were conducted with 1000 
Genomes Project imputed genetic data. This GWAS analysis was conducted separately in each 
cohort and within each ethnicity. In the model, age and sex were included in addition to each 
SNP, coded additively as a dosage of the coded allele.  PCs were also included to adjust for 
population stratification in each cohort. In a second model, BMI and height were added to the 
original models to approximate measures of interindividual variation of individual food intake 
(total energy intake). For family-based data, linear mixed effects modeling with “family” as a 
random intercept was conducted. The models in a family-based cohort are presented below: 
 24 − ℎ𝑜𝑜𝑜𝑜𝑜𝑜 𝑠𝑠𝑜𝑜𝑠𝑠𝑠𝑠𝑜𝑜𝑠𝑠 𝑜𝑜𝑜𝑜𝑠𝑠𝑢𝑢𝑢𝑢𝑜𝑜𝑢𝑢 𝑠𝑠𝑜𝑜𝑠𝑠𝑠𝑠𝑜𝑜𝑠𝑠 𝑒𝑒𝑒𝑒𝑒𝑒𝑜𝑜𝑒𝑒𝑒𝑒𝑠𝑠𝑜𝑜𝑢𝑢𝑖𝑖𝑖𝑖, 24 − ℎ𝑜𝑜𝑜𝑜𝑜𝑜 𝑜𝑜𝑜𝑜𝑠𝑠𝑢𝑢𝑢𝑢𝑜𝑜𝑢𝑢 𝑝𝑝𝑜𝑜𝑒𝑒𝑢𝑢𝑠𝑠𝑠𝑠𝑠𝑠𝑜𝑜𝑠𝑠 𝑒𝑒𝑒𝑒𝑒𝑒𝑜𝑜𝑒𝑒𝑒𝑒𝑠𝑠𝑜𝑜𝑢𝑢𝑖𝑖𝑖𝑖, 
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or 𝑆𝑆𝑜𝑜𝑠𝑠𝑠𝑠𝑜𝑜𝑠𝑠 − 𝑒𝑒𝑜𝑜 − 𝑝𝑝𝑜𝑜𝑒𝑒𝑢𝑢𝑠𝑠𝑠𝑠𝑠𝑠𝑜𝑜𝑠𝑠 𝑒𝑒𝑒𝑒𝑒𝑒𝑜𝑜𝑒𝑒𝑒𝑒𝑠𝑠𝑜𝑜𝑢𝑢 𝑜𝑜𝑢𝑢𝑒𝑒𝑠𝑠𝑜𝑜𝑖𝑖𝑖𝑖                      =  𝛽𝛽0 + 𝛽𝛽1 ∙ 𝑢𝑢𝑎𝑎𝑒𝑒𝑖𝑖𝑖𝑖 + 𝛽𝛽2 ∙ 𝑠𝑠𝑒𝑒𝑒𝑒𝑖𝑖𝑖𝑖 + 𝛽𝛽3 ∙ 𝑃𝑃𝑃𝑃1𝑖𝑖𝑖𝑖 + 𝛽𝛽4 ∙ 𝑃𝑃𝑃𝑃2𝑖𝑖𝑖𝑖 + 𝛽𝛽5 ∙ 𝑃𝑃𝑃𝑃3𝑖𝑖𝑖𝑖 + 𝛽𝛽6 ∙ 𝑃𝑃𝑃𝑃4𝑖𝑖𝑖𝑖+ 𝛽𝛽7 ∙ 𝑆𝑆𝑆𝑆𝑃𝑃𝑖𝑖𝑖𝑖 + 𝑜𝑜𝑖𝑖 + 𝜖𝜖𝑖𝑖𝑖𝑖 
where i is an individual, j is a family,  𝛽𝛽0 is a fixed intercept, 𝛽𝛽1 − 𝛽𝛽7 are fixed coefficients 
representing the estimated effects of each following term, 𝑜𝑜𝑖𝑖 is a random intercept for family j, 
and 𝜖𝜖𝑖𝑖𝑖𝑖  is a random error for an individual i in family j. 
Meta-analysis and replication 
Before conducting the meta-analysis, individual GWAS results were cleaned. This was 
done using EasyQC software [73] to check the collected allele frequencies against the ancestry-
specific 1000 Genomes Reference panel, and to harmonize genetic marker names for consistency 
across cohorts. To improve the power of GWAS and reduce false-positive results, a fixed-effect 
meta-analysis using inverse-variance weightings was performed on summary statistics (beta 
estimate from the association, and standard error of beta estimate) and corrected for study-
specific genomic control lambda when lambda was greater than 1. The only SNPs that were 
included were the ones present in at least two participating studies with minor allele frequency 
(MAF) greater than 0.01, and imputation quality greater than 0.3. We conducted a meta-analysis 
across cohorts with European ancestry using the METAL package in R [74], and genomic 
control correction was again applied after the meta-analysis. To adjust for the inflation of type I 
error due to multiple testing, we used an alpha level of 5 X 10-8 to declare significant association. 
To assess the homogeneity of results across cohorts, we estimated the Cochran’s Q statistic and 
I2 statistic for each SNP, and we calculated the percentage of total variation across studies that 
was due to heterogeneity rather than chance [37, 38]. A cut-off of 25% was used to represent 
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minimal heterogeneity, 50% to represent moderate, and 75% to represent considerable 
heterogeneity [37, 38]. 
For SNPs with at least suggestive association in EA (P < 5 X 10-6), we examined the 
SNPs in cohorts with AA and Asian ancestry (overview shown in Figure 2). We considered P < 
0.05 before correcting multiple comparison to represent replication. 
 
 
 
Figure 2 Schematic of the study design 
 
2.3 Results 
Meta-analysis of 24-hour sodium excretion, potassium excretion, and their ratio was 
conducted in 7,363 participants of European ancestry from 5 cohorts. Only suggestive or 
significant SNPs (P ≤ 5 X 10-6) were further tested for replication in the participants of African 
Americans (N=1,246) and Koreans (N=844). The descriptive characteristics of the cohorts are 
presented in the Table 1.  On average, the 24-hour urinary sodium excretions of participants were 
much higher in HyperGEN, HAPI Heart, and HTS (range: 203.3 -237.8 mmol/day) than in 
GENOA, REVEND, and FHS (range: 136.6 -144.9 mmol/day). In HyperGEN and HAPI Heart, 
the average sodium-to-potassium ratio ranged from 3.7-4.7, while in HTS, it was 2.7. The 
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prevalence of hypertension was greater than 50% in the American cohorts, except for in HAPI 
Heart (Amish cohort), and it lower (10 - 30%) in HTS and PREVEND, likely due to the 
participants’ younger age. 
Discovery meta-analysis 
From the discovery meta-analyses (both with and without adjustment for BMI and 
height), we identified 52, 75, and 27 SNPs with at least suggestive association (P <5x10-6) with 
24-hour sodium excretion, 24-hour potassium excretion, and their ratio, respectively (Tables 4 
and 5). Figure 3 shows the QQ plots of the meta-analysis results, and Figure 4 shows the Miami 
plots. 
We found few genome-wide significant SNPs from the meta-analyses. The most 
significant SNP was in the FCGR2B -FCGR2C-RP11-25K21.6-FCGR3A gene cluster on 
chromosome 1 (rs71639080, P=6.88 x10-9 and 6.21 x10-9) from GWAS of 24-hour sodium 
excretion with and without adjustment for BMI and height, respectively. The most significant 
SNP from GWAS of 24-hour potassium excretion was rs111345501 near genes PATZ1-RP3-
400N23.6 on chromosome 22 with adjustment for BMI and height in the model (P=8.11 x10-8). 
From the sodium-to-potassium ratio meta-analysis with adjustment for BMI and height, we 
found two genome-wide significant SNPs (rs77958157 on chromosome 5 with P=2.3 x10-8, and 
rs148459019 on chromosome 6 with P=3.7 x10-8). Regional plots for the significant SNPs are 
shown in Figure 5.
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Figure 3 QQ plots of discovery GWAS meta-analysis for 24-hour sodium excretion, 24-hour potassium excretion, and sodium-to-
potassium ratio in Aim 1 
 
Blue line: without BMI and height adjustment 
Red line: with BMI and height adjustment
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Figure 4 Miami plots of discovery GWAS meta-analysis for 24-hour sodium excretion, 24-hour 
potassium excretion, and sodium-to-potassium ratio in Aim 1 
 
Above Miami plot: without BMI and height adjustment 
Below Miami plot: with BMI and height adjustment 
 
 
24-hour sodium excretion 
 
 
 
 
24-hour potassium excretion 
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Sodium-to-potassium ratio 
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Figure 5 Regional plots for the most significant loci from 24-hour sodium excretion, 24-hour potassium excretion, and sodium-to-
potassium ratio using LocusZoom in Aim 1 
 
24-hour sodium excretion 
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24-hour potassium excretion 
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Replication 
We conducted replication analysis of 154 SNPs with P <5x10-6 from the European 
Ancestry cohorts (52 for 24-hour sodium excretion, 75 for 24-hour potassium excretion, and 27 
for sodium-to-potassium ratio, respectively) in the African American and Asian ancestry 
populations (Table 6). One SNP, rs1033925 on chromosome 10 from the 24-hour sodium 
excretion GWAS replicated in the Asian cohort (P=0.031).  From the 24-hour potassium 
excretion GWAS, 4 SNPs (rs200543390, rs201934692, rs143513312, and rs188284329) from 
the same locus on chromosome 11 replicated in the African American cohort (P=0.026 - 0.05), 
and one SNP, rs74459597 on chromosome 13, replicated in the Asian cohort (P=0.03).  
 
2.4 Discussion   
We conducted a GWAS meta-analysis of 24-hour sodium excretion, 24-hour potassium 
excretion, and sodium-to-potassium ratio using 5 European ancestry cohorts (N=7,363), followed 
by the analysis of replication in an African American cohort (N=1,246) and an Asian cohort 
(N=2,475). From the meta-analysis in European ancestry population, we found a total of 52, 75, 
and 27 SNPs with at least suggestive associations (P <5x10-6) with 24-hour sodium excretion, 
24-hour potassium excretion, and their ratio, respectively. Three of those SNPs were replicated 
either in African Americans or Asian populations (P<0.05). Although the total sample size is 
small compared to other large GWAS, this is the largest genome-wide investigation of these 
phenotypes to date. 
Several of our identified loci are located in or near 69 gene regions from any of GWAS in 
Aim 1.  Out of 69 genes, the 12 genes that have a known function are listed below. From the 
sodium excretion meta-analysis, the most significant SNPs were found near the Fc fragment of 
 
 
 
26 
IgG receptor genes (FCGR2B-FCGR2C- FCGR3A) on chromosome 1. The genes encode a 
receptor found on the surface of immune response cells, and mutations in these genes have been 
suggestively associated with autoimmune disease [75]. While excess sodium intake could induce 
excessive immune responses, which can be damaging to immune homeostasis in human body 
[76] [77], there is no known reason why these genes would be associated with sodium or 
potassium intake. Further studies are needed to elucidate the function of these genes, and their 
relationship with the genetics of sodium excretion and the immune system. 
Multiple genes from the sodium excretion meta-analysis, including GTPBP1 (GTP 
binding protein 1) on chromosome 22, and CDC42SE1 (CDC42 small effector 1) on 
chromosome 1, have been suggestively associated with the activity of GTPases. GTPases are 
suggestively associated with blood pressure regulation, hypertension, kidney function, and other 
traits that are related with cardiovascular system and disease. Studies have identified GTPases as 
a mechanism for salt intake triggering hypertension and other cardiovascular damage [78] [79]. 
The gene ARHGAP22 (GTPase activating protein 22) near the variant rs56319019 identified 
from the potassium excretion meta-analysis on chromosome 10 encodes Rho GTPase. The Rho 
GTPases have important roles in salt-sensitive hypertension [78] and renal tubular epithelial cell 
function [80]. 
The gene CLMP (CXADR like membrane protein) on chromosome 11 from the sodium 
excretion meta-analysis with adjustment for BMI and height has been suggestively involved in 
adipocyte maturation, intestinal development, body mass index, and development of diet-induced 
obesity [79]. Although the link between the gene, sodium intake, and obesity has not been well 
established, it is promising that this may support the positive association between sodium intake 
and obesity [81] [82]. 
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We found multiple genes that have important roles in regulation of blood pressure and 
cardiovascular disease. The gene DLEU2 (deleted in lymphocytic leukemia 2) on chromosome 
13 identified from the potassium excretion meta-analysis is suggestively associated with 
angiotensin converting enzyme 2 (ACE 2) in the cell cycle of vascular endothelial cells [83]. 
ACE has important role in blood pressure regulation by controlling the volume of fluids in the 
body. In addition, multiple SNPs located in the intronic region of gene CUL3 (cullin 3) on 
chromosome 2 were found from the potassium excretion meta-analysis. The mutation in the gene 
is associated with pseudohypoaldosteronism type two, a rare Mendelian syndrome involving 
hypertension [84]. The mechanisms of the disease have been suggestively associated with salt 
reabsorption and potassium secretion in the kidney [85]. We also found a suggestive SNP, 
rs145526382 near gene ABO (alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-
galactosyltransferase) on chromosome 9 from the meta-analysis of potassium excretion. Previous 
GWAS found that SNPs near the ABO gene were associated with ACE activity [86] and venous 
thromboembolism (VTE) [87].  
Several genes identified in suggestive GWAS regions identified appear to be associated 
with neuromuscular function. From the meta-analyses of sodium-to-potassium ratio, we found a 
suggestive SNP near gene EIF2B5 (eukaryotic translation initiation factor 2B subunit epsilon) on 
chromosome 3. The gene has been suggestively associated with multiple sclerosis, a 
neurodegenerative disorder [56]. The important role of sodium and potassium ions in the human 
body involves their functions in the transmission of nerve impulses in neuron. The associations 
between sodium/potassium intake and multiple sclerosis have been inconclusive [88] [89] [90]. 
We also identified a suggestive SNP from the meta-analysis of sodium-to potassium ratio near 
KIRREL3 (kirre like nephrin family adhesion molecule 3) on chromosome 11, which is involved 
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in encoding a member of the nephrine-like protein family that is present in kidney podocytes 
[91]. The main role of the nephrine protein is the proper functioning of the renal filtration barrier 
in the kidney. The nephrine proteins interacts with podocin, another important protein in renal 
filtration function, which is associated with the permeability of sodium and potassium in kidney 
ultrafiltration. KIRREL3 has been also suggestively associated with human skeletal muscle and 
intellectual disability [92, 93]. While it may not seem that the sodium and potassium intakes are 
associated with those diseases, sodium and potassium are involved in transmitting nerve signals 
that induce muscle contraction, and sodium intake has been suggestively associated with skeletal 
muscle via loss of nitric oxide activity [94] [95]. In addition, studies have identified the potential 
role of KIRREL3 in neurodevelopment [93] [96]. KIRREL3 could potentially interact with 
ATP1B1 that belongs to the family of sodium-potassium ATPases [93]. However, further studies 
are needed to elucidate the mechanism of how the genes are related to sodium and potassium 
intake, perhaps through neurological feedback systems that affect taste or hunger mechanisms. 
To our knowledge, there has only been one genome-wide association study (GWAS) for 
sodium and potassium concentration (mEq/l) adjusted for age, sex, and BMI. The study had 
limited sample size (N=3,095 in discovery, and N=5,716 in replication using a subset of the 
same original cohorts) using only Japanese populations. In the Japanese study, sodium and 
potassium concentrations were measured from spot urine samples, which is a different phenotype 
from daily intake. The Japanese study found one genome-wide significant SNP, rs12092050 
(P=1.35 X 10-8) on chromosome 1, for sodium concentration level, but failed to replicate the 
SNP (P= 0.618) [9]. We did replication analysis of rs12092050 in our sample, and the SNP had a 
significant P value from the sodium-to-potassium ratio GWAS results adjusted for age, sex, 
BMI, and height in Korean cohort, HTS (P=0.044, Table 7). 
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A notable strength of our research is that urinary sodium intakes were measured in 
populations with multiple ancestries (N=11,084). A large number of high quality samples may 
have helped us provide accurate identification of genetic factors for sodium and potassium 
intake. Since sodium and potassium intake are highly variable among different populations, it is 
important to include multiethnic populations in the analyses. The current study included multiple 
populations with both higher and lower mean sodium intakes, which allowed us to generalize 
these results across a variety of populations.  
Our power to detect the genetic loci associated with sodium and potassium intake might 
have been limited due to our relatively small sample size. Generally, 24-hour urinary sodium 
excretion is regarded as the gold standard for intake assessment of sodium intake, and is more 
accurate than data measured from self-reported dietary questionnaires [20-22]. Collecting 24-
hour urinary samples is, however, very challenging compared to using self-reported dietary 
questionnaires. Thus, sodium excretions from half-day and spot urine samples are measured 
instead, and they have reasonably high correlation coefficients with the excretions from 24-hour 
urine samples (0.837 and 0.53 – 0.82, respectively) [11, 25].  
The low rate of replication from the European American meta-analysis in the African 
American and Asian cohorts may be due to the different linkage disequilibrium structure in each 
ancestry. SNPs found in different race/ethnicity groups may not be replicated in other groups 
even if the underlying genes that influence the trait are the same. Thus, a gene-based approach 
may be needed to replicate our findings in populations with different ancestry since the gene is a 
functional unit that does not vary by race/ethnicity group. Another reason for the low replication 
rate might be related to the different characteristics of participants in multiethnic populations, 
which includes different level of sodium potassium intake or different recruitment methods of 
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participants. It is possible that the genetic effects on high intakes of sodium or potassium is 
different than on low intakes of sodium or potassium. In addition, some of participants in Aim 1 
were selected like in GENOA and HyperGEN that were targeting hypertensive subjects or 
subjects with a family history of hypertension. 
The identification of genetic variants that influence sodium and potassium intake and 
corresponding susceptible groups may improve personalized nutritional recommendations by 
identifying individuals at high risk of excess sodium intake and low potassium intake, and by 
proactively recommending behavior modifications to reduce the risk of high blood pressure. 
These initial discoveries may shed light on the importance of the genetic architecture of sodium 
and potassium intake. Future work is now required to identify functional variants in these 
genomic regions, and to provide more insight to the regulation of sodium and potassium intake 
that may improve the health of multiple populations. 
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Table 1 The basic characteristics of participating cohorts in Aim 1 
 GENOA PREVEND FHS HyperGEN EA HyperGEN AA HTS HAPI Heart 
Cohort Family-based Population-based Family-based Family-based Family-based Family-based Family-based 
Country USA Netherlands USA USA USA South Korea USA 
Total (N) 811 3,649 801 1,258 1,246 2,475 844 
Female, % 57.6 51.5 53.2 50.4 67 64.0 46.6 
Age in years 65.7 ± 9.1 49.6 ± 12.5 70.2 ± 7.62 50 ± 14 45 ± 13 44.1 ± 13.3 43.8 ± 14.0 
Race/ethnicity EA Europeans (Dutch) EA EA AA Asian EA (Amish) 
SBP 146.7 ± 22.8 129.1±19.9 125.1 ± 16.2 123.5 ± 19.1 129.2 ± 22.2 116.8 ± 17.0 121.5 ± 14.6 
DBP 84.1 ± 10.8 74.1±9.9 71.3 ± 9.6 70.7 ± 10.0 74.0 ± 11.6 73.7 ± 10.9 76.8 ± 8.7 
Hypertension, % 88.2 34.4 52.6 52.2 63 10.7 13.6 
BP lowering 
medication use, % 
76.2 12.3 52.4 47.7 61.1 8.09 0.0 
BMI 30.9 ± 5.9 26.1±4.3 28.1 29.47 ± 6.13 32.55 ± 8.04 23.7 ± 3.3 26.6 ± 4.5 
Measurement of source 24-hour urine 24-hour urine 24-hour urine Half-day urine Half-day urine Half-day & 
Spot urine 
Spot urine 
24-h sodium excretion 
(mmol/day) 
139.4 ± 58.3 144.9 ± 50.3 136.6 ± 57.0 203.3±107.3 237.8±121.9 212.8± 77.8 216.6 ± 50.8 
24-h potassium 
excretion (mmol/day) 
58.5 ± 22.9 73.6 ± 21 67.9 ± 23.2 65.1±36.3 65.7±41.4 84.0 ± 32.2 47.9 ± 13.4 
Sodium-to-potassium 
excretion ratio 
2.5 ± 1.0 2 ± 0.7 2.1 ± 0.9 3.7 ± 1.9 3.7 ± 2.3 2.7 ± 1.0 4.7 ± 1.2 
For continuous variables: mean ± SD, For binary variables: %  
Abbreviations:  EA- European American, AA- African American, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, BP: 
Blood pressure, BMI: Body Mass Index (kg/m2), GENOA: Genetic Epidemiology of Arteriopathy, PREVEND: Prevention of REnal 
and Vascular ENd-stage Disease, FHS: Framingham Heart Study, HyperGEN: Family Blood Pressure Program, HTS: Healthy Twin 
Study, Korea, HAPI Heart: Heredity and Phenotype Intervention Heart Study 
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Table 2 Urinary sodium and potassium excretion measurement methods of participating cohorts in Aim 1 
 
Cohort Brief Description of Urinary Sodium and Potassium Excretion Measurement Relevant References 
Genetic Epidemiology 
Network of Arteriopathy 
(GENOA) 
 
USA 
In GENOA, participants completed at least one 24-hour urine collection at a CKD and/or GDUL study visit. A total of 333, 
295, and 183 participants had a total of 1, 2, or 3 urine collections, respectively. For individuals with 2 or 3 urine 
collections, values were averaged for analysis. The mean time between the earliest CKD and latest GDUL urine collections 
was 1.73 years (range ¼ 0.9-3.6 years). The average time between the 2 GDUL collections was 22 days. Intraclass 
correlation coefficients for urine factors across collections revealed that most urine measures were relatively stable across 
time. Urine was collected with toluene as a preservative and twenty-four-hour urinary sodium and potassium excretion 
were measured in the Mayo Clinic Renal Testing Laboratory.  
Lieske, John C., et al. "Heritability of 
dietary traits that contribute to 
nephrolithiasis in a cohort of adult sibships." 
Journal of nephrology 29.1 (2016): 45-51. 
Prevention of REnal and 
Vascular ENd-stage Disease 
(PREVEND) 
Netherlands 
Urinary excretions of sodium and potassium were determined with a MEGA clinical chemistry analyzer (Merck, 
Darmstadt, Germany). Sodium and potassium were determined by indirect potentiometry. 
Verhave, Jacobien C., et al. "Sodium intake 
affects urinary albumin excretion especially 
in overweight subjects." Journal of internal 
medicine 256.4 (2004): 324-330. 
Hypertension Genetic 
Epidemiology Network 
(HyperGEN) 
USA 
An overnight urine sample was collected for sodium and potassium and extrapolated to 24-h urinary sodium and potassium 
excretion using the method of simple volume-time linear extrapolation. 
 
Province, Michael A., et al. "Association 
between the α-adducin gene and 
hypertension in the HyperGEN Study." 
American journal of hypertension 13.6 
(2000): 710-718. 
Heredity and Phenotype 
Intervention (HAPI) Heart 
USA 
The HAPI Heart study participants collected the first morning void on the day they were scheduled to come in for Clinic 
Visit 1.  Urine was measured for creatinine, sodium, and potassium at Quest Laboratories, Horsham, PA.  These spot urines 
were used to estimate 24-hour creatinine, sodium, and potassium variables using the Kawasaki formula. 
Mitchell, Braxton D., et al. "The genetic 
response to short-term interventions 
affecting cardiovascular function: rationale 
and design of the Heredity and Phenotype 
Intervention (HAPI) Heart Study." 
American heart journal 155.5 (2008): 823-
828. 
Framingham Heart Study 
(FHS) 
 
USA 
Twenty-four-hour urine sample was collected for sodium and potassium measurement.  
Healthy Twin Study, Korea 
(HTS) 
 
South Korea 
Half-day urine (HU) samples were collected from all participants in the Healthy Twin Study. HU collection started at 
~1900 on the day before their visit, after the subjects had completely voided and discarded their urine; the exact time was 
recorded. Each participant’s urine was collected in a bag until the next day’s visit for his or her health examination. In the 
morning, at ~0900 on site, any remaining urine was further voided and the time and the total volume were reported as final 
records. The amount of sodium and potassium in the urine samples was measured by ion-selective electrode potentiometry 
in one central laboratory, which was certified and had passed all quality-control regulations set forth by the government. 
The 24-h sodium excretion level was estimated by using simple volume-time linear extrapolation on the HU samples or by 
using Kawasaki formula on the excretion level if the duration of urine collection is less than 8 hours.  
Kho, M., Lee, J. E., Song, Y. M., Lee, K., 
Kim, K., Yang, S., ... & Sung, J. (2013). 
Genetic and environmental influences on 
sodium intake determined by using half-day 
urine samples: the Healthy Twin Study–. 
The American journal of clinical nutrition, 
98(6), 1410-1416. 
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Table 3 Genotyping information for participating cohorts in Aim 1 
 
Cohort Array type Genotype calling 
QC filters for 
genotyped SNPs used 
for imputation 
Imputation Software 
Data management 
and statistical 
analysis 
Population 
stratification or 
principal 
components 
Type of 
reported 
imputation 
quality 
GENOA Affymetrix Genome-Wide 
Human SNP Array 6.0 (91.9% 
of sample); Illumina Human 
1M-Duo, 660-Quad, or 610-
Quad (8.1% of sample) 
Birdseed; Illumina 
Genome Studio 
Call rate < 95% IMPUTE version 2 R  First 4 PCA INFO 
PREVEND Illumina Cyto SNP12 v2 array  HWE P <0.00001, MAF 
<1%, call rate <95% 
IMPUTE2 version 2.2.0 SNPtest V2.5 First 5 PCA INFO 
HyperGEN (EA) Affymetrix 5.0 BRLMM Mendelian errors, HWE 
P<10-6 
MaCH/minimac MMAP N/A Rsq 
HyperGEN (AA) Affymetrix 6.0 Birdseed Mendelian errors, HWE 
P<10-6 
MaCH/minimac MMAP PC 1 Rsq 
HAPI Heart Affymetrix 500K and 
Affymetrix 6.0 
BRLMM HWE < 1e-6, Call rate ≤ 
0.95, MAF < 0.01, 
mendelian errors, and 
sex mismatch 
MaCH/minimac MMAP Kinship matrix 
based on 14-
generation Amish 
pedigree 
Rsq 
FHS Affymetrix 500K mapping 
array and the Affymetrix 50K 
gene-focused molecular 
imprinted polymer array  
BRLMM HWE < 1e-6, Call rate < 
95%, MAF< 1% 
MACH R N/A Rsq 
HTS Affymetrix 6.0 Birdseed HWE <0.001, MAF 
<0.01, and genotype 
missing rate >0.05 
IMPUTE version 2 GenABEL Kinship matrix INFO 
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Table 4 Meta-analysis results of 24-hour sodium excretion, 24-hour potassium excretion, 
sodium-to-potassium ratio for all loci brought forward for replication (P <5x10-6 from discovery 
meta-analysis) in Aim 1 
 
Chr, chromosome; A1, effect allele; A2, non-effect allele; EAF, effect allele frequency 
Increasing beta indicates higher excretion of sodium and potassium 
Nearest Gene: Genes near index SNP (± 5Kb Upstream/Downstream distance bp) 
Gene names were obtained using variant effect predictor (VEP) from Ensembl using GRCh37 
Genes with intragenic index variants bolded. 
Direction of effect in GENOA, PREVEND, HpyperGEN EA, HAPI Heart, and FHS in European 
ancestry, respectively 
 
24-hour sodium excretion 
 
SNP Nearest Gene Chr Position A1 A2 EAF N Direction Beta SE P 
rs71639080 FCGR2B 
FCGR2C 
RP11-25K21.6 
FCGR3A 
1 161565867 t c 0.02 1651 +??+? 71.03 12.26 6.88E-09 
rs188869607 RPL9P28 
CTD-2377D24.2 
CTD-2377D24.8 
17 46764522 a t 0.48 7344 ++-++ 5.14 0.97 1.28E-07 
rs117259059 MLLT11 
CDC42SE1 
1 151034164 t c 0.02 6500 +++?- 19.78 3.79 1.84E-07 
rs7291524 JOSD1 
GTPBP1 
22 39100545 t c 0.04 7344 +++++ 12.54 2.41 1.87E-07 
rs145860590   1 151325810 d i 0.02 5699 ++-?? 21.75 4.18 1.97E-07 
rs16852403   1 178039226 t c 0.80 7344 +++++ 5.65 1.10 3.09E-07 
rs139574219   7 110287083 t c 0.99 1608 -???- -47.40 9.27 3.21E-07 
rs6703721   1 178037791 t c 0.21 7344 ----- -5.52 1.09 4.61E-07 
rs6662255   1 178040083 t c 0.21 7344 ----- -5.56 1.11 4.87E-07 
rs182773669 JOSD1 
GTPBP1 
22 39096945 t c 0.96 6500 ---?- -14.45 2.88 5.40E-07 
rs192132524 GABPB2 1 151064827 t c 0.03 5243 ++??- 17.17 3.43 5.66E-07 
rs200660817 TOMM22 
JOSD1 
RP3-508I15.9 
22 39077150 d i 0.07 7344 +++++ 10.09 2.02 5.94E-07 
rs182605199   2 74951285 t c 0.02 5286 ++?+? 27.14 5.47 6.98E-07 
rs144955294   7 110262691 t c 0.01 1608 +???+ 46.59 9.46 8.37E-07 
rs1033925   10 58606785 t c 0.93 7344 ----- -9.14 1.86 8.55E-07 
rs11583320   1 178042145 t c 0.80 7344 +++++ 5.45 1.11 8.91E-07 
rs73289729   10 58604226 a t 0.93 7344 ----- -9.11 1.86 9.40E-07 
rs73049336   1 178042298 a t 0.80 7344 +++++ 5.44 1.11 9.46E-07 
rs1925315   10 58591477 a t 0.07 7344 +++++ 9.00 1.86 1.29E-06 
rs111674304   1 178043192 t c 0.80 7344 +++++ 5.35 1.11 1.42E-06 
rs73287651   10 58580254 a g 0.07 7344 +++++ 9.01 1.87 1.42E-06 
rs981155   10 58573238 a c 0.93 7344 ----- -9.00 1.87 1.50E-06 
rs72653410 GLB1L2 11 134216182 a c 0.06 5286 --?-? -13.90 2.94 2.22E-06 
rs73159315 NPTXR 22 39213327 t c 0.10 7344 +++++ 8.18 1.74 2.50E-06 
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rs12538837   7 97684468 t c 0.72 7344 ++++- 4.66 1.00 2.86E-06 
rs200302969 SETD7 4 140491783 d i 0.32 7344 +++++ 4.79 1.03 2.93E-06 
rs3847055   7 97680645 a g 0.72 7344 ++++- 4.67 1.00 2.95E-06 
rs847573   7 97681761 t c 0.29 7344 ----- -4.59 0.98 3.04E-06 
rs5750620 DMC1 22 38952493 a t 0.04 7344 +++++ 11.22 2.42 3.44E-06 
rs1292811 DMC1 22 38927886 t c 0.04 7344 +++++ 11.42 2.47 3.76E-06 
rs7691513 SETD7 4 140498292 t c 0.22 7344 +++++ 5.03 1.09 3.84E-06 
rs4713599 TAP1 
PSMB8 
TAP2 
PSMB9 
TAPSAR1 
6 32811530 a c 0.92 7344 --+-- -7.95 1.73 4.10E-06 
rs59849088 SETD7 4 140499281 d i 0.22 7344 +++++ 5.00 1.09 4.20E-06 
rs200142350 AC005523.3 19 4786178 d i 0.54 5286 ++?-? 5.32 1.16 4.34E-06 
rs181724901 MUC22 6 30989117 a g 0.09 6087 --?-- -7.80 1.70 4.50E-06 
rs34262838   7 97675148 t c 0.28 7344 ----+ -4.61 1.01 4.55E-06 
rs144364970 RPL9P28 
CTD-2377D24.2 
CTD-2377D24.8 
17 46772982 d i 0.55 7344 ----- -4.15 0.91 4.74E-06 
rs5750666 CBY1 
TOMM22 
RP3-508I15.9 
22 39073210 a g 0.04 6500 +++?+ 13.48 2.95 4.87E-06 
rs10445381 RPL9P28 
CTD-2377D24.2 
CTD-2377D24.8 
17 46766306 a g 0.45 7344 +++++ 4.10 0.90 4.93E-06 
 
24-hour potassium excretion 
SNP Nearest Gene Chr Position A1 A2 EAF N Direction Beta SE P 
rs71409269 BCL2A1 15 80249333 t c 0.12 7346 ++-++ 2.82 0.55 2.70E-07 
rs139376539 
 
6 125681952 c g 0.01 2099 ??++? 20.44 4.09 6.11E-07 
rs78755596 ABO; 
RP11-430N14.4 
9 136124590 a t 0.06 7346 +++++ 4.79 0.96 6.15E-07 
rs114543420 RP11-431M7.2 4 36358412 a g 0.99 1612 -???- -19.08 3.83 6.57E-07 
rs201920383 LINC00672 17 37086244 d i 0.08 5290 ++?+? 3.70 0.75 7.42E-07 
rs111345501 PATZ1; 
RP3-400N23.6 
22 31719404 t g 0.01 4890 ?++?? 12.70 2.58 8.85E-07 
rs145526382 ABO; 
RP11-430N14.4 
9 136121623 t c 0.06 7346 +++++ 4.63 0.95 1.27E-06 
rs4262910 BCL2A1 15 80248501 a g 0.16 7346 +++++ 2.41 0.50 1.44E-06 
rs71409267 
 
15 80245221 t g 0.83 7346 ----- -2.39 0.50 1.47E-06 
rs142142409 
 
15 80245922 d i 0.17 7346 +++++ 2.39 0.50 1.48E-06 
rs6836562 
 
4 148278891 t c 0.16 7346 +++++ 2.34 0.49 1.54E-06 
rs185185619 
 
1 37906000 a c 0.99 4446 --??? -11.73 2.44 1.59E-06 
rs72857549 
 
2 30151870 a g 0.98 7346 +++++ 6.71 1.42 2.24E-06 
rs4765208 BRI3BP 12 125519633 t c 0.71 7346 ----- -1.87 0.40 2.27E-06 
rs78881198 CUL3 2 225434223 t c 0.01 2056 ??+?+ 19.13 4.04 2.28E-06 
rs56319019 ARHGAP22 10 49866788 a g 0.02 6502 +++?+ 7.39 1.57 2.61E-06 
rs13419091 
 
2 30150824 a t 0.02 7346 ----- -6.64 1.41 2.68E-06 
rs184017158 
 
6 37383326 t c 0.97 6502 --+?- -7.41 1.58 2.76E-06 
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rs112414910 EIF4ENIF1; 
SFI1; 
DRG1 
22 31886109 c g 0.98 6502 +--?+ -7.66 1.65 3.46E-06 
rs79591115 DDX31 9 135486329 c g 0.01 5247 --??- -11.12 2.40 3.59E-06 
rs72788784 
 
16 64818665 a g 0.01 6502 +++?+ 9.46 2.04 3.75E-06 
rs189560660 
 
2 129472735 t c 0.99 4446 ++??? 12.87 2.79 4.00E-06 
rs6836525 
 
4 148278846 t c 0.18 7346 +++++ 2.01 0.44 4.11E-06 
rs79332849 UNC13C 15 54301716 c g 0.03 7346 ----- -4.47 0.97 4.14E-06 
rs199583567 ASH1L; 
snoU13 
1 155381361 d i 0.25 7346 +---- -2.10 0.46 4.16E-06 
rs76323568 TSPEAR; 
KRTAP10-11; 
KRTAP12-4 
21 46070028 a g 0.04 6091 ++?++ 4.92 1.07 4.28E-06 
rs78761110 CUL3 2 225429316 t g 0.99 2056 ??-?- -18.28 3.98 4.43E-06 
rs138370749 DLEU2 13 50617864 t c 0.99 1612 -???- -16.87 3.67 4.54E-06 
rs71409262 
 
15 80216516 a c 0.86 7346 ----- -2.24 0.49 4.80E-06 
rs34149442 ST20-MTHFS; 
ST20; 
C15orf37 
15 80216176 t g 0.14 7346 +++++ 2.24 0.49 4.98E-06 
rs200218912 
 
2 119115839 d i 0.89 7346 ----- -3.83 0.84 4.98E-06 
 
Sodium-to-potassium ratio 
SNP Nearest Gene Chr Position A1 A2 EAF N Direction Beta SE P 
rs77958157 
 
5 71166807 a c 0.01 4441 ++??? 0.51 0.09 5.53E-08 
rs148459019 
 
6 32836582 t g 0.01 4436 ?+??+ 0.41 0.08 1.56E-07 
rs72824746 SH3RF3 2 110034953 t c 0.08 7339 +++++ 0.17 0.03 8.67E-07 
rs142729205 
 
3 140538834 d i 0.90 7339 +++++ 0.14 0.03 9.04E-07 
rs72987180 
 
3 140538648 a g 0.90 7339 +++++ 0.14 0.03 1.02E-06 
rs189926695 
 
6 78194765 a g 0.17 6495 --+?- -0.12 0.03 1.08E-06 
rs117738029 
 
14 43033528 a t 0.96 7339 +++++ 0.25 0.05 1.46E-06 
rs114631099 RP11-483H11.1; 
CTC-228N24.1 
5 127126945 a g 0.99 4888 ?++?? 0.43 0.09 1.68E-06 
rs115322212 
 
3 140538274 c g 0.92 7339 +++++ 0.15 0.03 1.83E-06 
rs201948417 RP11-433C9.2; 
EIF2B5; 
RP11-433C9.2 
3 184133284 d i 0.92 7339 --+-- -0.15 0.03 2.33E-06 
rs181723052 KLF12 13 74294499 t c 0.99 1607 +???+ 0.78 0.17 2.78E-06 
rs57782376 
 
3 140537390 a g 0.92 7339 +++++ 0.15 0.03 3.00E-06 
rs115979281 CTC-228N24.1 5 127143872 t c 0.01 4888 ?--?? -0.43 0.09 3.35E-06 
rs17790795 
 
8 57835147 a t 0.10 7339 ++-++ 0.11 0.02 3.76E-06 
rs147099958 SH3RF3 2 110037118 c g 0.08 7339 +++++ 0.15 0.03 3.88E-06 
rs201412779 
 
10 8545238 d i 0.34 7339 ----+ -0.07 0.02 3.93E-06 
rs113045433 
 
4 67219961 t c 0.01 7339 +++++ 0.31 0.07 4.08E-06 
rs113574066 
 
16 14080683 c g 0.02 6495 +++?+ 0.26 0.06 4.19E-06 
rs111794147 
 
16 14087498 t c 0.02 6495 +++?+ 0.27 0.06 4.38E-06 
rs143925020 
 
16 14084386 a g 0.98 6495 ---?- -0.26 0.06 4.94E-06 
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Table 5 Meta-analysis results of 24-hour sodium excretion, 24-hour potassium excretion, 
sodium-to-potassium ratio with adjustment for BMI and height for all loci brought forward for 
replication (P <5x10-6 from discovery meta-analysis) in Aim 1 
 
Chr, chromosome; A1, effect allele; A2, non-effect allele; EAF, effect allele frequency 
Increasing beta indicates higher excretion of sodium and potassium 
Nearest Gene: Genes near index SNP (± 5Kb Upstream/Downstream distance bp) 
Gene names were obtained using variant effect predictor (VEP) from Ensembl using GRCh37 
Genes with intragenic index variants bolded. 
Direction of effect in GENOA, PREVEND, HpyperGEN EA, HAPI Heart, and FHS in European 
ancestry, respectively 
 
24-hour sodium excretion  
SNP Nearest Gene Chr Position A1 A2 EAF N Direction Beta SE P 
rs71639080 FCGR2B 
FCGR2C 
RP11-25K21.6 
FCGR3A 
1 161565867 t c 0.02 1651 +??+? 69.41 11.94 6.21E-09 
rs145860590 
 
1 151325810 d i 0.02 5670 ++-?? 21.55 3.98 6.22E-08 
rs188869607 RPL9P28 
CTD-2377D24.2 
CTD-2377D24.8 
17 46764522 a t 0.48 7315 ++-++ 4.93 0.93 1.23E-07 
rs117259059 MLLT11 
CDC42SE1 
1 151034164 t c 0.02 6471 +++?- 17.96 3.61 6.46E-07 
rs139574219 
 
7 110287083 t c 0.99 1608 -???- -43.49 8.81 7.88E-07 
rs192132524 GABPB2 1 151064827 t c 0.03 5214 ++??- 16.10 3.26 7.95E-07 
rs16852403 
 
1 178039226 t c 0.80 7315 +++++ 5.21 1.06 8.21E-07 
rs202066699 
 
20 22448711 d i 0.99 5707 ?---? -29.34 5.96 8.52E-07 
rs144955294 
 
7 110262691 t c 0.01 1608 +???+ 43.85 8.98 1.04E-06 
rs6662255 
 
1 178040083 t c 0.21 7315 ----- -5.16 1.06 1.08E-06 
rs6703721 
 
1 178037791 t c 0.21 7315 ----- -5.06 1.05 1.38E-06 
rs73192435 
 
13 53525710 a g 0.92 7315 +++++ 7.75 1.63 1.96E-06 
rs11583320 
 
1 178042145 t c 0.80 7315 +++++ 5.04 1.06 2.05E-06 
rs73049336 
 
1 178042298 a t 0.80 7315 +++++ 5.03 1.06 2.17E-06 
rs149456297 COMMD10 5 115468458 a g 0.98 6514 ++++? 24.05 5.08 2.20E-06 
rs3847055 
 
7 97680645 a g 0.72 7315 ++++- 4.53 0.96 2.20E-06 
rs12538837 
 
7 97684468 t c 0.72 7315 ++++- 4.52 0.96 2.21E-06 
rs4750189 
 
10 6299461 a t 0.99 6471 +++?+ 23.58 5.01 2.51E-06 
rs847573 
 
7 97681761 t c 0.29 7315 ----+ -4.42 0.94 2.66E-06 
rs190632626 IBTK 6 82935144 a t 0.94 5257 --?-? -16.48 3.52 2.83E-06 
rs111674304 
 
1 178043192 t c 0.80 7315 +++++ 4.96 1.06 3.06E-06 
rs7691513 SETD7 4 140498292 t c 0.22 7315 ++++- 4.82 1.04 3.38E-06 
rs10445381 RPL9P28 
CTD-2377D24.2 
CTD-2377D24.8 
17 46766306 a g 0.45 7315 +++++ 4.00 0.86 3.41E-06 
rs34262838 
 
7 97675148 t c 0.27 7315 ----+ -4.47 0.96 3.43E-06 
rs4713599 TAP1 
PSMB8 
6 32811530 a c 0.92 7315 ----- -7.70 1.66 3.46E-06 
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24-hour potassium excretion 
TAP2 
PSMB9 
TAPSAR1 
rs144364970 RPL9P28 
CTD-2377D24.2 
CTD-2377D24.8 
17 46772982 d i 0.55 7315 ----- -4.03 0.87 3.46E-06 
rs3096643 RPL9P28 
CTD-2377D24.2 
CTD-2377D24.8 
17 46769448 t g 0.55 7315 ----- -4.00 0.86 3.66E-06 
rs59849088 SETD7 4 140499281 d i 0.22 7315 ++++- 4.80 1.04 3.69E-06 
rs112609688 CTD-2377D24.8 17 46775760 t c 0.45 7315 +++++ 4.04 0.88 3.91E-06 
rs184839545 ANTXR2 4 81038950 a c 0.01 7315 ++-++ 21.30 4.62 4.07E-06 
rs706327 SETD7 4 140508093 a g 0.27 7315 ++++- 4.49 0.98 4.27E-06 
rs182605199 
 
2 74951285 t c 0.02 5257 ++?+? 23.99 5.22 4.33E-06 
rs75040643 RBM47 4 40577657 c g 0.03 7315 ----- -15.89 3.46 4.41E-06 
rs77416301 PI4KB 
ZNF687 
1 151266354 t c 0.03 6471 +++?- 15.07 3.29 4.63E-06 
rs181407375 
 
1 151455888 a t 0.96 7315 --+-- -12.86 2.81 4.70E-06 
rs185109580 CLMP 11 122951118 t c 0.99 1608 -???- -47.79 10.46 4.93E-06 
SNP Nearest Gene Chr Position A1 A2 EAF N Direction Beta SE P 
rs111345501 PATZ1 
RP3-400N23.6 
22 31719404 t g 0.01 4861 ?++?? 13.58 2.53 8.11E-08 
rs114543420 RP11-431M7.2 4 36358412 a g 0.99 1608 -???- -19.12 3.80 4.79E-07 
rs76323568 TSPEAR 
KRTAP10-11 
KRTAP12-4 
21 46070028 a g 0.04 6058 ++?++ 5.28 1.06 6.42E-07 
rs4262910 BCL2A1 15 80248501 a g 0.16 7313 +++++ 2.43 0.49 8.69E-07 
rs139944666 OFCC1 6 9725540 a g 0.73 7313 +++++ 1.84 0.37 8.94E-07 
rs71409269 BCL2A1 15 80249333 t c 0.12 7313 ++-++ 2.66 0.54 9.09E-07 
rs71409267   15 80245221 t g 0.83 7313 ----- -2.40 0.49 9.28E-07 
rs78881198   2 225434223 t c 0.01 2056 ??+?+ 19.63 4.00 9.55E-07 
rs142142409   15 80245922 d i 0.16 7313 +++++ 2.40 0.49 9.75E-07 
rs201920383 LINC00672 17 37086244 d i 0.09 5257 ++?+? 3.61 0.74 1.00E-06 
rs12206466 OFCC1 6 9726060 a t 0.70 7313 +++++ 1.74 0.36 1.14E-06 
rs1410361 OFCC1 6 9720100 t c 0.71 7313 +++++ 1.75 0.36 1.16E-06 
rs6836562   4 148278891 t c 0.16 7313 +++++ 2.34 0.48 1.19E-06 
rs78755596 ABO 
RP11-430N14.4 
9 136124590 a t 0.06 7313 +++++ 4.61 0.95 1.24E-06 
rs112414910 EIF4ENIF1 
SFI1 
DRG1 
22 31886109 c g 0.98 6469 +--?+ -7.84 1.62 1.24E-06 
rs56067143 OFCC1 6 9718581 t c 0.71 7313 +++++ 1.74 0.36 1.30E-06 
rs10456766 OFCC1 6 9723199 a g 0.70 7313 +++++ 1.72 0.36 1.42E-06 
rs4498339 OFCC1 6 9720266 a g 0.29 7313 ----- -1.73 0.36 1.57E-06 
rs73723509 OFCC1 6 9734887 a g 0.70 7313 +++++ 1.71 0.36 1.66E-06 
rs79278948 OFCC1 6 9718880 a g 0.70 7313 +++++ 1.73 0.36 1.67E-06 
rs200543390   11 42492593 d i 0.12 7313 +++++ 2.51 0.53 1.71E-06 
rs10949284 OFCC1 6 9750430 t c 0.70 7313 ??++? 1.71 0.36 1.75E-06 
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rs139376539   6 125681952 c g 0.01 2099 +++++ 19.58 4.09 1.75E-06 
rs6919349 OFCC1 6 9743243 a t 0.70 7313 +++++ 1.70 0.36 1.78E-06 
rs6936947 OFCC1 6 9743225 t g 0.30 7313 ----- -1.70 0.36 1.78E-06 
rs7765635 OFCC1 6 9751165 t g 0.70 7313 +++++ 1.70 0.36 1.80E-06 
rs12197949 OFCC1 6 9740445 t g 0.70 7313 +++++ 1.70 0.36 1.82E-06 
rs10949276 OFCC1 6 9743309 a t 0.70 7313 +++++ 1.70 0.36 1.82E-06 
rs6906634 OFCC1 6 9748140 a c 0.70 7313 +++++ 1.70 0.36 1.86E-06 
rs201934692   11 42492594 d i 0.12 7313 +++++ 2.50 0.52 1.87E-06 
rs143513312   11 42492595 d i 0.12 7313 +++++ 2.50 0.52 1.87E-06 
rs10949277 OFCC1 6 9743509 t c 0.70 7313 +++++ 1.70 0.36 1.88E-06 
rs4765208 BRI3BP 12 125519633 t c 0.71 7313 ----- -1.86 0.39 1.97E-06 
rs12194264 OFCC1 6 9738557 t c 0.70 7313 +++++ 1.70 0.36 2.04E-06 
rs185185619   1 37906000 a c 0.99 4413 --??? -11.36 2.39 2.10E-06 
rs200218912   2 119115839 d i 0.89 7313 ----- -3.91 0.82 2.12E-06 
rs150588856   21 40450627 d i 0.06 2900 ??+++ 6.17 1.31 2.27E-06 
rs78761110 CUL3 2 225429316 t g 0.99 2056 ??-?- -18.63 3.94 2.28E-06 
rs145526382 ABO 
RP11-430N14.4 
9 136121623 t c 0.06 7313 +++++ 4.43 0.95 2.82E-06 
rs143562963   13 73815106 a g 0.01 6506 ?+-++ 7.68 1.64 2.86E-06 
rs79810257 TSPEAR 
KRTAP12-2 
21 46083419 t c 0.04 6058 ++?++ 4.83 1.03 2.92E-06 
rs189560660   2 129472735 t c 0.99 4413 ++??? 12.89 2.76 3.04E-06 
rs12195113 OFCC1 6 9754520 a t 0.30 7313 ----- -1.67 0.36 3.05E-06 
rs199783078 OFCC1 6 9760632 d i 0.70 7313 +++++ 1.67 0.36 3.20E-06 
rs3038005 OFCC1 6 9760633 d i 0.70 7313 +++++ 1.67 0.36 3.24E-06 
rs12212374 OFCC1 6 9754467 c g 0.30 7313 ----- -1.67 0.36 3.38E-06 
rs113305219   2 179948126 a c 0.01 1651 +??+? 14.53 3.13 3.50E-06 
rs184017158   6 37383326 t c 0.97 6469 --+?- -7.20 1.55 3.51E-06 
rs79332849 UNC13C 15 54301716 c g 0.03 7313 ----- -4.44 0.96 3.60E-06 
rs188284329   11 42538203 a c 0.91 7313 ----- -2.81 0.61 3.60E-06 
rs719947 OFCC1 6 9760323 t c 0.70 7313 +++++ 1.66 0.36 3.71E-06 
rs11142909 RPL35AP21 9 74207717 t c 0.04 2900 ??+++ 6.19 1.34 4.10E-06 
rs11142908 RPL35AP21 9 74207715 t g 0.96 2900 ??--- -6.19 1.34 4.11E-06 
rs11142910 RPL35AP21 9 74207739 t c 0.04 2900 ??+++ 6.19 1.34 4.11E-06 
rs72737924 RPL35AP21 9 74208364 t c 0.04 2900 ??+++ 6.19 1.34 4.13E-06 
rs28623525   4 148291243 t c 0.82 7313 ----- -1.96 0.43 4.32E-06 
rs6836525   4 148278846 t c 0.18 7313 +++++ 1.98 0.43 4.34E-06 
rs28720373   4 148291242 t c 0.18 7313 +++++ 1.96 0.43 4.37E-06 
rs11142911 RPL35AP21 9 74207812 a g 0.04 2900 ??+++ 6.18 1.35 4.38E-06 
rs138370749 DLEU2 13 50617864 t c 0.99 1608 -???- -16.74 3.65 4.43E-06 
rs72857549   2 30151870 a g 0.98 7313 +++++ 6.42 1.40 4.44E-06 
rs4819363   21 45421448 c g 0.96 1651 -??-? -9.54 2.08 4.51E-06 
rs149875098   8 134673221 t c 0.02 4407 ?-??- -9.26 2.02 4.54E-06 
rs116446684 CUL3 2 225384862 t c 0.01 2863 +?+?+ 14.55 3.17 4.55E-06 
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Sodium-to-potassium ratio 
SNP Nearest Gene Chr Position A1 A2 EAF N Direction Beta SE P 
rs77958157 
 
5 71166807 a c 0.01 4413 ++??? 0.52 0.09 2.33E-08 
rs148459019 
 
6 32836582 t g 0.01 4407 ?+??+ 0.42 0.08 3.71E-08 
rs142729205 
 
3 140538834 d i 0.90 7311 +++++ 0.15 0.03 1.81E-07 
rs72987180 
 
3 140538648 a g 0.90 7311 +++++ 0.15 0.03 1.91E-07 
rs115322212 
 
3 140538274 c g 0.92 7311 +++++ 0.16 0.03 2.59E-07 
rs57782376 
 
3 140537390 a g 0.92 7311 +++++ 0.16 0.03 4.93E-07 
rs117738029 CTD-2307P3.1 14 43033528 a t 0.97 7311 +++++ 0.24 0.05 1.59E-06 
rs189926695 
 
6 78194765 a g 0.17 6467 --+?- -0.12 0.02 1.78E-06 
rs4845198 RP11-398M15.1 1 189786356 a g 0.19 7311 ---+- -0.09 0.02 1.85E-06 
rs184355489 KIRREL3 11 126822059 a t 0.99 1651 -??-? -0.88 0.19 1.88E-06 
rs114631099 RP11-483H11.1; 
CTC-228N24.1 
5 127126945 a g 0.99 4859 ?++?? 0.42 0.09 1.90E-06 
rs9427449 RP11-398M15.1 1 189786693 a g 0.18 7311 ---+- -0.09 0.02 2.19E-06 
rs1339433 RP11-398M15.1 1 189783443 a g 0.82 7311 +++-+ 0.09 0.02 2.28E-06 
rs4845199 RP11-398M15.1 1 189786362 a g 0.18 7311 ---+- -0.09 0.02 2.88E-06 
rs201948417 RP11-433C9.2; 
EIF2B5 
3 184133284 d i 0.92 7311 --+-- -0.14 0.03 2.92E-06 
rs113045433 
 
4 67219961 t c 0.02 7311 +++++ 0.30 0.07 3.31E-06 
rs2418519 
 
1 189818353 t c 0.22 7311 ---+- -0.08 0.02 3.55E-06 
rs115979281 CTC-228N24.1 5 127143872 t c 0.01 4859 ?--?? -0.42 0.09 3.97E-06 
rs73007388 
 
3 6445318 a g 0.97 6467 --+?- -0.22 0.05 4.80E-06 
rs67929684   15 80336031 t g 0.95 7313 ----- -3.67 0.80 4.60E-06 
rs72788784   16 64818665 a g 0.01 6469 +++?+ 9.24 2.02 4.65E-06 
rs71308048   15 80333868 d i 0.95 7313 ----- -3.62 0.79 4.75E-06 
rs74459597   13 73795820 a g 0.02 5257 -+?+? 8.84 1.93 4.79E-06 
rs72737927   9 74218054 t c 0.04 2900 ??+++ 6.16 1.35 4.88E-06 
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Table 6 Replication of SNPs from the meta-analysis results of 24-hour sodium excretion, 24-hour potassium excretion, sodium-to-
potassium ratio in African Americans and Asians (P <5x10-6 from discovery meta-analysis) in Aim 1. 
 
Replication in African Americans 
 
Replication in Asians 
 
Chr, chromosome; A1, effect allele; A2, non-effect allele 
Increasing beta indicates higher excretion of sodium and potassium 
Results displayed for SNPs with P value ≤ 0.05 in replication analysis 
Analysis SNP Chr Position A1 A2 N Beta SE P 
Potassium (adjusted for BMI and height) rs200543390 11 42492593 I D 1244 -6.82 3.06 0.026 
Potassium (adjusted for BMI and height) rs201934692 11 42492594 I D 1244 -6.79 3.06 0.027 
Potassium (adjusted for BMI and height) rs143513312 11 42492595 I D 1244 -6.79 3.06 0.026 
Potassium (adjusted for BMI and height) rs188284329 11 42538203 A C 1244 -12.46 6.36 0.050 
Analysis SNP Chr Position A1 A2 N Beta SE P 
Sodium  rs72653410 11 134216182 C A 869 6.82 3.34 0.031 
Potassium (adjusted for BMI and height) rs74459597 13 73795820 G A 2221 5.08 2.46 0.031 
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Table 7 Replication of previously identified SNP rs12092050 from Tabara et al. 2015 in Aim 1 
 
Outcome Race/Ethinicity Covariates EA N Beta SE P 
GWAS results of sodium, potassium, and sodium-to-potassium ratio           
Sodium European Ancestry age, sex a 7344 -0.02 0.96 0.985 
Sodium African American age, sex a 1246 3.37 6.09 0.580 
Sodium Asian (Korean) age, sex g 2458 0.68 2.53 0.774 
Potassium European Ancestry age, sex a 7346 0.11 0.36 0.764 
Potassium African American age, sex a 1246 1.70 2.14 0.428 
Potassium Asian (Korean) age, sex g 2462 -1.42 0.86 0.085 
Sodium-to-potassium ratio European Ancestry age, sex a 7339 0.00 0.02 0.804 
Sodium-to-potassium ratio African American age, sex a 1233 0.00 0.13 0.999 
Sodium-to-potassium ratio Asian (Korean) age, sex g 2417 0.07 0.04 0.058 
GWAS results of sodium, potassium, and sodium-to-potassium ratio adjusted for BMI and height    
Sodium European Ancestry age, sex, BMI, height a 7315 0.16 0.92 0.865 
Sodium African American age, sex, BMI, height a - - - - 
Sodium Asian (Korean) age, sex, BMI, height g 2458 1.03 2.50 0.657 
Potassium European Ancestry age, sex, BMI, height a 7313 0.11 0.36 0.751 
Potassium African American age, sex, BMI, height a 1244 1.63 2.14 0.447 
Potassium Asian (Korean) age, sex, BMI, height g 2462 -1.42 0.85 0.086 
Sodium-to-potassium ratio European Ancestry age, sex, BMI, height a 7311 0.01 0.02 0.709 
Sodium-to-potassium ratio African American age, sex, BMI, height a 1231 0.00 0.13 0.993 
Sodium-to-potassium ratio Asian (Korean) age, sex, BMI, height g 2417 0.07 0.04 0.044 
 
Results in European ancestry are from the meta-analysis 
Significant P value (P<0.05) bolded 
EA: Effect allele 
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CHAPTER III: Gene-based associations and effect modification underlying variation in 
sodium intake, potassium intake, and their ratio in two European American cohorts 
 
3.1 Introduction 
Excess sodium intake and insufficient potassium intake are established risk factors for 
hypertension and cardiovascular disease (CVD) [2, 53, 97]. In 2010, about 1.7 million, or 9.5%, 
of all deaths from cardiovascular causes were attributed to high sodium intake globally [5]. On 
the other hand, potassium is a established protective factor for hypertension and related CVD.  
Individual sodium intake and potassium intake have a wide range of variability in the human 
population and are influenced by many factors. [32, 33]. The determinants of sodium and 
potassium intake have not been fully defined, but physiological, physical, developmental, 
cultural, genetic, and environmental factors as well as the interactions among these factors have 
been reported to influence variation in individual sodium and potassium intake [16, 27, 34]. In 
this Aim, we use gene-level association methods to better understand the relationship between 
genetic variation in genomic regions and variation in individual sodium and potassium intake, 
including the potential for interaction with sex, age, and education, since consumption differs 
from recommended values for men, older people, and people with low education [10]. 
Although many common disease risk factors have high heritability, genetic variants 
discovered from GWAS usually explain only a small portion of heritability, a phenomenon 
typically called “missing heritability.” Identifying gene-environment interactions, as well as rare 
genetic variants that have not been detected by GWAS, could reduce the gap between estimated 
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heritability and the portion of trait variation explained by genetic factors [98, 99]. To 
characterize susceptible populations and better explain the variation in sodium and potassium 
intake, it is necessary to identify genetic effects and gene-by-environment interactions on sodium 
and potassium intake using common and rare genetic variants data [10]. However, to our 
knowledge, no study exists that investigates gene-environment interaction for sodium and 
potassium intake. In the present study, we investigate whether the effects of genetic factors that 
influence sodium and potassium intake differ based on an individual's age, sex, and education 
level. 
 
3.2 Methods 
Study populations 
The analyses were conducted using two European American cohorts. The Genetic 
Epidemiology Network of Arteriopathy (GENOA) study [60] is a community-based study that 
aims to identify genes influencing blood pressure in participants from Rochester, MN and 
Jackson, MS. The study recruited sibships with at least two adults with clinically diagnosed 
essential hypertension before 60 years of age and then enrolled all available siblings within the 
family [60]. The Framingham Heart Study (FHS) is a community-based study that began in 1948 
with the recruitment of an original cohort to identify risk factors for CVD and other chronic 
disease from the town of Framingham, MA, who had not yet developed CVD. The FHS cohort 
continued to recruit the second generation of study participants (children and spouses of children 
of the original cohort) in 1971 and a third generation of study participants (children of offspring 
cohort participants) in 2002-2005. Urinary sodium and potassium excretions were measured in 
the Offspring Study participants approximately every 4 years [64]. The analyses included a total 
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of 811 GENOA and 766 FHS participants who had genotype data and measurements of 24-hour 
urinary sodium excretion, 24-hour urinary potassium excretion, and adjustment variables 
including age, sex and education level. 
 
Measurements 
Sodium and potassium intake were quantified as continuous variables (mmol/day) from 
urine collections. In GENOA, urine was collected with toluene as a preservative, and twenty-
four-hour urinary sodium and potassium excretions were measured in the Mayo Clinic Renal 
Testing Laboratory [100]. In FHS, the urinary sodium and potassium excretions were measured 
using an automated Ion-Selective Electrode (ISE) in the Offspring cohort. In each study, 24-hour 
sodium and potassium excretion measures were checked for normality, and outliers ± 4 standard 
deviations from the mean were removed. 
For age, participants were grouped as age 65 and older or less than 65. For education 
level, participants were characterized as having less than a college/university education or having 
at least a college/university education. 
 
Genotyping and imputation 
GENOA participants were genotyped using the Affymetrix 6.0 (91.9 % of sample) arrays 
or the Illumina Human 1M-Duo, 660-Quad, or 610-Quad (8.1% of sample) genotyping arrays as 
well as the Illumina HumanExome Beadchip. In FHS, the genotyping was measured using the 
Affymetrix 500K/50K array and the Illumina HumanExome Beadchip. Each cohort performed 
internal quality control (QC) assessments of initial genotype data including excluding individuals 
with poor genotype call rate (i.e., <95%) and checking for relatedness across individuals. Quality 
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checks for single nucleotide polymorphisms (SNPs) included exclusion of SNPs with poor call 
rate (i.e., <95%), SNPs with Hardy-Weinberg disequilibrium P<10-4, SNPs with high duplicate 
discordance rates, and monomorphic SNPs. Imputation for the Affymetrix genotype data and the 
Illumina Human 1M-Duo genotype data was performed using the 1000 Genomes Project Phase I 
Integrated Release Version 3 [March 2012] cosmopolitan reference panel using IMPUTE version 
2 in GENOA and MACH in FHS. Genotyping variants with imputation quality less than 0.3 
were excluded before the analysis.  
 
Statistical analysis 
We investigated gene-level associations and their interactions with age, sex, and 
education level in gene regions near SNPs that had significant (P<5X10-8) or suggestive (P< 
5X10-6) association with 24-hour urinary sodium excretion, potassium intake, and sodium-to-
potassium intake ratio in GWAS from Aim 1. For those genes near SNPs with at least suggetive 
significance (P<5X10-6) in Aim 1, we first tested the gene-level associations with each trait, and 
then evaluated the effect modification by sex, age, and education level on the gene-level 
associations in GENOA and FHS. We used a powerful set of kernel-based methods to test gene-
level associations and gene-by-age, gene-by-sex, and gene-by-education level interactions [101, 
102].  
In order to use the existing SKAT and iSKAT program that were developed for unrelated 
samples, we transformed 24-hour urinary sodium and potassium excretion measured from related 
samples (GENOA and FHS) using GRAMMAR+ before the analysis [103]. SKAT is a 
supervised, flexible, and efficient score-based variance-component test to evaluate association 
between genetic variants and traits in a gene- or genomic-region [101, 102]. All position 
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information was based on genome assembly GRCh37, and the start and end position of each 
gene was defined by GENCODE annotation version 19. All SNPs within a gene region were 
used for each gene in the SKAT analysis. In GENOA, age, sex, and 4 principal components 
(PCs) were included as covariates for SKAT analysis. In FHS, age and sex were included as 
covariates. For gene-environment interactions, we used the interaction sequence kernel 
association test (iSKAT), which is an extension of SKAT methods [104, 105]. Similar to SKAT, 
iSKAT uses the score statistic after adjusting for the main effects of the gene and factors 
underlying differences in sodium and potassium intake (age, sex, and education level). In the 
analysis evaluating gene-by-age ≥ 65 interactions, sex was included in the model as a covariate, 
and when evaluating the gene-by-sex interaction, age was included in the model as a covariate. 
For an analysis of gene-by-education interactions, both age and sex were included in the model, 
and the analysis was only conducted in GENOA. In GENOA, 4 PCs were additionally added to 
the models. The results for genes with number of genetic markers greater than 1,000 were 
excluded to have reliable results in the SKAT and iSKAT analyses. For weighting methods in 
SKAT and iSKAT, we used beta (1, 25) to upweight the rare variants from exome chip data, and 
beta (1, 1) to give equal weight to all variants from 1000G data. To resolve the multiple 
comparison problem, we calculated FDR adjusted P values, and all variants with FDR adjusted P 
value less than 0.1 were considered significant.  
 
3.3 Results 
The characteristics of the participants from the two European American cohorts, GENOA 
and FHS, are shown in Table 8. The participants in FHS were, on average, 4.5 years younger 
than those in GENOA (70.2 years in FHS and 65.7 years in GENOA). In GENOA, more than 
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95% of participants had at least a high school education, and almost 20% of participants had at 
least a college/university education. Additionally, almost 90% of participants in GENOA were 
hypertensive while only 52.6% of FHS participants were hypertensive. The 24-hour urinary 
sodium excretion level in GENOA was 139.4 on average and that of FHS was 136.5 mmol/day. 
On the other hand, the 24-hour urinary potassium in GENOA was 58.5 mmol/day on average and 
that of FHS was 67.9. As a result, the average sodium-to-potassium ratio was 2.5 in GENOA and 
2.1 in FHS. 
 
Gene-based associations with 24-hour sodium excretion, 24-hour potassium excretions, and 
sodium-to-potassium ratio 
We had a total of 26, 23, and 6 genes to evaluate the gene-based association using SKAT 
and iSKAT with 24-hour urinary sodium excretion, 24-hour potassium excretion, and sodium-to-
potassium ratio, respectively (Table 9). Table 10 and Table 12 show the P-values of gene-based 
association between genes and 24-hour urinary sodium excretion, 24-hour potassium excretion, 
and sodium-to-potassium ratio using 1000G and exome chip data in GENOA and FHS. 
In GENOA, we found 4 and 2 genes that had at least a marginal significance (P<0.05) for 
24-hour sodium excretion and 24-hour potassium excretion, respectively, using the gene-based 
analysis. Of the 6 genes, 3 genes had P values that passed FDR correction (FDR adjusted P value 
< 0.1): 1) SETD7 gene-region on chromosome 4 from the SKAT analysis of 24-hour urinary 
sodium excretion using 1000G data (P value=0.004); 2) genes ASH1L on chromosome 1 and 
RP11-431M7.2 on chromosome 4 from the SKAT analysis for 24-hour urinary potassium 
excretion using exome chip data (P=0.007 and 0.002, respectively). 
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In FHS, we found 2 gene-based associations with P-value <0.05 for each excretion trait 
(24-hour urinary sodium excretion, 24-hour potassium excretion, and sodium-to-potassium 
ratio). Out of 6 genes, BRO3BP and LINC00672 genes had FDR adjusted P-value <0.1 in the 
gene-based association analysis for 24-hour potassium excretion (P=0.003 and 0.002, 
respectively), and RP11-433C9.2 gene also had FDR adjusted P-value <0.1 for sodium-to-
potassium ratio in the gene-based association analysis (P=0.016). 
 
Gene-by-age interactions, gene-by-sex interactions, and gene-by-college education interactions 
with 24-hour sodium excretion, 24-hour potassium excretions, and sodium-to-potassium ratio 
In the analysis of gene-by-environment interactions, 13 genes had at least marginally 
significant interactions (P<0.05) with age ≥ 65 years, sex, or college education on any of three 
outcome traits (24-hour urinary sodium excretion, 24-hour potassium excretion, and sodium-to-
potassium ratio) in GENOA (Table 11). Of the genes, gene TAPSAR1 had P-value that passed 
FDR correction (FDR adjusted P-value <0.1) from the analysis of gene-by-age ≥65 years 
interactions using exome chip data. CTC-228N24.1 had FDR adjusted P-value <0.1 from the 
both analysis of gene-by-sex interactions using 1000G data and gene-by-college education 
interactions using exome chip data. The genes RP11-433C9.2 and RP11-483H11.1 also had FDR 
adjusted P-value <0.1 from the analysis of gene-by-sex interactions using 1000G data and gene-
by-college education using exome chip data, respectively.  
In FHS, we found three genes that had at least a marginal significance (P<0.05) in the 
analyses of gene-by-age ≥65 years interactions (CDC42SE and MLLT11) or gene-by-sex 
interactions (PSMB9) on 24-hour sodium excretion using 1000G data, but none of the 
interactions had P-value that passed FDR correction (Table 11, FDR adjusted P-value <0.05) 
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3.4 Discussion 
In the present study, we evaluated the association between gene-regions and outcomes 
from a previous GWAS including 24-hour urinary sodium excretion, 24-hour urinary potassium 
excretion, and sodium-to-potassium ratio in two European ancestry cohorts, GENOA and FHS. 
To do this, we used a gene-based approach with genetic variants from both 1000G imputed data 
and exome chip data. In GENOA, we found 4 and 2 gene-regions that had P value less than 0.05 
in the SKAT analysis with 24-hour urinary sodium excretion or 24-hour urinary potassium 
excretion, respectively. In FHS, 2, 2, and 1 genes that had P-value less than 0.05 in the SKAT 
analysis with 24-hour urinary sodium excretion, 24-hour urinary potassium excretion, or their 
ratio, respectively. We also evaluated the interaction between genes and three demographic 
variables (age ≥ 65 years, sex, and college education) on 24-hour urinary sodium excretion, 24-
hour urinary potassium excretion, or their ratio using iSKAT and found 16 interactions in 
GENOA, and 3 in FHS that had P value less than 0.05. 
To identify the SNPs most strongly driving the association between the gene-region and three 
outcome phenotypes (24-hour sodium excretion, 24-hour potassium excretion, sodium-to-
potassium ratio) or gene-by-demographic factors (age ≥ 65 years, sex, and college education), 
each SNP-outcome phenotype association and SNP-by-demographic factor interaction were 
modeled within a gene-region with P-value less than 0.5 from SKAT and iSKAT analysis using 
1000 Genome imputed data (Figure 6 and 7). In the association analysis between the single SNP 
and the outcome variable, each SNP with the strongest signal was in linkage disequilibrium (LD) 
with multiple other SNPs in the regions of SETD7 and JOSD1 (24-hour sodium excretion) in 
GENOA, and BRI3BP and LINC00672 (24-hour potassium excretion) in FHS, respectively 
 
 
 
51 
(Figure 6). In the single SNP analysis of gene-by-sex on sodium to potassium ratio, each top 
SNP (rs245177 and rs6443960) was in high LD with multiple other SNPs in each gene-region of 
CTC-228N24.1 and RP11-433C9.2 in GENOA (Figure 7).  
We used the gene-level approach to reduce the burden of multiple testing of individual 
SNPs from Aim 1, and improve the power to detect significant effect modification in genetic 
associations with factors including age, sex, and education. Another benefit of using the gene-
based strategy lies in the characteristic of a gene-level analyses. It is well known that the SNPs 
that influence a trait may differ across ethnicities, even if the underlying genetic mechanisms are 
the same. However, genes are a functional unit, so they do not vary across race/ethnicity, even 
though allele frequency and linkage disequilibrium patterns may differ. These differences are 
due to the ancestral origins of mutation and linkage disequilibrium (SNP correlation) patterns 
that differ across ethnic groups. Although we used significant or suggestive SNPs from meta-
analysis in European American populations, we may replicate the significant SNPs from one 
ancestry group in a different ancestry group in the future. 
We set the age group cut-off at age 65 due to the aging process in human body. Many 
studies have examined the change in prevalence of disease in individuals age 65 and over and 
have found increased disease burden. For education level, we set the cut-off as completion of 
college/university education. This is because most of our participants had completed a high 
school education, and we wanted to evaluate the impact of a higher-level education in the 
association between gene and sodium/potassium sodium intake level. 
To illustrate the interaction effects, we created plots of interaction between top single 
SNPs (rs245177 for CTC-228N24.1 and rs6443960 for RP11-433C9.2) from the analysis of 
single SNP-by-sex interactions, and sex on sodium-to-potassium ratio in GENOA (Figure 7). 
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Average predicted sodium-to-potassium ratio values by top SNP genotype, adjusted for age and 
the top 4 PCs for each sex group are presented in the bottom of Figure 7. The average predicted 
sodium-to-potassium ratio level increased with each additional copy of C in female group, but 
not in male group for rs245177 genotype from CTC-228N24.1. In the stratified analyses by sex, 
rs6443960 genotype from RP11-433C9.2 was only associated with sodium-to-potassium level in 
male participants, and not in female participants in GENOA after adjusting for age and 4PCs (P 
in male group = 0.006 and P in female group = 0.26). Both CTC-228N24.1 (coiled-coil domain 
containing 192) on chromosome 5 and RP11-433C9.2 (long intergenic non-protein coding RNA 
2054) on chromosome 3 are protein coding genes, but there has been no research that supports 
the mechanism of how these genes would be associated with sodium-to-potassium ratio. 
The 24-hour urinary sodium and potassium excretion level were measured from related 
samples in GENOA and FHS. Although SKAT is able to work with correlated phenotypes using 
its advanced option of using a kinship matrix of the sample, the method has not been developed 
for iSKAT. Fortunately, the GRAMMAR+ from GeneABEL R package is able to transform 
traits from related samples into independent observations. The results from the standard SKAT 
analyses using the decorrelated phenotypes generated from GRAMMAR+ looked very similar to 
those from the advanced SKAT analyses that incorporated the familiar kinship matrix of 
samples. 
The strengths of this present study include: 1) evaluation and confirmation of the genetic 
association from Aim 1 using state-of-the-art gene-based approach with improved power, 2) 
using both rare and common variants in the analyses of association, 3) testing multiple 
interactions with gene and epidemiological factors including age, sex, and education level. 
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However, we could not evaluate the associations and interactions in several genes 
including KRTAP10-11 and KRTAP12-4 when using rare variants from exome chip data, since 
our data set did not include variants located in the gene-regions. We decided on this selection of 
genes using the meta-analysis where the two cohorts in current study were included (not from 
independent cohorts), which could lead the increase of type 1 error. However, in the results of 
Aim 2, only a few genes had an FDR-adjusted P-value less than 0.1 with sodium and potassium 
excretion levels and their ratio. The low rate of replication in this gene-based approach may be 
due to inadequate sample sizes because only two out of the five European ancestry cohorts from 
Aim 1 were used in Aim 2. In future studies, we will extend the gene-based analyses to other 
cohorts, and SKAT results will be combined by conducting a meta-analysis using skatMeta R 
package, which will improve the power in future analyses [106, 107]. Another potential reason 
that the majority of genes had weak associations or interactions with outcome phenotypes is that 
the number of markers for each gene in 1000G exceeded the recommend level by SKAT 
program (the number of recommended markers is smaller than the sample size divided by 3).  
The present study might help us better understand the genetics of sodium and potassium 
intake and explain missing heritability by using both common and rare variants as well as using 
advanced gene-based analytic strategies. Much more research is needed with larger cohorts, as 
we did not see significant replication of the gene-level findings in these two European cohorts.  
However, identifying preliminary evidence of effect modification of genetic effects on sodium 
and/or potassium intake by traditional epidemiological factors such as age, sex, and education 
does raise the important long-range question about how to tailor messaging about dietary 
behaviors to be more precise in order to have the desired health benefits for those individuals.    
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Table 8 The basic characteristics of participating cohorts from GENOA and FHS in Aim 2 
 
  
GENOA (N=811) FHS (N=766) 
Cohort Family-based Family-based 
Country USA USA 
Race/ethnicity European American European American 
Female (%) 57.6 53.1 
Age in years 65.7 ± 9.1 70.2 
   Age ≥ 65 years (%) 57.5 77.3 
Education   
   ≥ College/University (%) 19.5 - 
Hypertension, % 88.2 52.6 
Blood pressure lowering medication use, % 76.2 52.4 
24-h sodium excretion (mmol/day) 139.4 ± 58.3 136.5 ± 57.0 
24-h potassium excretion (mmol/day) 58.5 ± 22.9 67.9 ± 23.4 
Sodium-to-potassium excretion ratio 2.5 ± 1.0 2.1 ± 0.9 
Measurement of source 24-hour urine 24-hour urine 
 
For continuous variable: mean ± SD, For binary variable: %  
Abbreviations:  EA- European American; GENOA- Genetic Epidemiology Network of 
Arteriopathy; FHS- Framingham Heart Study  
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Table 9 Genes near genome-wide significant or suggestive SNPs from Aim 1 and number of 
genetic markers from 1000G and exome chip data available for each gene in Aim 2 analysis 
 
CHR: chromosome, START: start position of gene based on genome assembly GRCh37, END: 
end position of gene based on genome assembly GRCh37, 1000G: 1000 Genomes Project 
imputed data, Exome: exome chip data 
 
 
 
24-hour sodium excretion 
 
  
Gene 
  
CHR 
  
START 
  
END 
  
Gene 
size 
 (kb) 
GENOA FHS 
1000G 
Marker 
N 
Exome 
Marker 
N 
1000G 
Marker 
N 
Exome 
Marker 
N 
CDC42SE1 1 151023447 151042801 19.4 89 2 39 2 
MLLT11 1 151030234 151040970 10.7 53 1 21 1 
GABPB2 1 151043054 151098018 55.0 345 12 165 12 
RP11-25K21.6 1 161482966 161574889 91.9 460 6 4 7 
FCGR3A 1 161511549 161600917 89.4 513 6 0 6 
FCGR2B 1 161551101 161648444 97.3 579 5 26 5 
FCGR2C 1 161551129 161575452 24.3 133 2 0 2 
SETD7 4 140417095 140527853 110.8 592 7 412 7 
MUC22 6 30978251 31003179 24.9 529 46 568 40 
TAP2 6 32781544 32806599 25.1 369 63 369 61 
PSMB8 6 32808494 32812480 4.0 28 8 33 9 
TAPSAR1 6 32811863 32814272 2.4 26 6 28 6 
PSMB9 6 32811913 32827362 15.4 183 47 200 47 
TAP1 6 32812986 32821755 8.8 120 35 133 35 
GLB1L2 11 134201768 134248235 46.5 315 16 122 19 
CTD-2377D24.8 17 46760729 46781844 21.1 154 2 119 2 
CTD-2377D24.2 17 46767843 46767986 0.1 0 2 0 2 
RPL9P28 17 46768478 46769056 0.6 7 2 5 2 
AC005523.3 19 4785132 4791219 6.1 52 2 12 2 
DMC1 22 38914954 38966291 51.3 206 3 106 3 
CBY1 22 39052641 39069859 17.2 127 3 84 3 
RP3-508I15.9 22 39063590 39077825 14.2 109 3 84 3 
TOMM22 22 39077953 39080818 2.9 13 4 10 4 
JOSD1 22 39081548 39097561 16.0 61 2 29 2 
GTPBP1 22 39101728 39134304 32.6 138 4 83 4 
NPTXR 22 39214457 39239987 25.5 156 6 97 5 
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24-hour potassium excretion 
 
  
Gene 
  
CHR 
  
START 
  
END 
  
Gene 
size 
 (kb) 
GENOA FHS 
1000G 
Marker 
N 
Exome 
Marker 
N 
1000G 
Marker 
N 
Exome 
Marker 
N 
ASH1L 1 155305059 155532598 227.5 636 33 259 33 
CUL3 2 225334867 225450110 115.2 507 1 551 1 
RP11-431M7.2 4 36312812 36394032 81.2 627 5 652 5 
DDX31 9 135468384 135545788 77.4 396 37 377 38 
ABO 9 136125788 136150617 24.8 320 36 268 32 
RP11-430N14.4 9 136125788 136130950 5.2 59 2 46 2 
ARHGAP22 10 49654077 49864310 210.2 1332 20 1255 19 
BRI3BP 12 125478246 125515777 37.5 307 3 217 3 
DLEU2 13 50601269 50699856 98.6 349 2 396 2 
UNC13C 15 54305101 54920806 615.7 4471 41 4855 42 
ST20-MTHFS 15 80137537 80216096 78.6 617 15 698 14 
ST20 15 80191182 80216044 24.9 275 3 299 2 
C15orf37 15 80215113 80217194 2.1 22 2 21 1 
BCL2A1 15 80253231 80263788 10.6 59 7 49 7 
LINC00672 17 37081421 37084310 2.9 14 2 5 2 
TSPEAR 21 45917775 46131495 213.7 2025 81 872 70 
KRTAP10-11 21 46066331 46067564 1.2 13 1 2 0 
KRTAP12-4 21 46074130 46074576 0.4 3 2 2 0 
RP3-400N23.6 22 31688485 31734007 45.5 242 3 197 3 
PATZ1 22 31721790 31742218 20.4 104 7 76 7 
DRG1 22 31795509 31924726 129.2 728 18 679 17 
EIF4ENIF1 22 31832963 31892094 59.1 334 16 326 15 
SFI1 22 31884674 32014572 129.9 862 44 806 43 
 
Sodium-to-potassium ratio 
 
  
Gene 
  
CHR 
  
START 
  
END 
  
Gene 
size 
 (kb) 
GENOA FHS 
1000G 
Marker 
N 
Exome 
Marker 
N 
1000G 
Marker 
N 
Exome 
Marker 
N 
SH3RF3 2 109745804 110262207 516.4 2585 16 2527 17 
EIF2B5 3 183852826 184402546 549.7 3332 197 2204 195 
RP11-433C9.2 3 184119325 184157436 38.1 291 2 187 2 
CTC-228N24.1 5 127039082 127277326 238.2 996 2 1128 2 
RP11-483H11.1 5 127120310 127122734 2.4 11 2 13 2 
KLF12 13 74260226 74708394 448.2 2755 9 2452 9 
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Table 10 P-values for gene-based association between genes and 24-hour sodium excretion, 24-
hour potassium excretion, and sodium-to-potassium ratio in GENOA and FHS in Aim 2  
 
GENOA 
  24-hour sodium excretion 24-hour potassium excretion Sodium-to-potassium ratio 
Gene 
1000G 
(N=807) 
Exome 
(N=784) 
1000G 
(N=811) 
Exome 
(N=788) 
1000G 
(N=806) 
Exome 
(N=783) 
CDC42SE1 0.042 1.000     
MLLT11 0.048 1.000     
SETD7 0.004* 0.541     
JOSD1 0.029 1.000     
ASH1L   0.490 0.007*   
RP11-431M7.2   0.410 0.002*   
 
 
FHS 
  24-hour sodium excretion 24-hour potassium excretion Sodium-to-potassium ratio 
Gene 
1000G 
(N=766) 
Exome 
(N=753) 
1000G 
(N=766) 
Exome 
(N=753) 
1000G 
(N=766) 
Exome 
(N=753) 
GABPB2 0.519 0.041     
GTPBP1 0.461 0.020     
BRI3BP   0.003* 1.000   
LINC00672   0.002* 0.328   
RP11-433C9.2     0.328 0.016* 
 
1000G: Variants from 1000 Genomes Project imputed data 
Exome: Variants from exome chip data 
P-values bolded if < 0.05 
* indicates its FDR adjusted P-value <0.1 
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Table 11 P-values for gene-by-age ≥ 65, gene-by-sex, and gene-by-college education 
interactions on 24-hour sodium excretion, 24-hour potassium excretion, and sodium-to-
potassium ratio in GENOA and FHS in Aim 2 
 
GENOA 
  
  
gene-by-age ≥65 
interactions 
gene-by-sex 
interactions 
gene-by-college 
interactions 
Outcome Gene 1000G Exome 1000G Exome 1000G Exome 
24-hour sodium excretion PSMB9 0.057 0.030 0.030 0.603   
24-hour sodium excretion TAPSAR1 0.028 0.007*     
24-hour sodium excretion TAP1 0.008 0.020     
24-hour sodium excretion CTD-2377D24.8 0.038 0.323     
24-hour sodium excretion RPL9P28 0.034 0.323     
24-hour sodium excretion PSMB8 0.037 0.127     
24-hour sodium excretion SETD7   0.263 0.029   
24-hour sodium excretion GLB1L2     0.579 0.020 
24-hour potassium excretion ASH1L   0.854 0.048   
Sodium-to-potassium ratio CTC-228N24.1   0.005* 0.683 0.109 0.039* 
Sodium-to-potassium ratio RP11-433C9.2   0.021* -   
Sodium-to-potassium ratio RP11-483H11.1     0.285 0.039* 
 
FHS 
  
  
gene-by-age ≥ 65 
interactions 
gene-by-sex 
interactions 
gene-by-college 
interactions 
Outcome Gene 1000G Exome 1000G Exome 1000G Exome 
24-hour sodium excretion CDC42SE1 0.020 -     
24-hour sodium excretion MLLT11 0.016 -     
24-hour sodium excretion PSMB9   0.041 0.52   
 
1000G: Variants from 1000 Genomes Project imputed data 
Exome: Variants from exome chip data 
GENOA, Sample size for all SNPs/variants: 807; Sample size for rare variants: 784 
FHS, Sample size for all SNPs/variants: 766; Sample size for rare variants: 753 
 
P-values bolded if < 0.05 
- : No results due to no genetic variation by environment variable 
* indicates its FDR adjusted P-value <0.1
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Table 12 Total list of P-values for gene-based association between each gene and 24-hour 
sodium excretion, 24-hour potassium excretion, and sodium-to-potassium ratio in GENOA and 
FHS in Aim 2 
 
1000G: Variants from 1000 Genomes Project imputed data, Exome: Variants from exome chip 
data 
P-values bolded if < 0.05 
* indicates its FDR adjusted P-value <0.1 
 
24-hour sodium excretion  
 
 
GENOA FHS 
1000G Exome 1000G Exome 
Gene N P Value N P Value N P Value N P Value 
CDC42SE1 807 0.042 784 1.000 766 0.602 753 1.000 
MLLT11 807 0.048 784 1.000 766 0.604 753 1.000 
GABPB2 807 0.071 784 0.501 766 0.519 753 0.041 
RP11-25K21.6 807 0.384 784 0.995 766 0.959 752 0.859 
FCGR3A 807 0.550 784 1.000     753 1.000 
FCGR2B 807 0.462 784 0.526 766 0.486 753 0.375 
FCGR2C 807 0.108 784 1.000     753 1.000 
SETD7 807 0.004* 784 0.541 766 0.689 753 0.326 
MUC22 807 0.720 773 0.450 766 0.335 730 0.587 
TAP2 807 0.135 775 0.068 766 0.732 751 0.162 
PSMB8 807 0.546 784 0.158 766 0.515 753 0.095 
TAPSAR1 807 0.512 784 0.870 766 0.704 752 0.933 
PSMB9 807 0.538 784 0.522 766 0.458 749 0.142 
TAP1 807 0.421 784 0.844 766 0.367 750 0.336 
GLB1L2 807 0.655 784 0.878 766 0.309 752 0.256 
CTD-2377D24.8 807 0.193 784 0.109 766 0.313 753 0.639 
CTD-2377D24.2 - - 784 0.109 - - 753 0.639 
RPL9P28 807 0.899 784 0.109 766 0.901 753 0.639 
AC005523.3 807 0.119 784 0.882 766 0.165 753 0.860 
DMC1 807 0.142 784 1.000 766 0.760 753 0.488 
CBY1 807 0.067 784 0.512 766 0.483 753 0.314 
RP3-508I15.9 807 0.067 784 0.512 766 0.488 753 0.314 
TOMM22 807 0.093 784 1.000 766 0.563 753 1.000 
JOSD1 807 0.029 784 1.000 766 0.547 753 1.000 
GTPBP1 807 0.067 784 0.334 766 0.461 753 0.020 
NPTXR 807 0.867 784 0.269 766 0.756 753 0.655 
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24-hour potassium excretion  
 
 
GENOA FHS 
1000G Exome 1000G Exome 
Gene N P Value N P Value N P Value N P Value 
ASH1L 811 0.490 788 0.007* 766 0.063 752 0.729 
CUL3 811 0.261 788 0.780 766 0.500 753 0.495 
RP11-431M7.2 811 0.410 788 0.002* 766 0.233 753 0.340 
DDX31 811 0.858 788 0.270 766 0.144 753 0.932 
ABO 811 0.579 772 0.347 766 0.334 744 0.656 
RP11-430N14.4 811 0.830 788 1.000 766 0.142 753 1.000 
ARHGAP22 811 0.231 784 0.407 766 0.691 752 0.912 
BRI3BP 811 0.127 788 0.142 766 0.003* 753 1.000 
DLEU2 811 0.413 788 0.806 766 0.182 753 0.093 
UNC13C 811 0.090 785 0.242 766 0.097 751 0.636 
ST20-MTHFS 811 0.186 784 0.108 766 0.630 751 0.716 
ST20 811 0.165 784 0.845 766 0.773 752 0.400 
C15orf37 811 0.106 784 0.912 766 0.370 753 1.000 
BCL2A1 811 0.737 788 0.962 766 0.844 753 0.219 
LINC00672 811 0.198 788 0.965 766 0.002* 753 0.328 
TSPEAR 811 0.103 787 0.946 766 0.416 751 0.849 
KRTAP10-11 811 0.113 788 0.684 766 0.386 - - 
KRTAP12-4 811 0.206 788 0.684 766 0.351 - - 
RP3-400N23.6 811 0.868 788 0.810 766 0.714 753 0.724 
PATZ1 811 0.818 788 0.810 766 0.885 753 0.925 
DRG1 811 0.687 787 0.693 766 0.695 753 0.969 
EIF4ENIF1 811 0.607 787 0.693 766 0.618 753 0.969 
SFI1 811 0.389 783 0.861 766 0.831 753 0.527 
 
Sodium-to-potassium ratio 
 
  
 
GENOA FHS 
1000G Exome 1000G Exome 
Gene N P Value N P Value N P Value N P Value 
SH3RF3 806 0.785 783 0.817 766 0.462 749 0.734 
EIF2B5 806 0.605 765 0.677 766 0.256 746 0.639 
RP11-433C9.2 806 0.514 783 0.471 766 0.328 753 0.016* 
CTC-228N24.1 806 0.437 783 0.489 766 0.337 753 0.763 
RP11-483H11.1 806 0.203 783 0.489 766 0.910 753 0.763 
KLF12 806 0.184 783 0.993 766 0.240 753 0.333 
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Figure 6 Regional plots of P-values for single SNP association analysis with 24-hour sodium 
excretion, 24-hour potassium excretion, and sodium-to-potassium ratio in Aim 2 
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FHS 
 
24-hour potassium excretion using variants from 1000 Genomes Project imputed data 
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Figure 7 Plots of SNP-by-demographic factor interactions in Aim 2 
 
Regional Plot of p-values for single SNP analysis of gene-by-sex on sodium-to-potassium 
ratio in GENOA 
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Interaction between single SNP (rs245177 for CTC-228N24.1 and rs6443960 for RP11-
433C9.2) and sex on sodium-to-potassium ratio in GENOA 
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CHAPTER IV: A multi-ancestry genome-wide study of gene-sodium interaction 
underlying blood pressure variation 
 
4.1 Introduction  
High blood pressure is strongly related to cardiovascular disease (CVD) and chronic 
kidney disease (CKD) [108]. Consequently, for preventative purposes, both systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) are the most common intervention targets if 
one has been diagnosed with hypertension [109-111]. Mean arterial pressure (MAP), the average 
pressure in an individual's arteries during one cardiac cycle, and pulse pressure (PP), the 
difference between the systolic and diastolic pressure readings, are also often predictors of CVD 
[4, 112, 113]. 
Since measures of blood pressure (SBP, DBP, MAP, and PP) are complex phenotypes, 
identifying risk factors that could modify the genetic effects of blood pressure is being actively 
studied [44-46]. GWAS have identified numerous SNPs that are associated with SBP, but the 
identified associated genetic loci explain only a small portion of SBP and DBP variability, even 
though heritability is relatively high (~40-50%) [37-43]. Blood pressure is also influenced by an 
individual’s lifestyle including lack of physical activity, diet, alcohol and smoking; these lifestyle 
factors have become important intervention targets [114-116]. In particular, high sodium intake 
is a strong and independent risk factor for high blood pressure, has a large variation at both the 
individual and population level [32, 47, 48]. Thus, it is important to research whether and how 
individual sodium intake modifies the genetics of blood pressure, and to investigate whether 
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there are susceptible genetic groups within a population that are disproportionately affected by 
sodium intake. In epidemiological samples, measuring sodium excretion using 24-hour or 12-
hour urine collection is often used as a high-quality measure of sodium intake [117]. Li et al. 
recently conducted a study involving a genome-wide SNP-based and gene-based gene-sodium 
interaction analysis on SBP, DBP, MAP, and PP using one discovery cohort (N=1,876) and one 
replication cohort (N=775) in a Chinese population, and found 8 novel loci [118]. Sodium intake 
level was measured from a 24-hour urine sample in the discovery set and spot urine sample in 
replication set. Evaluating the gene-by-sodium intake interaction using larger multi-ethnic 
populations, including European and African ancestries with large sample sizes is needed to 
confirm and extend these preliminary findings. 
To examine the role of interactions between sodium intake and genetic variations on 
blood pressure, we conducted a meta-analysis of a genome-wide gene-by-sodium interaction 
study on blood pressure measures, including SBP, DBP, MAP, and PP using high-quality 
measurements of sodium intake (i.e. 24-hour or half-day urine samples) from 6 cohorts 
comprising almost 6,000 participants of European, African, and Asian ancestry.  
 
4.2 Methods 
The study is part of a series of multi-ancestry genome-wide interaction projects 
conducted by the Gene-Lifestyle Interactions Working Group within the Cohorts for Heart and 
Aging Research in Genomic Epidemiology (CHARGE) to assess the impact of genetic 
interactions with multiple lifestyle factors on cardiovascular traits [119]. Men and women 
between the ages of 18 and 80 from three ancestry groups were considered for analysis: 1) 
European ancestry (EA) - Genetic Epidemiology Network of Arteriopathy (GENOA), the 
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Hypertension Genetic Epidemiology Network (HyperGEN), and the Framingham Heart Study 
(FHS); 2) African ancestry (AA) – HyperGEN; and 3) Asian ancestry (AS) - Genetic 
Epidemiological Network of Salt-Sensitivity (GenSalt) study. The description of each study is 
included in Appendix 1. Participants were included if they had blood pressure measures, urinary 
sodium excretion measured from ≥ 8-hour urine sample, and imputed genotypes from the 1000 
Genomes Project reference panel. A total of 6 cohorts were included (N=6,020) in this study, 
with 2,547 EA, 1,650 AA, and 1,823 AS participants. 
Preliminary study 
For gene-by-sodium interaction analyses, 24-hour urinary sodium excretion level was 
dichotomized at a particular cut-off point to ensure interpretability of the regression model. To 
identify the appropriate dichotomization threshold of 24-hour urinary sodium excretion for the 
interaction analyses, we evaluated the relationship between 24-hour urinary sodium excretion 
and blood pressure measures (SBP and DBP) using data from GENOA, FHS, HyperGEN (EA 
and AA), and GenSalt. In addition, we also examined whether the relationship between sodium 
excretion and blood pressure differed by diuretic use, since the relationship between diuretic use 
and sodium excretion is not well established. Diuretics, which are medications that are designed 
to increase the amount of water and sodium excreted as urine, may help lower blood pressure 
and may influence the relationship between sodium intake and blood pressure. 
 Participants were grouped by their 24-hour urinary sodium excretion levels: group 1 
(<160 mmol/day, N=1,296), group 2 (≥160 and <220 mmol/day, N=1,373), group 3 (≥220 and 
<280 mmol/day, N=1,276), and group 4 (≥280 mmol/day, N=1,563). In each group, the weighted 
mean value for age- and sex-adjusted SBP and DPB values was first calculated by weighting by 
the sample size of each cohort. SBP and DBP differences in each sodium group were then 
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calculated by subtracting blood pressure in the reference group (sodium group 1) from blood 
pressure in each sodium group. We found linear relationships between blood pressure difference 
and sodium groups in all participants and in participants without diuretic use (Figure 8). 
The preliminary results showed that 220 mmol/day was an appropriate cutoff for 
dichotomization. Approximately 40% of participants in the preliminary study had 24-hour 
urinary sodium ≥ 220 mmol/day. Since the associations between blood pressure measures and 
24-hour urinary sodium excretion levels varied by use of diuretics, we decided to conduct the 
main analyses using 1) all participants and 2) participants without diuretic use.
 
Figure 8 The association between blood pressure difference and sodium groups in Aim 3 
 
Twenty-four-hour urinary sodium excretion levels: group 1 (<160 mmol/day, N=1,296), group 2 
(≥160 and <220 mmol/day, N=1,373), group 3 (≥220 and <280 mmol/day, N=1,276), and group 
4 (≥280 mmol/day, N=1,563). SBP and DBP difference value for each sodium group = blood 
pressure in each sodium group - blood pressure in the reference group (sodium group 1) 
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Phenotypes, urinary sodium excretion, and covariates 
Resting SBP (mmHg) and DBP (mmHg) were obtained. When multiple BP readings 
were available at the same visit, the average of all SBP readings and of all DBP readings were 
used. For subjects taking any blood pressure lowering medications, SBP and DBP values were 
adjusted by adding 15 mmHg to SBP and 10 mmHg to DBP [38, 120]. MAP (DBP + (SBP – 
DBP)/3) and PP (SBP – DBP) were also derived by using SBP and DBP values. SBP, DBP, 
MAP, and PP were analyzed separately. For each of the 4 blood pressure measures (SBP, DBP, 
MAP, and PP), outliers were set at 6 standard deviations (SD) from the mean. 
Sodium excretion level was measured either from 24-hour or half-day urine samples 
(Table 13). If urinary sodium excretion was measured from half-day urinary samples (>8-hour 
duration), simple volume-time linear extrapolation was used to estimate 24-hour urinary sodium 
excretions. Dichotomous urinary sodium excretion (SODIUM) was defined as 0 if 24-hour 
urinary sodium excretion was <220 mmol/day, and as 1 if 24-hour urinary sodium excretion was 
≥220 mmol/day. Information about covariates, including age, sex, and diuretic use, was also 
collected in each cohort. 
Genotyping 
The analyses for each cohort used the dosage of SNPs (chromosomes 1-22) imputed from 
the 1000 Genomes Project. For imputation, the ALL ancestry panel from 1000G Phase I 
Integrated Release Version 3 Haplotypes (March 2012) was used. The details of genotyping and 
genotype imputation for each cohort are described in Table 14. Each cohort applied a 
preliminary filter by excluding SNPs with very low imputation quality (R2 or INFO <0.1) and 
low minor allele frequency (MAF<0.01). Principal components (PCs) were included in the 
analysis to adjust for population stratification in each cohort [72]. 
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Statistical analysis 
Genome-wide association study in each cohort 
The genome-wide association study (GWAS) was conducted separately for each ancestry 
group within each cohort. Analyses were conducted separately for 1) all participants (ALL) and 
2) participants not taking diuretic medications (WOD). For each BP trait, a total of six analyses 
were conducted within each ancestry group: three models were used (MODEL 1, MODEL 2, and 
MODEL 3). 
In MODEL 1 (joint model), a regression model was used in each cohort that included 
both the genetic main effect and GxE interaction effects. MODEL 2 was additionally tested in 
each cohort to discern whether the SNP could be discovered without accounting for exposure and 
GxE interaction. MODEL 3, on the other hand, investigated the presence of G-E correlation. 
The models are as follows: 
MODEL 1 (Joint analysis of main and interaction effects): 
Y = β0 + βE1 E + βG1 G + βGE E * G + βC1C 
MODEL 2 (Analysis of main effect only): 
Y = β0 + βG2 G + βC2C 
MODEL 3 (Analysis of main effect adjusted for SODIUM): 
Y = β0 + βE3 E + βG3 G + βC3C 
where Y is the medication-adjusted blood pressure phenotype value; β0 is the intercept; E is 
dichotomous urinary sodium excretion; G is the dosage of the imputed genetic variant, coded 
additively; and C is the vector of covariates including age, sex, study-specific confounders, and 
PCs. 
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The genetic main effects (βG1, βG2, βG3), the GxE interaction term effect βGE1, their robust 
standard errors (SEs) and the robust covariance between the betas were collected in each cohort 
for each model. Robust estimates of SE and covariance were obtained because the error terms 
may not have the same variance across sodium excretion groups (heteroscedasticity) and there is 
a possibility of misspecification of the mean model [121, 122]. 
For association analyses in studies with unrelated subjects, linear regression with robust 
estimates of standard errors were conducted using ProbABEL [123]. For studies with related 
subjects, linear mixed models using a kinship matrix with a random polygenic component (for 
which the covariance matrix depends on the kinship matrix) were analyzed using ProbABEL or 
MMAP (Mixed Model Analysis in Pedigrees and Populations) [54] to account for family 
relationships. 
Quality Control (QC) before meta-analysis 
Before conducting the meta-analysis, individual GWAS results were cleaned by 
performing QC using the R package EasyQC [73]. In the study-level QC, the collected allele 
frequencies were checked against the ancestry-specific 1000 Genomes Project reference panel 
and genetic marker names were harmonized. In the meta-level QC, summary statistics for 
collected variables were compared in each specific analysis (e.g., SBP-Model1) across all 
cohorts. In addition, SE-N plot and QQ plots were used to check the errors in trait 
transformation, as well as other analytical problems. 
If imputation quality was < 0.1 in a given cohort, the genetic variants were preliminarily 
excluded; if the measure was <0.5, the genetic variants were further excluded in the QC step. In 
addition, genetic variants with low MAF or low imputation quality measures were excluded if 
min (MAC0, MAC1) * imputation quality measure was < 10 in European and Asian ancestry 
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groups, or <15 in African ancestry, where MAC0 = 2 * MAFE0 * NE0 for the unexposed group 
(with MAFE0 and sample size NE0 for E=0 stratum) and MAC1 = 2 * MAFE1 * NE1 for the 
exposed group. This ensured that the study only included stable cohort-specific results with a 
large enough sample size for each genetic variant in the meta-analyses. For family studies, NE 
was computed as (n+N)/2 where n= the number of sibships with at least one exposed member, 
and N= the total number of exposed subjects across all sibships. This is a compromise between 
using n alone (which underestimates NE as multiple exposed subjects in a family are counted 
only once) or N alone (which overestimates NE as this ignores sibling correlation). 
GWAS meta-analysis 
 Meta-analyses were conducted for those who did and did not use diuretics within each 
ancestry. For MODEL 1, two meta-analyses were performed in METAL: 1) 1 degree of freedom 
(DF) test of the interaction effect (SNP x E term) and 2) 2 DF test (joint fixed-effects) [124] that 
tested both the SNP main effect term and the SNP*E interaction term, while considering the 
covariance between them [74]. For the 1 DF test, a Wald test statistic was used that 
approximately follows a chi-squared distribution with 1 DF under H0: βGxE = 0. For the 2 DF test, 
a Wald test statistic was used, which approximately follows a chi-squared distribution with 2 DF 
under H0: βG = βGxE = 0. 
 For MODELs 2 and 3, the fixed-effects inverse-variance weighted meta-analysis of 
the SNP main effect term was conducted in METAL [74]. In the meta-analysis, genomic control 
correction [125] was applied first for cohort-specific GWAS results when lambda value > 1, and 
then again to the meta-analysis results. From the meta-analysis results, genetic variants were 
excluded if they were represented by GWAS data in fewer than 2 cohorts. Genetic variants that 
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were genome-wide significant (P < 5×10-8) or suggestive (P < 1×10-6) in any of the meta-
analyses will be replicated in independent cohorts in future studies. 
 
4.3 Results 
The characteristics of participating cohorts are shown in Table 13. All cohorts except JHS 
were family-based cohorts. The blood pressure measures and frequency of using diuretics were 
lowest in the Asian cohort (GenSalt). However, participants from GenSalt had highest portion of 
sodium excretion ≥220 mmol/day. 
From the analyses using all participants, out of about 5-9 million SNPs from meta-
analyses, we found 26 (EA), 91 (AA), and 17 (AS) genome-wide significant (2DF P < 5×10-8) or 
suggestive SNPs (2DF P < 1×10-6). When participants with diuretic use were excluded, 51 (EA), 
44 (AA), and 25 (AS) genome-wide significant (2DF P < 5×10-8) or suggestive SNPs (2DF P < 
1×10-6) were found in the meta-analyses (Table 16). 
In Table 15, we present the most significant SNP at 12 independent genetic loci that 
reached genome-wide significance (P < 5×10-8) in meta-analyses using the 2DF interaction test. 
From the meta-analysis results in African ancestry, six significant genetic loci were found. The 
most significant locus in AA was rs113300617 near FBXO10 and RP11-613M10.8 on 
chromosome 9 (2DF P=1.12×10-10). In EA, found significant loci near genes ZDHHC19 
(rs11185517, 2DF P=1.36×10-8), RUSC2 (rs17370852, 2DF P=2.41×10-12), U3 (rs17753104, 
2DF P=2.49×10-8), RP11-507B12.2 (rs7179425, 2DF P=9.40×10-9), and DCC (rs7243864, 2DF 
P=2.71×10-8). The genetic variant rs6922858 on chromosome 6 had a genome-wide significant 
P-value (2DF P=1.2×10-8) from multiple analyses (DBP in both ALL and WOD, MAP in WOD) 
in the Asian cohort. Table 16 provides all genome-wide significant results.  
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In the presence of interaction, it is well known that the main effects of a simple linear 
regression are difficult to interpret. By examining the p-values associated with the genetic main 
effects (βG1, βG2, βG3), the GxE interaction term effect βGE1, and the 2 DF test in Table 15, we can 
begin to identify the genetic loci that appear to have both main and interactions effects, and 
separate them from the genetic loci that have only interactions effects. Out of 12 genome-wide 
significant loci in EA, only two loci had a genome-wide significant P-value in 1DF interaction 
test (rs17370852 with 1DF interaction P=7.65×10-13 on chromosome 9 and rs7179425 with 1DF 
interaction P=3.21×10-10 on chromosome 15).  
Quantile-quantile (QQ) plots and Miami plots for each GWAS using the 2DF joint test 
are presented in Figures 9-12. Regional plots for the 12 significant loci using LocusZoom are 
shown in Figure 13.  
 
4.4 Discussion 
In this study, we identified 12 independent genome-wide significant genetic loci (P < 5 × 
10-8) and 206 suggestive genetic SNPs from meta-analyses of a genome-wide gene-by-sodium 
interaction study on blood pressure measures (SBP, DBP, MAP, and PP) using 6 cohorts 
comprising more than 6,000 participants of European, African American, and Asian ancestry. 
 Most interestingly, we identified rs868549 in AA, which is in the intronic region of 
NKAIN2 (sodium/potassium transporting ATPase interacting 2) that is expressed in the brain and 
in the heart [126]. The gene, which interacts with the beta subunit of Na, K-ATPase, has the 
important function of regulating sodium ion transport by modulating the frequency, rate or extent 
of the mobility of sodium ions (Na+) in/between cells [127]. Although it is clear that there is an 
apparent relationship between the gene and sodium, additional studies are needed to elucidate the 
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mechanism for how this promising genetic locus is associated with blood pressure regulation. At 
first glance, the genetic loci from EA have no apparent relationship with known blood pressure 
or sodium handling phenotypes. For example, the intronic variant rs11185517 on chromosome 3 
is in a region of a protein coding gene, ZDHHC19 (zinc finger DHHC-type containing 19), that 
is functionally associated with protein-cysteine S-palmitoyltransferase activity [126]. The gene is 
located in the cell membrane, and suggestively associated with proteins that influence 
endothelial nitric oxide synthase (eNOS), which is important for cardiovascular homeostasis 
[128]. From previous association studies, ZDHHC19 has been associated with metabolism, 
erythrocyte indices, and hemoglobin [129, 130]. rs17370852 is an intronic variant in RUSC2 
(RUN and SH3 domain containing 2) on chromosome 9, which is expressed in the human brain. 
RUSC2 protein may interact with interacting with RAB GTPase binding, which plays a role in 
intracellular vesicular trafficking [131]. It has suggested that GTPases have important roles in 
renal tubular epithelial cell function [80]. For example, GTPases may be associated with the 
retention process of the sodium hydrogen exchanger (NHE3) at the surface of membranes in the 
renal proximal tubular epithelia; further, NHE3 is associated with renal and intestinal ion 
homeostasis and control of cellular volume [132]. Variant rs7243864 is located in the DCC 
(DCC netrin 1 receptor) on chromosome 18. The gene encodes a netrin 1 receptor, and is known 
to mediate axon outgrowth and steering response [133]. rs8101144 is an intronic genetic variant 
of the gene. Future studies are warranted to understand the potential functional relevance of the 
genes in the relationship between sodium intake and blood pressure. 
When we compare the P-values from each meta-analysis, we have a better understanding 
of what kind of information each model could provide in Aim 3. In the study of the SNP 
association, the SNP effects are often first evaluated without accounting for exposure and gene-
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by-environment interaction terms (main effect only model, Model 2) before conducting 
regressions of interaction terms like Model 1 in Aim 3 [124]. However, when both SNP main 
effect and interaction effect are jointly estimated in Model 1, we cannot separate the main effect 
from the interaction effect. From Model 1 where both the interaction and SNP main effect terms 
were included, the meta-analyses of 1DF interaction test and 2DF joint test were conducted. 
From the Manning et al paper, except for the extreme cases (no interaction effect or no SNP 
effects), 2DF joint test had the highest power. In simulations, the explained portion of outcome 
variation increased when both main and interaction effects were jointly evaluated in the model 
[124]. This might explain why there were no loci that had a genome-wide significant SNP main 
effect from Model 1 and 2 (βG1 and βG2, SNP main effect P < 5×10-8) and why there were only 2 
significant loci from 1DF interaction test from Model 1 (βGE, 1 DF interaction P < 5×10-8) where 
all loci had significant P-values from 2DF joint test in Table 15. In the paper of Manning et al, 
on the other hand, when there is an interaction effect with no or small main effect, the meta-
analysis of the interaction alone (βGE, 1DF interaction test) had the highest power because it has 
a lower degree of freedom (1DF) [124]. This might explain why locus 6 and 11 in Table 15 had a 
less significant P-value in the 2DF joint test when compared to the 1DF interaction test. In 
Model 3, the presence of correlation between genetic and environmental effects was investigated 
by adding the environment variable, SODIUM, and examining its impact on the 1DF SNP effect. 
Despite the importance of gene-sodium intake interactions on blood pressure, there have 
been few studies in this area. Li et al recently found several novel loci using Chinese participants 
from GenSalt and MESA [118]. They did not have adequate power in their discovery sample to 
detect genome-wide significant effects, but detected significant SNPs from the combined results 
of discovery and replication samples. In addition, sodium intake was estimated from spot a urine 
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sample in the replication set, which could decrease the accuracy of the findings. We evaluated 
the 3 novel loci (rs11104632 on chromosome 12, rs13211840 on chromosome 6, rs2567241 on 
chromosome 4) from single variant analysis results in the Li et al study, using our European and 
African ancestry meta-analysis (Table 17). None of loci were significant (P value<0.05) in any of 
our analyses. Since different ancestry groups may have different linkage disequilibrium 
structures, a SNP found in one ancestry group may not replicate in other ancestries. We did not 
conduct the replication in AS since the results were from the same cohort, GenSalt. 
Traditionally, the SNP-by-environment interactions have been evaluated for the subset of 
SNPs with significant main effects [134]. This approach could improve power by limiting the 
number of interaction tests performed, but its critical limitation is to prevent the identification of 
genetic variants that are associated with diseases mainly through an interaction effect with no or 
small marginal effects. In the interaction test with known blood pressure loci (until June 2017, 
M=239) from previous large GWAS with successful replication that exist in our SNP list, only 3 
loci out of 239 had an FDR adjusted P-value less than 0.1 from the 2DF joint test (Table 18). The 
three loci included variant rs13139571 on chromosome 4 near genes GUCY1A3-GUCY1B3, 
which was replicated with SBP and PP in AA participants (FDR adjusted P=0.069 and 0.059, 
respectively) and with MAP in AA participants without diuretics (FDR adjusted P=0.021); 
variant rs62012628 on chromosome 15 near gene ADAMTS7, which had a FDR adjusted 
P=0.0369 with SBP; and variant rs743757 on chromosome 3 near gene CAC2D2, which also had 
a FDR adjusted P=0.077 with DBP in EA participants without diuretics. This low rate of 
replication highlights the importance of using the 2DF joint test in Aim 3 because the loci that 
had significant P-values in our discovery analysis would not have been identified if we only used 
known blood pressure loci for interaction testing. 
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The strength of this work includes using 1) multiethnic populations; 2) high-quality 
measurements (24-hour or half-day urinary sodium excretion); 3) a sensitivity analysis approach 
by conducting meta-analyses excluding participants with diuretic use; and 4) a powerful 
statistical approach in identifying gene-by-sodium environment interaction loci from meta-
analyses (2DF joint test). 
However, a limited number of cohorts had either a 24-hour or half-day urine samples as 
well as genotyping data since collecting 24-hour or half-day urine samples is expensive and 
time-consuming. Thus, the sample size limited our power to conduct the gene-sodium interaction 
meta-analyses. We also had only one Asian cohort. 
To expand on our results, we are currently reaching out to additional cohorts to confirm 
suggestive or significant loci found from the discovery stage. Potential cohorts include 1) 24-
hour urine sample: Prevention of REnal and Vascular ENd-stage Disease (PREVEND) 
(N=3,649) [61], 2) Spot urine sample: Heredity and Phenotype Intervention (HAPI) Heart Study 
(N=844) [70], Multiethnic Study of Atherosclerosis (MESA) cohort (N=2,462), [135] and UK 
Biobank (N=500,000) [136], and 3) FFQ: Health and Retirement Study (N=8,035) [137]. 
Identifying genetic variations that modify the relationship between sodium intake/excretion and 
blood pressure could have an effect on stratifying treatment and prevention recommendations for 
millions of adults who have high blood pressure or hypertension, since these gene variations 
would indicate which subgroups of the population have an increased risk of elevated blood 
pressure from excess sodium consumption. 
 
 
 
78 
Table 13 Characteristics of participating cohorts in Aim 3 
 
  
GENOA FHS HyperGEN 
EA 
HyperGEN 
AA 
JHS GenSalt 
Race/ethnicity EA (N=2,547) AA (N=1,650) AS (N=1,823) 
Cohort Family-based Family-based Family-based Family-based Population-based Family-based 
Country USA USA USA USA USA USA 
Total (N) 625 747 1,175 1,017 633 1,823 
Diuretic use, % 49.9 19.3 23.5 38.2 41.4 0.4 
24-hour urinary  
sodium excretion  
≥ 220 mmol/day, % 
11.7 10.2 36.9 47.9 19.6 58.4 
SBP 154.3 ± 24.2 132.8 ± 18.3 131.5 ± 23.1 138.4 ± 25.0 136.6 ± 19.1 117.2 ± 14.1 
DBP 83.7 ± 10.8 77.4 ± 9.9 76.0 ± 11.5 80.0 ± 13.0 81.2 ± 9.7 74.1 ± 10.2 
MAP 107.2 ± 13.7 90.0 ± 9.6 94.5 ± 14.2 99.5 ± 15.9 100.0 ± 11.5 88.4 ± 10.8 
PP 70.7 ± 19.5 52.9 ± 14.1 55.5 ± 16.8 58.4 ± 17.4 56.4 ± 15.3 43.1 ± 9.4 
Urine Sample 24-hour 24-hour Half-day Half-day 24-hour 24-hour 
 
For continuous variables: mean ± SD, For binary variables: % (N)  
Abbreviations:  EA: European American, AA: African American, AS: Asian, SBP: Systolic blood pressure, DBP: Diastolic blood 
pressure, MAP: Mean Arterial Pressure, PP: Pulse Pressure, GENOA: Genetic Epidemiology of Arteriopathy, FHS: Framingham 
Heart Study, HyperGEN: Family Blood Pressure Program, JHS: Jackson Heart Study, GenSalt: Genetic Epidemiology Network of 
Salt Sensitivity  
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Table 14 Genotyping information for participating cohorts in Aim 3 
 
Cohort Ancestry Study 
design 
N PCs Genotyping platform Genotyping 
calling 
algorithm 
Imputation 
software 
Imputation: 
reference 
panel 
Analysis 
Software 
GENOA EA FB 4 
Affymetrix Genome-Wide 
Human SNP Array 6.0 (91.9% 
of sample); Illumina Human 
1M-Duo, 660-Quad, or 610-
Quad (8.1% of sample) 
Birdseed; 
Genome 
Studio 
IMPUTE2 1000G Phase1 v3 MMAP 
FHS EA FB 0 
Affymetrix 500K mapping 
array and the Affymetrix 50K 
gene-focused molecular 
imprinted polymer array 
BRLMM MACH 1000G Phase1 v3 MMAP 
HyperGEN 
EA EA FB 0 
Affymetrix Genome-Wide 
Human SNP Array 5.0 BRLMM MACH/ minimac 
1000G 
Phase1 v3 MMAP 
HyperGEN 
AA AA FB 1 
Affymetrix Genome-Wide 
Human SNP Array 6.0 Birdseed MACH/ minimac 
1000G 
Phase1 v3 MMAP 
JHS AA PB 10 
Affymetrix Genome-Wide 
Human SNP Array 6.0 Birdseed2 IMPUTE2 1000G Phase1 v3 ProbABEL 
GenSalt AS FB N/A 
Affymetrix Genome-Wide 
Human SNP Array 6.0 Birdseed Minimac 1000G Phase1 v3 ProbABEL 
Abbreviations:  EA: European American, AA: African American, AS: Asian, FB: Family-based, PB: Population-based, GENOA: 
Genetic Epidemiology of Arteriopathy, FHS: Framingham Heart Study, HyperGEN: Family Blood Pressure Program, JHS: Jackson 
Heart Study, GenSalt: Genetic Epidemiology Network of Salt Sensitivity 
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Table 15 Genetic loci that were genome-wide significant (P < 5×10-8) from 2DF joint test in the discovery sample in Aim 3 
 
Locus1 Nearest Genes2 rsID CHR:POS3 EA EAF N 
Effect4 Direction5 P value6 
Most 
significant 
Analysis 
Additional 
significant 
Analysis G GxE G GxE 
2 DF 
Joint 
1 DF 
Int. 
(βGE) 
Model 1 
SNP 
(βG1) 
Model 2 
SNP 
(βG2 ) 
Model 3 
SNP 
(βG3) 
 
1 Y_RNA; 
ZDHHC19; 
SLC51A; 
PCYT1A 
rs11185517 3:195931583 t 0.20 916 -0.40 -11.38 --(-) --(+) 1.36E-08 1.73E-06 6.52E-01 2.06E-01 2.84E-01 EA.WOD.PP  
2 RP11-313E19.1 rs7678931 4:177545534 t 0.06 1650 1.27 -8.49 +- -- 4.82E-08 6.33E-06 3.87E-01 4.12E-02 3.64E-02 AA.ALL.PP  
3  rs6922858 6:888734 a 0.97 1816 -1.17 -8.90 - - 1.20E-08 3.60E-04 5.30E-01 1.99E-06 1.70E-06 AS.WOD.DBP AS.ALL.DBP; 
AS.WOD.MAP 
4 NKAIN2 rs868549 6:125027163 t 0.07 1650 0.89 -8.65 ++ -- 1.09E-09 3.03E-06 5.21E-01 1.85E-01 1.95E-01 AA.ALL.PP  
5 FOXP2 rs6953359 7:114188174 a 0.93 1650 -1.19 -7.67 -- -- 5.20E-09 3.55E-06 2.12E-01 2.24E-02 1.28E-02 AA.ALL.DBP AA.ALL.MAP 
6 RUSC2; 
RPL36AP33 
rs17370852 9:35510178 a 0.91 1800 -0.31 9.76 -(-)- +(-)+ 2.41E-12 7.65E-13 3.79E-01 5.79E-01 4.47E-01 EA.ALL.SBP EA.ALL.PP; 
EA.ALL.MAP 
7 FBXO10; 
RP11-
613M10.8 
rs113300617 9:37544221 a 0.07 1650 -0.69 -6.75 -- -- 1.12E-10 4.90E-05 5.80E-01 5.65E-03 6.25E-03 AA.ALL.MAP  
8 U3 rs17753104 10:28700861 a 0.14 1372 -0.87 -12.47 +-(+) --(-) 2.49E-08 5.20E-06 4.71E-01 9.46E-02 1.11E-01 EA.ALL.SBP  
9  rs115038395 12:11757330 a 0.08 1650 -2.62 -7.94 -- -- 1.36E-08 3.42E-03 1.82E-01 1.00E-02 1.46E-02 AA.ALL.SBP  
10 AC067735.1 rs189689705 12:39316220 a 0.93 1650 0.58 6.78 -+ ++ 2.57E-08 6.90E-03 6.93E-01 2.18E-03 1.90E-03 AA.ALL.MAP  
11 RP11-507B12.2 rs7179425 15:61595293 t 0.90 1800 -1.83 6.71 -(+)- +(-)+ 9.40E-09 3.21E-10 7.33E-03 5.38E-01 5.12E-01 EA.ALL.DBP  
12 DCC rs7243864 18:50713748 t 0.10 2547 -2.34 -2.42 --- -+- 2.71E-08 4.88E-02 4.98E-05 1.90E-06 3.02E-06 EA.ALL.MAP  
 
1Each locus was determined through LD-based clumping, using ± 1 Mb around index variants, followed by LD threshold of r2 > 0.1; ancestry-specific LDs from 1000 Genomes Project were used when 
clumping within each ancestry  
2Genes near index SNP (+/- 10K upstream/downstream distance bp). Gene names were obtained using variant effect predictor (VEP) from Ensembl. Genes with intragenic index variants bolded.  
3Positions are based on build 37  
4Effect is in mmHg unit  
5Direction of effect in GENOA, FHS, and HyperGEN in European ancestry, respectively; Direction of effect in JHA and HyperGEN in African ancestry, respectively; in parenthesis if cohort was not 
included in a meta-analysis  
6Genome-wide significant P-values (P < 5×10-8) bolded  
Abbreviations: BP: blood pressure; SBP: systolic BP; DBP: diastolic BP; EA: effect allele; EAF: effect allele frequency; 1 DF Interaction P: P-value of the interaction test with 1 degree of freedom; 2 
DF Joint P: P-value of the joint test with 2 degrees of freedom of genetic main and interaction effects; Model 2: P-value of SNP only model; Model 3: P-value of SNP in a model with SNP and E; EA: 
European ancestry; AA: African American ancestry; AS: Asian ancestry;  G: Genetic Main; GxE: Interaction; Int.: Interaction; ALL: All participants; WOD: Subject without diuretic u
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Table 16 SNPs that are genome-wide significant (P < 5×10-8) or suggestive (P < 1×10-6) from 2DF joint test in meta-analysis without 
LD clumping in Aim 3 
 
Locus rsID1 CHR POS EA EAF N 
Discovery meta-analysis 
Effect2 Direction3 P value Analysis 
G GxE G GxE 2 DF Joint 
1 DF 
Interaction 
(βGE) 
Model 1 
SNP 
(βG1) 
Model 2 
SNP 
(βG2 ) 
Model 3 
SNP 
(βG3) 
 
1 rs17370852 9 35510178 a 0.91 1800 -1.45 18.71 -?- +?+ 2.41E-12 7.65E-13 3.79E-01 5.79E-01 4.47E-01 EA_ALL_SBP 
2 rs113300617 9 37544221 a 0.07 1650 -0.69 -6.75 -- -- 1.12E-10 4.90E-05 5.80E-01 5.65E-03 6.25E-03 AA_ALL_MAP 
3 rs6953359 7 114188174 a 0.93 1650 -1.49 -8.55 -- -- 2.50E-10 4.30E-06 1.93E-01 2.79E-02 1.53E-02 AA_ALL_MAP 
4 rs868549 6 125027163 t 0.07 1650 0.89 -8.65 ++ -- 1.09E-09 3.03E-06 5.21E-01 1.85E-01 1.95E-01 AA_ALL_PP 
5 rs17370852 9 35510178 a 0.91 1800 -0.31 9.76 +?- +?+ 1.98E-09 7.17E-08 8.02E-01 8.18E-01 7.00E-01 EA_ALL_PP 
6 rs6953359 7 114188174 a 0.93 1650 -1.19 -7.67 -- -- 5.20E-09 3.55E-06 2.12E-01 2.24E-02 1.28E-02 AA_ALL_DBP 
7 rs17370852 9 35510178 a 0.91 1800 -1.29 11.60 -?- +?+ 5.89E-09 2.45E-10 1.94E-01 5.33E-01 4.21E-01 EA_ALL_MAP 
8 rs7179425 15 61595293 t 0.90 1800 -1.83 6.71 -?- +?+ 9.40E-09 3.21E-10 7.33E-03 5.38E-01 5.12E-01 EA_ALL_DBP 
9 rs7179308 15 61595355 a 0.10 1800 1.84 -6.70 +?+ -?- 9.92E-09 3.33E-10 6.91E-03 5.27E-01 5.01E-01 EA_ALL_DBP 
10 rs6922858 6 888734 a 0.97 1816 -1.17 -8.90 - - 1.19E-08 3.61E-04 5.30E-01 1.99E-06 1.70E-06 AS_WOD_DBP 
11 rs11185517 3 195931583 t 0.20 916 -0.40 -11.38 --? --? 1.36E-08 1.73E-06 6.52E-01 2.06E-01 2.84E-01 EA_WOD_PP 
12 rs115038395 12 11757330 a 0.08 1650 -2.62 -7.94 -- -- 1.36E-08 3.42E-03 1.82E-01 1.00E-02 1.46E-02 AA_ALL_SBP 
13 rs75149358 12 11757243 a 0.92 1650 2.59 7.96 ++ ++ 1.42E-08 3.41E-03 1.89E-01 1.08E-02 1.57E-02 AA_ALL_SBP 
14 rs4324488 3 195931868 t 0.20 916 -0.41 -11.32 --? --? 1.44E-08 1.83E-06 6.39E-01 2.01E-01 2.77E-01 EA_WOD_PP 
15 rs74652398 12 11754748 c 0.93 1650 1.95 8.55 ++ ++ 1.65E-08 1.60E-03 3.24E-01 2.13E-02 2.98E-02 AA_ALL_SBP 
16 rs6922858 6 888734 a 0.97 1823 -1.07 -8.95 - - 2.18E-08 3.94E-04 5.70E-01 3.08E-06 2.74E-06 AS_ALL_DBP 
17 rs17753104 10 28700861 a 0.14 1372 -0.87 -12.47 +-? --? 2.49E-08 5.20E-06 4.71E-01 9.46E-02 1.11E-01 EA_ALL_SBP 
18 rs189689705 12 39316220 a 0.93 1650 0.58 6.78 -+ ++ 2.57E-08 6.90E-03 6.93E-01 2.18E-03 1.90E-03 AA_ALL_MAP 
19 rs7243864 18 50713748 t 0.10 2547 -2.34 -2.42 --- -+- 2.71E-08 4.88E-02 4.98E-05 1.90E-06 3.02E-06 EA_ALL_MAP 
20 rs6788070 3 195932512 t 0.20 916 -0.40 -11.09 --? --? 2.91E-08 2.66E-06 6.49E-01 2.10E-01 2.88E-01 EA_WOD_PP 
21 rs6922858 6 888734 a 0.97 1816 -2.44 -7.43 - - 3.05E-08 3.67E-03 2.04E-01 5.25E-07 4.45E-07 AS_WOD_MAP 
22 rs6778521 3 195932613 a 0.21 916 -0.39 -11.04 --? --? 3.58E-08 2.96E-06 6.61E-01 2.14E-01 2.93E-01 EA_WOD_PP 
23 rs7678931 4 177545534 t 0.06 1650 1.27 -8.49 +- -- 4.82E-08 6.33E-06 3.87E-01 4.12E-02 3.64E-02 AA_ALL_PP 
24 rs114796468 6 480849 c 0.93 1650 1.20 6.65 ++ ++ 5.00E-08 1.75E-03 4.62E-01 1.11E-03 1.13E-03 AA_ALL_MAP 
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25 rs11721985 4 177542233 a 0.94 1650 -1.10 8.35 -+ ++ 5.40E-08 8.82E-06 4.51E-01 3.25E-02 2.79E-02 AA_ALL_PP 
26 rs6922858 6 888734 a 0.97 1823 -2.34 -7.45 - - 5.57E-08 4.01E-03 2.28E-01 8.06E-07 7.16E-07 AS_ALL_MAP 
27 rs7622198 3 159962614 a 0.93 1800 0.97 5.22 -?+ +?+ 6.65E-08 2.82E-04 2.05E-01 1.59E-02 1.94E-02 EA_ALL_DBP 
28 rs58242808 4 177552843 d 0.07 1650 1.31 -8.34 +- -- 7.07E-08 8.59E-06 3.67E-01 4.96E-02 4.41E-02 AA_ALL_PP 
29 rs116587610 6 31243389 a 0.45 916 -0.64 -3.84 --? -+? 7.29E-08 1.15E-02 3.60E-01 3.95E-01 3.92E-01 EA_WOD_PP 
30 rs115987494 6 31243410 t 0.45 916 -0.64 -3.84 --? -+? 7.39E-08 1.16E-02 3.59E-01 3.93E-01 3.90E-01 EA_WOD_PP 
31 rs17037007 3 37845418 t 0.07 1650 -2.56 -8.05 -+ -- 7.58E-08 2.16E-04 4.71E-02 7.05E-04 9.39E-04 AA_ALL_PP 
32 rs480935 9 124382470 t 0.08 1650 4.71 -8.34 ++ -- 7.67E-08 5.31E-07 9.26E-08 2.00E-03 2.65E-03 AA_ALL_DBP 
33 rs55900682 6 888396 a 0.98 1816 -1.31 -9.18 - - 7.68E-08 8.16E-04 5.21E-01 5.38E-06 5.19E-06 AS_WOD_DBP 
34 rs75269061 6 888821 a 0.02 1816 1.34 9.19 + + 7.79E-08 8.58E-04 5.13E-01 5.10E-06 5.00E-06 AS_WOD_DBP 
35 rs9834427 3 165772627 a 0.11 1000 6.89 -10.71 ++ -- 8.90E-08 1.09E-04 1.56E-07 4.50E-03 5.12E-03 AA_WOD_PP 
36 rs12508778 4 177548451 a 0.06 1650 1.42 -8.42 +- -- 9.78E-08 8.42E-06 3.33E-01 6.40E-02 5.67E-02 AA_ALL_PP 
37 rs17078700 13 33747458 a 0.12 1650 -4.71 8.75 -- ++ 1.11E-07 7.40E-06 2.14E-07 2.60E-02 2.78E-02 AA_ALL_PP 
38 rs114796468 6 480849 c 0.93 1650 0.22 11.38 -+ ++ 1.17E-07 4.08E-04 9.29E-01 5.74E-03 5.81E-03 AA_ALL_SBP 
39 rs55900682 6 888396 a 0.98 1823 -1.23 -9.24 - - 1.20E-07 8.76E-04 5.53E-01 7.33E-06 7.31E-06 AS_ALL_DBP 
40 rs17753104 10 28700861 a 0.14 1372 -0.20 -7.06 +-? --? 1.21E-07 8.49E-06 7.73E-01 1.99E-01 2.19E-01 EA_ALL_MAP 
41 rs75269061 6 888821 a 0.02 1823 1.26 9.25 + + 1.22E-07 9.18E-04 5.45E-01 7.07E-06 7.14E-06 AS_ALL_DBP 
42 rs75269061 6 888821 a 0.02 1816 2.76 7.67 + + 1.23E-07 6.63E-03 1.93E-01 1.10E-06 1.07E-06 AS_WOD_MAP 
43 rs4439939 2 34988474 t 0.66 1815 2.09 0.24 +++ +-- 1.24E-07 7.98E-01 1.51E-06 4.57E-08 5.88E-08 EA_WOD_MAP 
44 rs55900682 6 888396 a 0.98 1816 -2.70 -7.68 - - 1.25E-07 6.24E-03 2.01E-01 1.20E-06 1.16E-06 AS_WOD_MAP 
45 rs1947534 18 41905790 a 0.96 1823 -2.12 -3.99 - - 1.26E-07 2.53E-02 1.25E-01 3.48E-07 4.08E-07 AS_ALL_DBP 
46 rs111983094 1 19847611 d 0.18 1000 -4.83 11.49 -- ++ 1.34E-07 2.04E-09 6.87E-06 1.73E-01 1.79E-01 AA_WOD_MAP 
47 rs17773338 7 5878333 a 0.88 1502 1.96 4.37 ?++ ?++ 1.40E-07 2.60E-03 2.47E-02 9.89E-05 1.07E-04 EA_WOD_PP 
48 rs75800997 11 79797734 t 0.06 1650 -3.19 -8.98 -- -- 1.41E-07 1.26E-03 8.39E-02 2.26E-04 2.74E-04 AA_ALL_SBP 
49 rs926555 6 1039373 a 0.34 2547 -0.81 3.75 --- +++ 1.51E-07 1.24E-07 2.50E-02 9.23E-01 9.27E-01 EA_ALL_DBP 
50 rs78476095 11 79777103 c 0.94 1650 1.72 10.98 +- ++ 1.57E-07 8.53E-05 3.63E-01 3.29E-03 3.91E-03 AA_ALL_SBP 
51 rs200938184 13 92688020 d 0.94 1650 0.11 14.63 -+ ++ 1.62E-07 1.84E-06 9.54E-01 8.60E-02 1.08E-01 AA_ALL_SBP 
52 rs4344598 13 89419933 a 0.11 1000 1.21 -8.71 +- -- 1.64E-07 2.14E-04 3.61E-01 4.99E-02 6.72E-02 AA_WOD_PP 
53 rs9588408 13 89420896 a 0.89 1000 -1.21 8.67 -+ ++ 1.67E-07 2.25E-04 3.61E-01 4.97E-02 6.68E-02 AA_WOD_PP 
54 rs7243864 18 50713748 t 0.10 2547 -2.14 -2.08 --- -+- 1.73E-07 6.42E-02 6.26E-05 1.67E-06 2.50E-06 EA_ALL_DBP 
55 rs9406244 6 1041616 t 0.66 2547 0.80 -3.73 +++ --- 1.77E-07 1.38E-07 2.71E-02 9.03E-01 9.07E-01 EA_ALL_DBP 
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56 rs77071256 12 131921244 a 0.09 1650 -1.21 -7.36 -- -- 1.78E-07 7.19E-04 4.17E-01 1.46E-03 1.30E-03 AA_ALL_SBP 
57 rs4304213 6 1038795 a 0.34 2547 -0.78 3.69 --- +++ 1.81E-07 1.54E-07 2.89E-02 8.94E-01 8.97E-01 EA_ALL_DBP 
58 rs9964923 18 21828099 a 0.02 1816 -5.30 14.60 - + 1.88E-07 2.61E-07 1.30E-02 4.28E-02 3.82E-02 AS_WOD_SBP 
59 rs76774947 3 195933301 a 0.20 916 -0.40 -10.73 --? --? 1.95E-07 6.75E-06 6.46E-01 2.13E-01 2.90E-01 EA_WOD_PP 
60 rs17097805 14 99262153 a 0.49 1823 -1.10 0.27 - + 1.95E-07 4.44E-01 3.24E-05 4.72E-08 5.00E-08 AS_ALL_PP 
61 rs75269061 6 888821 a 0.02 1823 2.68 7.69 + + 1.96E-07 7.15E-03 2.12E-01 1.51E-06 1.52E-06 AS_ALL_MAP 
62 rs61981355 14 99257470 a 0.49 1823 -1.08 0.23 - + 1.96E-07 5.13E-01 4.49E-05 4.47E-08 4.74E-08 AS_ALL_PP 
63 rs55900682 6 888396 a 0.98 1823 -2.62 -7.71 - - 1.97E-07 6.73E-03 2.20E-01 1.64E-06 1.61E-06 AS_ALL_MAP 
64 rs9949360 18 21833586 a 0.02 1816 -5.58 15.04 - + 2.05E-07 2.27E-07 1.05E-02 5.54E-02 4.94E-02 AS_WOD_SBP 
65 rs61981355 14 99257470 a 0.49 1816 -1.08 0.23 - + 2.06E-07 5.05E-01 4.54E-05 4.76E-08 5.09E-08 AS_WOD_PP 
66 rs56882310 18 41912072 a 0.96 1823 -2.18 -3.88 - - 2.06E-07 3.02E-02 1.14E-01 5.22E-07 5.70E-07 AS_ALL_DBP 
67 rs9959834 18 21827805 a 0.98 1816 5.35 -14.71 + - 2.08E-07 2.70E-07 1.27E-02 4.63E-02 4.13E-02 AS_WOD_SBP 
68 rs1947534 18 41905790 a 0.96 1816 -2.27 -3.65 - - 2.10E-07 3.82E-02 9.68E-02 4.73E-07 5.08E-07 AS_WOD_DBP 
69 rs76358082 4 177563281 c 0.93 1650 -1.31 8.23 -+ ++ 2.13E-07 1.18E-05 3.55E-01 5.63E-02 5.00E-02 AA_ALL_PP 
70 rs7149860 14 99264257 a 0.51 1823 1.09 -0.26 + - 2.18E-07 4.47E-01 3.48E-05 5.33E-08 5.64E-08 AS_ALL_PP 
71 rs79041712 15 94443760 a 0.90 1000 -2.02 7.80 -- ++ 2.18E-07 5.73E-04 8.60E-02 2.87E-01 3.17E-01 AA_WOD_MAP 
72 rs74355665 3 195933337 t 0.20 916 -0.40 -10.71 --? --? 2.19E-07 7.15E-06 6.45E-01 2.13E-01 2.90E-01 EA_WOD_PP 
73 rs7150005 14 99264259 a 0.51 1823 1.09 -0.26 + - 2.20E-07 4.45E-01 3.48E-05 5.53E-08 5.85E-08 AS_ALL_PP 
74 rs4991185 12 119841693 t 0.89 1372 -4.57 9.64 --? ++? 2.21E-07 1.79E-04 6.10E-05 8.49E-04 8.97E-04 EA_ALL_PP 
75 rs4300442 12 119840132 a 0.89 1372 -4.57 9.61 --? ++? 2.23E-07 1.85E-04 5.86E-05 8.08E-04 8.53E-04 EA_ALL_PP 
76 rs11650288 17 10018145 a 0.20 1815 2.46 -6.89 +++ --- 2.24E-07 3.33E-07 1.45E-03 9.90E-02 1.09E-01 EA_WOD_PP 
77 rs12715418 3 4720118 c 0.90 1000 1.63 4.29 ++ -+ 2.26E-07 6.58E-02 2.07E-01 8.36E-04 1.20E-03 AA_WOD_PP 
78 rs12523737 6 120595996 a 0.94 1650 -2.56 12.84 -- ++ 2.28E-07 9.36E-06 2.28E-01 1.52E-01 1.49E-01 AA_ALL_SBP 
79 rs71176194 19 33571006 d 0.07 1650 -2.75 -4.81 -- -- 2.31E-07 1.49E-02 9.74E-03 3.95E-06 4.90E-06 AA_ALL_PP 
80 rs8101144 19 18715121 a 0.14 1650 -7.37 5.84 -- ++ 2.33E-07 1.20E-02 1.91E-08 4.95E-06 3.89E-06 AA_ALL_SBP 
81 rs17097805 14 99262153 a 0.49 1816 -1.09 0.28 - + 2.35E-07 4.19E-01 3.23E-05 6.19E-08 6.53E-08 AS_WOD_PP 
82 rs9964923 18 21828099 a 0.02 1823 -5.40 14.60 - + 2.41E-07 2.71E-07 1.15E-02 5.06E-02 4.58E-02 AS_ALL_SBP 
83 rs74491996 3 195933371 a 0.20 916 -0.40 -10.70 --? --? 2.42E-07 7.50E-06 6.45E-01 2.13E-01 2.90E-01 EA_WOD_PP 
84 rs72995446 19 18716141 a 0.14 1650 -7.41 6.13 -- ++ 2.52E-07 8.88E-03 1.99E-08 7.73E-06 5.98E-06 AA_ALL_SBP 
85 rs79041712 15 94443760 a 0.90 1000 -0.64 6.14 -- ++ 2.52E-07 9.92E-04 5.30E-01 2.58E-02 2.80E-02 AA_WOD_DBP 
86 rs75809135 19 46790972 t 0.06 1650 -6.56 3.05 -- ++ 2.52E-07 2.72E-01 3.45E-08 1.62E-07 2.68E-07 AA_ALL_PP 
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87 rs114264676 19 46790358 a 0.06 1650 -6.54 3.03 -- ++ 2.54E-07 2.74E-01 3.50E-08 1.65E-07 2.80E-07 AA_ALL_PP 
88 rs115905395 5 63473312 t 0.97 1816 -10.28 15.58 - + 2.55E-07 2.59E-08 2.14E-06 4.82E-01 5.15E-01 AS_WOD_MAP 
89 rs71358291 17 10189273 a 0.06 1650 9.55 -9.85 ++ +- 2.60E-07 5.31E-04 3.53E-08 2.13E-05 1.73E-05 AA_ALL_PP 
90 rs7149860 14 99264257 a 0.51 1816 1.09 -0.28 + - 2.61E-07 4.22E-01 3.46E-05 6.98E-08 7.35E-08 AS_WOD_PP 
91 rs1598669 18 41914949 a 0.96 1823 -2.16 -3.89 - - 2.62E-07 3.01E-02 1.18E-01 6.51E-07 6.99E-07 AS_ALL_DBP 
92 rs28594175 4 109264778 a 0.84 1000 -0.58 9.40 -- ++ 2.62E-07 2.96E-04 6.69E-01 1.73E-02 2.77E-02 AA_WOD_SBP 
93 rs772563 12 63305545 t 0.45 1815 -3.44 -0.34 --- ++- 2.63E-07 7.97E-01 1.30E-06 5.71E-08 5.20E-08 EA_WOD_SBP 
94 rs7097658 10 3709316 t 0.62 1650 3.16 -0.73 ++ +- 2.65E-07 5.47E-01 7.64E-06 4.09E-08 3.43E-08 AA_ALL_PP 
95 rs1666872 12 63305152 a 0.55 1815 3.44 0.34 +++ --+ 2.67E-07 7.96E-01 1.32E-06 5.71E-08 5.18E-08 EA_WOD_SBP 
96 rs9964923 18 21828099 a 0.02 1816 -3.51 11.81 - + 2.69E-07 8.61E-07 5.16E-02 1.25E-02 1.05E-02 AS_WOD_MAP 
97 rs9959834 18 21827805 a 0.98 1823 5.45 -14.70 + - 2.72E-07 2.86E-07 1.13E-02 5.46E-02 4.94E-02 AS_ALL_SBP 
98 rs926555 6 1039373 a 0.34 2547 -0.90 3.87 --- +++ 2.73E-07 7.58E-07 2.15E-02 9.00E-01 8.90E-01 EA_ALL_MAP 
99 rs9949360 18 21833586 a 0.02 1823 -5.68 15.02 - + 2.74E-07 2.45E-07 9.29E-03 6.51E-02 5.88E-02 AS_ALL_SBP 
100 rs2906924 17 27609209 a 0.84 1650 -0.48 6.91 +- ++ 2.75E-07 3.34E-05 6.49E-01 2.64E-02 2.75E-02 AA_ALL_PP 
101 rs28884496 18 21837697 a 0.98 1816 5.68 -15.23 + - 2.77E-07 2.82E-07 1.07E-02 6.18E-02 5.50E-02 AS_WOD_SBP 
102 rs7150005 14 99264259 a 0.51 1816 1.09 -0.28 + - 2.79E-07 4.21E-01 3.55E-05 7.11E-08 7.63E-08 AS_WOD_PP 
103 rs11898121 2 203088731 a 0.41 1650 -0.09 4.05 +- ++ 2.82E-07 1.26E-05 8.60E-01 1.15E-02 1.18E-02 AA_ALL_DBP 
104 rs772560 12 63304807 a 0.55 1815 3.43 0.32 +++ --+ 2.85E-07 8.08E-01 1.32E-06 6.16E-08 5.61E-08 EA_WOD_SBP 
105 rs11938527 4 109270817 a 0.16 1000 0.63 -9.52 ++ -- 2.86E-07 2.40E-04 6.37E-01 2.30E-02 3.65E-02 AA_WOD_SBP 
106 rs772561 12 63304963 a 0.45 1815 -3.44 -0.32 --- ++- 2.86E-07 8.08E-01 1.33E-06 6.14E-08 5.56E-08 EA_WOD_SBP 
107 rs888586 7 5878648 t 0.86 1502 1.99 3.39 ?++ ?++ 2.88E-07 9.82E-03 1.30E-02 4.53E-05 4.81E-05 EA_WOD_PP 
108 rs772555 12 63304283 a 0.45 1815 -3.44 -0.32 --- ++- 2.90E-07 8.09E-01 1.34E-06 6.21E-08 5.62E-08 EA_WOD_SBP 
109 rs772557 12 63304584 a 0.55 1815 3.43 0.32 +++ --+ 2.91E-07 8.08E-01 1.34E-06 6.17E-08 5.59E-08 EA_WOD_SBP 
110 rs9959834 18 21827805 a 0.98 1816 3.56 -11.91 + - 2.94E-07 8.68E-07 5.00E-02 1.37E-02 1.14E-02 AS_WOD_MAP 
111 rs59078432 8 22697576 t 0.86 1650 4.48 -0.46 ++ -+ 2.95E-07 7.79E-01 3.32E-07 1.11E-07 1.31E-07 AA_ALL_MAP 
112 rs116741667 6 31243170 a 0.50 916 -0.18 -3.70 -+? -+? 2.97E-07 1.31E-02 7.90E-01 8.56E-01 8.62E-01 EA_WOD_PP 
113 rs772559 12 63304757 a 0.55 1815 3.47 0.26 +++ --+ 2.98E-07 8.46E-01 1.23E-06 6.61E-08 5.97E-08 EA_WOD_SBP 
114 rs8004974 14 99257911 t 0.51 1823 1.07 -0.23 + - 3.00E-07 5.11E-01 5.68E-05 6.97E-08 7.50E-08 AS_ALL_PP 
115 rs28478722 4 109269457 a 0.16 1000 0.62 -9.50 ++ -- 3.04E-07 2.53E-04 6.43E-01 2.29E-02 3.61E-02 AA_WOD_SBP 
116 rs2246214 12 63304868 a 0.55 1815 3.42 0.34 +++ --+ 3.07E-07 8.01E-01 1.45E-06 6.88E-08 6.06E-08 EA_WOD_SBP 
117 rs141541522 14 99257953 d 0.51 1823 1.07 -0.23 + - 3.11E-07 5.14E-01 5.87E-05 7.13E-08 7.54E-08 AS_ALL_PP 
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118 rs28526354 4 109263616 a 0.16 1000 0.56 -9.33 ++ -- 3.12E-07 3.38E-04 6.79E-01 1.70E-02 2.70E-02 AA_WOD_SBP 
119 rs4304213 6 1038795 a 0.34 2547 -0.89 3.83 --- +++ 3.14E-07 9.28E-07 2.20E-02 8.96E-01 8.87E-01 EA_ALL_MAP 
120 rs73212121 3 195933424 t 0.79 916 0.39 10.62 ++? ++? 3.14E-07 9.04E-06 6.55E-01 2.21E-01 2.99E-01 EA_WOD_PP 
121 rs17033685 1 115867742 a 0.92 1650 2.01 8.52 ++ ++ 3.15E-07 9.16E-04 1.93E-01 3.51E-04 4.07E-04 AA_ALL_SBP 
122 rs772568 12 63307346 c 0.55 1815 3.48 0.17 +++ --+ 3.28E-07 8.99E-01 1.14E-06 6.89E-08 6.37E-08 EA_WOD_SBP 
123 rs699586 12 63306382 t 0.55 1815 3.47 0.18 +++ --+ 3.30E-07 8.92E-01 1.18E-06 7.01E-08 6.43E-08 EA_WOD_SBP 
124 rs772567 12 63307326 t 0.55 1815 3.48 0.17 +++ --+ 3.30E-07 8.99E-01 1.15E-06 6.89E-08 6.35E-08 EA_WOD_SBP 
125 rs772566 12 63307248 t 0.55 1815 3.48 0.17 +++ --+ 3.31E-07 9.00E-01 1.14E-06 6.94E-08 6.39E-08 EA_WOD_SBP 
126 rs148910075 11 79798963 a 0.06 1650 -3.17 -9.05 -- -- 3.31E-07 1.62E-03 9.18E-02 3.12E-04 3.79E-04 AA_ALL_SBP 
127 rs28482267 15 94352467 a 0.14 1000 4.62 -15.79 ++ -- 3.32E-07 2.33E-06 1.28E-02 9.95E-01 9.79E-01 AA_WOD_SBP 
128 rs115905395 5 63473312 t 0.97 1823 -10.19 15.59 - + 3.32E-07 3.74E-08 3.31E-06 5.29E-01 5.64E-01 AS_ALL_MAP 
129 rs28380415 4 109266821 t 0.16 1000 0.58 -9.50 ++ -- 3.32E-07 2.68E-04 6.65E-01 2.13E-02 3.34E-02 AA_WOD_SBP 
130 rs772565 12 63306853 t 0.55 1815 3.47 0.17 +++ --+ 3.33E-07 8.97E-01 1.17E-06 7.04E-08 6.51E-08 EA_WOD_SBP 
131 rs9406244 6 1041616 t 0.66 2547 0.89 -3.83 +++ --- 3.35E-07 8.94E-07 2.29E-02 9.05E-01 8.95E-01 EA_ALL_MAP 
132 rs699585 12 63306132 t 0.55 1815 3.47 0.17 +++ --+ 3.36E-07 8.98E-01 1.17E-06 7.01E-08 6.49E-08 EA_WOD_SBP 
133 rs9949360 18 21833586 a 0.02 1816 -3.73 12.14 - + 3.40E-07 8.02E-07 4.34E-02 1.72E-02 1.43E-02 AS_WOD_MAP 
134 rs772569 12 63307760 a 0.45 1815 -3.48 -0.18 --- ++- 3.49E-07 8.93E-01 1.19E-06 7.27E-08 6.71E-08 EA_WOD_SBP 
135 rs772556 12 63304447 t 0.45 1815 -3.47 -0.14 --- ++- 3.52E-07 9.17E-01 1.17E-06 6.85E-08 6.32E-08 EA_WOD_SBP 
136 rs56882310 18 41912072 a 0.96 1816 -2.32 -3.55 - - 3.54E-07 4.50E-02 8.84E-02 6.94E-07 6.93E-07 AS_WOD_DBP 
137 rs79474826 4 177571411 a 0.07 1650 1.45 -8.45 +- -- 3.57E-07 1.05E-05 3.13E-01 7.39E-02 6.66E-02 AA_ALL_PP 
138 rs1729531 13 72893992 t 0.40 1212 -0.04 5.06 +?- +?+ 3.59E-07 1.06E-06 9.53E-01 9.26E-03 1.19E-02 EA_WOD_DBP 
139 rs1860132 4 109262095 c 0.16 1000 0.54 -9.22 ++ -- 3.62E-07 4.06E-04 6.88E-01 1.69E-02 2.66E-02 AA_WOD_SBP 
140 rs258097 16 55765906 a 0.09 1650 -4.70 -2.75 -- -- 3.64E-07 2.58E-01 7.63E-04 5.44E-07 7.36E-07 AA_ALL_SBP 
141 rs115100192 18 41929553 c 0.04 1823 2.11 3.94 + + 3.67E-07 2.88E-02 1.29E-01 9.68E-07 1.01E-06 AS_ALL_DBP 
142 rs28668769 4 109264793 a 0.16 1000 0.94 -10.03 ++ -- 3.70E-07 1.22E-04 4.87E-01 4.25E-02 6.52E-02 AA_WOD_SBP 
143 rs2200226 4 53738359 t 0.42 1000 -3.67 0.73 -- ++ 3.71E-07 5.51E-01 1.12E-07 7.81E-07 5.81E-07 AA_WOD_MAP 
144 rs28884496 18 21837697 a 0.98 1823 5.78 -15.21 + - 3.71E-07 3.06E-07 9.46E-03 7.23E-02 6.51E-02 AS_ALL_SBP 
145 rs1537905 1 88672066 a 0.05 1650 -5.20 0.80 -- +- 3.71E-07 6.98E-01 1.83E-07 4.29E-06 3.54E-06 AA_ALL_MAP 
146 rs9964923 18 21828099 a 0.02 1823 -3.63 11.86 - + 3.74E-07 1.06E-06 4.64E-02 1.56E-02 1.32E-02 AS_ALL_MAP 
147 rs8004974 14 99257911 t 0.51 1816 1.06 -0.24 + - 3.76E-07 4.85E-01 5.75E-05 9.17E-08 9.62E-08 AS_WOD_PP 
148 rs10163977 18 41935966 a 0.04 1823 2.11 3.93 + + 3.81E-07 2.96E-02 1.27E-01 1.02E-06 1.06E-06 AS_ALL_DBP 
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149 rs10600624 3 144108989 d 0.88 1000 -3.75 11.52 -- ++ 3.82E-07 1.14E-07 1.36E-02 8.92E-01 8.53E-01 AA_WOD_PP 
150 rs148258828 18 41909525 a 0.96 1823 -2.04 -4.16 - - 3.86E-07 2.42E-02 1.51E-01 1.30E-06 1.31E-06 AS_ALL_DBP 
151 rs17097800 14 99257740 t 0.49 1823 -1.06 0.22 - + 3.89E-07 5.22E-01 6.84E-05 8.85E-08 9.36E-08 AS_ALL_PP 
152 rs141541522 14 99257953 d 0.51 1816 1.06 -0.24 + - 3.90E-07 4.88E-01 5.94E-05 9.37E-08 9.87E-08 AS_WOD_PP 
153 rs16861081 1 168592866 a 0.87 1000 -4.18 5.70 -- ++ 3.93E-07 1.61E-04 1.65E-06 3.91E-02 4.59E-02 AA_WOD_DBP 
154 rs76905458 10 28695807 t 0.14 1372 -1.01 -11.55 +-? --? 3.94E-07 3.94E-05 4.07E-01 8.93E-02 1.05E-01 EA_ALL_SBP 
155 rs73132694 5 93926680 t 0.18 1650 -3.73 5.93 -- ++ 3.94E-07 6.73E-06 3.18E-07 4.61E-03 3.10E-03 AA_ALL_MAP 
156 rs7711380 5 93928945 t 0.82 1650 3.73 -5.94 ++ -- 3.95E-07 6.71E-06 3.22E-07 4.65E-03 3.12E-03 AA_ALL_MAP 
157 rs7725462 5 93928868 t 0.18 1650 -3.73 5.94 -- ++ 3.95E-07 6.72E-06 3.22E-07 4.65E-03 3.12E-03 AA_ALL_MAP 
158 rs59078432 8 22697576 t 0.86 1650 7.17 -1.50 ++ -+ 3.97E-07 5.44E-01 2.36E-07 2.86E-07 3.28E-07 AA_ALL_SBP 
159 rs77979528 1 115869092 a 0.08 1650 -2.21 -8.33 -- -- 3.98E-07 1.19E-03 1.55E-01 2.55E-04 2.78E-04 AA_ALL_SBP 
160 rs138824325 10 28702905 a 0.14 1372 -1.02 -11.38 +-? --? 4.00E-07 4.39E-05 4.02E-01 8.76E-02 1.03E-01 EA_ALL_SBP 
161 rs79465916 16 73454000 t 0.82 1000 -1.09 10.62 -- ++ 4.00E-07 1.57E-05 4.99E-01 2.10E-02 2.49E-02 AA_WOD_SBP 
162 rs200700876 2 67436058 d 0.06 1650 -1.40 -5.11 -- -- 4.02E-07 3.07E-03 2.06E-01 1.81E-04 1.03E-04 AA_ALL_DBP 
163 rs151312462 2 67436059 d 0.06 1650 -1.40 -5.11 -- -- 4.04E-07 3.07E-03 2.06E-01 1.82E-04 1.03E-04 AA_ALL_DBP 
164 rs8287 4 53732586 t 0.53 1000 5.63 -2.18 ++ -- 4.06E-07 2.36E-01 7.27E-08 1.22E-06 1.03E-06 AA_WOD_SBP 
165 rs112520268 7 5880020 t 0.15 1815 -2.09 -2.74 --- +-- 4.06E-07 3.49E-02 3.59E-03 2.96E-05 3.15E-05 EA_WOD_PP 
166 rs9959834 18 21827805 a 0.98 1823 3.68 -11.96 + - 4.12E-07 1.07E-06 4.52E-02 1.71E-02 1.44E-02 AS_ALL_MAP 
167 rs1598669 18 41914949 a 0.96 1816 -2.30 -3.57 - - 4.14E-07 4.48E-02 9.14E-02 8.68E-07 8.59E-07 AS_WOD_DBP 
168 rs28482267 15 94352467 a 0.14 1000 1.39 -9.24 ++ -- 4.16E-07 7.40E-06 2.34E-01 1.63E-01 1.55E-01 AA_WOD_MAP 
169 rs7030417 9 134502556 a 0.13 1650 -7.35 3.98 -- ++ 4.20E-07 1.37E-01 3.78E-08 6.11E-06 8.33E-06 AA_ALL_SBP 
170 rs4968882 17 66310599 a 0.73 1815 0.18 4.07 -++ +++ 4.25E-07 1.66E-04 7.71E-01 1.95E-02 2.12E-02 EA_WOD_PP 
171 rs9997202 4 109260797 a 0.16 1000 0.56 -9.12 ++ -- 4.30E-07 4.85E-04 6.82E-01 1.87E-02 2.90E-02 AA_WOD_SBP 
172 rs12603759 17 10022257 t 0.20 1815 2.21 -6.42 +++ --- 4.31E-07 7.63E-07 3.29E-03 1.75E-01 1.95E-01 EA_WOD_PP 
173 rs1331485 6 1045462 a 0.35 2547 -0.83 3.67 --- +++ 4.41E-07 2.96E-07 2.18E-02 9.97E-01 1.00E+00 EA_ALL_DBP 
174 rs115905395 5 63473312 t 0.97 1816 -12.18 17.58 - + 4.42E-07 1.06E-07 2.07E-06 3.03E-01 3.24E-01 AS_WOD_SBP 
175 rs114194661 6 476348 t 0.06 1650 -1.64 -6.11 -- -- 4.43E-07 4.71E-03 3.10E-01 1.06E-03 1.14E-03 AA_ALL_MAP 
176 rs189689705 12 39316220 a 0.93 1650 0.39 5.68 -+ ++ 4.46E-07 6.93E-03 7.48E-01 3.40E-03 3.09E-03 AA_ALL_DBP 
177 rs112142223 7 5883137 t 0.15 1815 -2.30 -2.47 --- +-- 4.53E-07 5.73E-02 1.35E-03 1.22E-05 1.31E-05 EA_WOD_PP 
178 rs11220332 11 125940800 a 0.88 1650 1.66 7.83 ++ ++ 4.60E-07 1.96E-03 2.86E-01 1.45E-04 1.89E-04 AA_ALL_SBP 
179 rs2240405 7 5880392 c 0.14 1815 -2.08 -2.71 --- +-- 4.63E-07 3.62E-02 3.73E-03 3.22E-05 3.47E-05 EA_WOD_PP 
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180 rs9949360 18 21833586 a 0.02 1823 -3.84 12.19 - + 4.66E-07 9.86E-07 3.92E-02 2.12E-02 1.79E-02 AS_ALL_MAP 
181 rs28884496 18 21837697 a 0.98 1816 3.81 -12.30 + - 4.70E-07 9.76E-07 4.29E-02 2.03E-02 1.68E-02 AS_WOD_MAP 
182 rs72884862 18 21843356 a 0.02 1816 -6.03 15.70 - + 4.74E-07 3.44E-07 8.73E-03 9.34E-02 8.23E-02 AS_WOD_SBP 
183 rs17097800 14 99257740 t 0.49 1816 -1.05 0.24 - + 4.79E-07 4.96E-01 6.93E-05 1.14E-07 1.22E-07 AS_WOD_PP 
184 rs17033692 1 115869850 t 0.92 1650 2.13 8.38 ++ ++ 4.83E-07 1.15E-03 1.70E-01 3.13E-04 3.38E-04 AA_ALL_SBP 
185 rs113300617 9 37544221 a 0.07 1650 -1.63 -8.58 -- -- 4.86E-07 1.17E-03 3.99E-01 7.15E-03 8.14E-03 AA_ALL_SBP 
186 rs11931137 4 109259817 a 0.16 1000 0.57 -9.03 ++ -- 4.88E-07 5.74E-04 6.76E-01 2.03E-02 3.13E-02 AA_WOD_SBP 
187 rs75620742 1 162117393 a 0.07 1650 -0.32 7.45 +- ++ 4.91E-07 1.52E-06 7.07E-01 1.38E-02 1.47E-02 AA_ALL_DBP 
188 rs73196659 3 107082584 a 0.90 1800 -3.15 10.43 -?- +?+ 4.95E-07 1.11E-07 6.23E-03 4.30E-01 4.29E-01 EA_ALL_PP 
189 rs500945 13 72912370 a 0.36 1815 -1.01 -3.29 --- --- 5.00E-07 8.98E-04 4.73E-02 3.13E-04 4.04E-04 EA_WOD_MAP 
190 rs885581 1 62445706 a 0.47 1650 -1.21 -2.23 -- -- 5.13E-07 7.44E-03 1.83E-02 8.58E-06 9.78E-06 AA_ALL_DBP 
191 rs80315633 5 93955316 d 0.29 1000 -3.69 4.35 -- ++ 5.15E-07 3.65E-04 8.92E-08 4.88E-04 3.89E-04 AA_WOD_DBP 
192 rs1331486 6 1045382 t 0.65 2547 0.80 -3.65 +++ --- 5.22E-07 3.37E-07 2.70E-02 9.35E-01 9.40E-01 EA_ALL_DBP 
193 rs138939593 18 41930279 c 0.04 1823 2.15 3.93 + + 5.32E-07 3.12E-02 1.23E-01 1.42E-06 1.38E-06 AS_ALL_DBP 
194 rs72646023 13 85079520 t 0.06 1650 -0.05 -9.95 -+ -- 5.44E-07 5.82E-04 9.80E-01 7.20E-02 5.68E-02 AA_ALL_SBP 
195 rs843605 4 121426884 t 0.93 1650 3.29 6.95 ++ ++ 5.50E-07 1.75E-02 4.91E-02 1.37E-05 1.35E-05 AA_ALL_SBP 
196 rs72646022 13 85079280 t 0.94 1650 0.04 9.93 +- ++ 5.56E-07 5.95E-04 9.81E-01 7.23E-02 5.71E-02 AA_ALL_SBP 
197 rs2643205 15 39007170 t 0.57 2547 0.92 -5.06 +++ --- 5.62E-07 3.70E-08 6.32E-02 8.53E-01 8.24E-01 EA_ALL_PP 
198 rs4960486 6 1044908 t 0.65 2547 0.79 -3.64 +++ --- 5.65E-07 3.68E-07 2.90E-02 9.22E-01 9.27E-01 EA_ALL_DBP 
199 rs115905395 5 63473312 t 0.97 1823 -12.04 17.53 - + 5.65E-07 1.20E-07 2.78E-06 3.37E-01 3.60E-01 AS_ALL_SBP 
200 rs2250624 12 47355587 a 0.29 1000 0.37 -6.08 -+ -- 5.70E-07 3.46E-06 6.72E-01 9.41E-03 9.74E-03 AA_WOD_DBP 
201 rs1331485 6 1045462 a 0.35 2547 -0.94 3.78 --- +++ 5.76E-07 1.35E-06 1.60E-02 7.76E-01 7.67E-01 EA_ALL_MAP 
202 rs147344979 8 83509698 t 0.93 1650 5.29 4.96 ++ ++ 5.77E-07 7.64E-02 1.36E-03 2.56E-06 2.96E-06 AA_ALL_SBP 
203 rs9392251 6 1045864 a 0.66 2547 0.79 -3.66 +++ --- 5.80E-07 3.72E-07 2.97E-02 9.13E-01 9.16E-01 EA_ALL_DBP 
204 rs1537905 1 88672066 a 0.05 1650 -8.30 3.80 -- +- 5.89E-07 2.81E-01 1.01E-07 1.22E-04 1.03E-04 AA_ALL_SBP 
205 rs115100192 18 41929553 c 0.04 1816 2.24 3.62 + + 5.91E-07 4.28E-02 1.02E-01 1.30E-06 1.26E-06 AS_WOD_DBP 
206 rs114194661 6 476348 t 0.06 1650 -0.86 -10.45 +- -- 5.94E-07 1.22E-03 7.26E-01 5.84E-03 6.18E-03 AA_ALL_SBP 
207 rs111769553 1 168590413 a 0.87 1000 -4.18 5.56 -- ++ 5.98E-07 2.49E-04 2.03E-06 3.63E-02 4.22E-02 AA_WOD_DBP 
208 rs3800570 7 138411332 c 0.92 1800 1.06 3.98 +?+ +?+ 6.14E-07 1.21E-03 1.74E-01 2.01E-02 2.33E-02 EA_ALL_DBP 
209 rs72884862 18 21843356 a 0.02 1823 -6.12 15.68 - + 6.15E-07 3.72E-07 7.80E-03 1.07E-01 9.58E-02 AS_ALL_SBP 
210 rs10849654 12 119838146 a 0.10 1372 4.35 -9.30 ++? --? 6.16E-07 3.14E-04 1.21E-04 1.24E-03 1.32E-03 EA_ALL_PP 
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211 rs112991830 2 203025238 a 0.54 1000 -0.59 5.10 -- -+ 6.28E-07 1.07E-04 4.50E-01 6.45E-02 6.20E-02 AA_WOD_MAP 
212 rs138824325 10 28702905 a 0.14 1372 -0.28 -6.67 +-? --? 6.34E-07 3.24E-05 6.82E-01 1.75E-01 1.95E-01 EA_ALL_MAP 
213 rs534618 13 72913721 a 0.63 1815 1.01 3.27 +++ +++ 6.36E-07 9.76E-04 4.76E-02 3.29E-04 4.26E-04 EA_WOD_MAP 
214 rs10163977 18 41935966 a 0.04 1816 2.25 3.60 + + 6.36E-07 4.40E-02 1.00E-01 1.38E-06 1.32E-06 AS_WOD_DBP 
215 rs13020769 2 152153552 a 0.52 1000 -1.86 -2.38 -- -- 6.37E-07 4.45E-02 6.50E-03 9.82E-07 1.24E-06 AA_WOD_DBP 
216 rs74135423 10 43429610 t 0.92 1650 0.66 4.79 ++ ++ 6.45E-07 7.79E-04 4.84E-01 1.22E-03 1.21E-03 AA_ALL_DBP 
217 rs72219928 13 72935136 d 0.32 1815 -1.00 -2.86 --- --- 6.54E-07 4.84E-03 4.69E-02 2.78E-04 3.21E-04 EA_WOD_MAP 
218 rs7580215 2 214045537 a 0.82 1000 3.11 -6.73 ++ -- 6.57E-07 2.40E-06 4.79E-05 3.05E-01 3.09E-01 AA_WOD_DBP 
219 rs28884496 18 21837697 a 0.98 1823 3.93 -12.34 + - 6.59E-07 1.22E-06 3.89E-02 2.49E-02 2.09E-02 AS_ALL_MAP 
220 rs55947090 13 85080173 a 0.94 1650 0.03 9.95 +- ++ 6.63E-07 6.04E-04 9.89E-01 7.44E-02 5.87E-02 AA_ALL_SBP 
221 rs73137851 7 64403345 t 0.10 1372 -1.80 -12.29 --? --? 6.65E-07 5.60E-04 2.45E-01 4.83E-02 4.89E-02 EA_ALL_SBP 
222 rs1332182 9 21507082 t 0.59 1000 0.66 -4.56 +- -- 6.82E-07 1.75E-03 4.57E-01 2.01E-02 2.22E-02 AA_WOD_PP 
223 rs343084 7 35572165 a 0.10 1000 -3.89 -3.91 -- -+ 6.85E-07 5.52E-02 2.97E-03 7.01E-05 1.03E-04 AA_WOD_PP 
224 rs62012629 15 79070351 a 0.25 916 3.32 6.67 ++? ++? 6.89E-07 3.71E-02 1.15E-02 1.50E-03 1.29E-03 EA_WOD_SBP 
225 rs111397655 7 38658037 t 0.09 1823 -2.97 -0.89 - - 6.91E-07 5.14E-01 5.88E-03 2.48E-07 1.63E-07 AS_ALL_SBP 
226 rs116552539 15 50465911 a 0.19 1000 -2.93 -1.28 -- -- 6.94E-07 3.47E-01 7.80E-04 4.72E-07 4.11E-07 AA_WOD_DBP 
227 rs9387798 6 120803246 a 0.06 1650 1.96 -12.16 ++ -- 6.94E-07 7.79E-06 3.08E-01 9.50E-02 8.91E-02 AA_ALL_SBP 
228 rs148258828 18 41909525 a 0.96 1816 -2.18 -3.83 - - 6.95E-07 3.65E-02 1.21E-01 1.80E-06 1.66E-06 AS_WOD_DBP 
229 rs138740080 20 20904948 d 0.25 1650 -0.21 -3.66 +- -- 6.95E-07 2.36E-04 7.06E-01 1.02E-03 7.36E-04 AA_ALL_DBP 
230 rs2777315 9 124383214 a 0.10 1650 3.44 -6.85 ++ -- 6.97E-07 1.63E-06 2.91E-06 2.36E-02 2.97E-02 AA_ALL_DBP 
231 rs58774946 1 168589420 t 0.13 1000 4.18 -5.50 ++ -- 6.99E-07 2.90E-04 2.16E-06 3.55E-02 4.12E-02 AA_WOD_DBP 
232 rs4238352 15 61593303 t 0.08 1800 1.90 -6.24 +?+ -?- 7.00E-07 1.59E-08 7.76E-03 3.20E-01 3.03E-01 EA_ALL_DBP 
233 rs138100114 7 5881839 d 0.84 1815 2.30 2.63 +++ --+ 7.02E-07 5.13E-02 2.32E-03 2.18E-05 2.17E-05 EA_WOD_PP 
234 rs9834427 3 165772627 a 0.11 1000 8.90 -14.41 ++ -- 7.04E-07 8.61E-05 5.42E-06 2.09E-02 2.27E-02 AA_WOD_SBP 
235 rs2777314 9 124383844 t 0.10 1650 3.44 -6.85 ++ -- 7.06E-07 1.63E-06 2.96E-06 2.37E-02 3.00E-02 AA_ALL_DBP 
236 rs76905458 10 28695807 t 0.14 1372 -0.27 -6.75 +-? --? 7.10E-07 3.13E-05 6.96E-01 1.81E-01 2.01E-01 EA_ALL_MAP 
237 rs2200226 4 53738359 t 0.42 1000 -5.58 1.24 -- ++ 7.32E-07 5.12E-01 1.47E-07 1.70E-06 1.28E-06 AA_WOD_SBP 
238 rs151312462 2 67436059 d 0.06 1650 -1.45 -5.85 -- -- 7.33E-07 3.33E-03 2.65E-01 4.01E-04 2.13E-04 AA_ALL_MAP 
239 rs1331486 6 1045382 t 0.65 2547 0.90 -3.76 +++ --- 7.34E-07 1.57E-06 2.10E-02 8.47E-01 8.37E-01 EA_ALL_MAP 
240 rs200700876 2 67436058 d 0.06 1650 -1.45 -5.85 -- -- 7.34E-07 3.33E-03 2.65E-01 3.99E-04 2.13E-04 AA_ALL_MAP 
241 rs2469761 8 22367274 a 0.41 1650 2.55 -3.74 ++ -- 7.44E-07 3.02E-05 1.59E-07 1.86E-03 2.02E-03 AA_ALL_DBP 
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242 rs67064413 1 238171619 d 0.18 1815 0.97 -5.73 -++ --- 7.50E-07 8.29E-06 1.83E-01 9.17E-01 8.73E-01 EA_WOD_PP 
243 rs560076 13 72935038 a 0.32 1815 -1.02 -2.81 --- --- 7.51E-07 5.27E-03 4.23E-02 2.48E-04 2.86E-04 EA_WOD_MAP 
244 rs74640988 13 72934978 a 0.67 1815 1.10 2.75 +++ +++ 7.56E-07 7.10E-03 2.93E-02 1.68E-04 1.95E-04 EA_WOD_MAP 
245 rs9392251 6 1045864 a 0.66 2547 0.90 -3.78 +++ --- 7.56E-07 1.61E-06 2.22E-02 8.61E-01 8.52E-01 EA_ALL_MAP 
246 rs6940225 6 120799255 a 0.94 1650 -1.75 11.89 -- ++ 7.59E-07 1.24E-05 3.63E-01 8.05E-02 7.47E-02 AA_ALL_SBP 
247 rs9401265 6 120798508 a 0.94 1650 -1.75 11.89 -- ++ 7.61E-07 1.24E-05 3.63E-01 8.05E-02 7.47E-02 AA_ALL_SBP 
248 rs111983094 1 19847611 d 0.18 1000 -4.04 9.15 -- ++ 7.61E-07 1.09E-08 2.17E-05 1.86E-01 1.91E-01 AA_WOD_DBP 
249 rs113876113 3 53719994 a 0.07 1650 -0.79 -7.50 -- -- 7.66E-07 1.22E-04 5.21E-01 1.45E-02 1.63E-02 AA_ALL_PP 
250 rs6050422 20 25177920 a 0.33 1000 2.23 -5.61 ++ -- 7.75E-07 2.03E-06 1.70E-03 6.97E-01 7.26E-01 AA_WOD_DBP 
251 rs79322622 14 78381284 t 0.07 1650 0.55 -8.14 -+ -- 7.79E-07 1.68E-04 6.99E-01 2.19E-01 2.22E-01 AA_ALL_MAP 
252 rs35867523 2 203095575 d 0.41 1650 -0.10 3.98 +- ++ 7.79E-07 1.95E-05 8.49E-01 1.40E-02 1.45E-02 AA_ALL_DBP 
253 rs12523737 6 120595996 a 0.94 1650 -2.39 8.33 -- ++ 7.85E-07 2.25E-06 6.23E-02 3.87E-01 3.67E-01 AA_ALL_MAP 
254 rs4960486 6 1044908 t 0.65 2547 0.89 -3.75 +++ --- 7.86E-07 1.68E-06 2.28E-02 8.66E-01 8.54E-01 EA_ALL_MAP 
255 rs13219862 6 120793223 t 0.06 1650 1.74 -11.87 ++ -- 8.08E-07 1.32E-05 3.66E-01 8.07E-02 7.49E-02 AA_ALL_SBP 
256 rs537143 9 124387137 a 0.10 1650 3.42 -6.90 ++ -- 8.17E-07 1.55E-06 3.93E-06 2.72E-02 3.42E-02 AA_ALL_DBP 
257 rs144597722 7 21473268 d 0.88 1000 -2.16 8.16 -- ++ 8.36E-07 5.24E-07 3.94E-02 5.26E-01 4.98E-01 AA_WOD_DBP 
258 rs10123663 9 132763543 a 0.83 2547 -0.17 -4.28 -+- --- 8.37E-07 2.19E-05 7.32E-01 3.94E-02 3.63E-02 EA_ALL_MAP 
259 rs10789860 11 111969965 t 0.09 1650 -3.24 -2.59 -- -- 8.57E-07 1.21E-01 1.31E-04 5.77E-08 1.41E-07 AA_ALL_DBP 
260 rs10006594 4 36652453 t 0.80 1815 1.20 4.70 +++ +++ 8.59E-07 9.34E-04 9.46E-02 2.11E-03 1.66E-03 EA_WOD_PP 
261 rs9895990 17 66712506 a 0.87 1800 2.98 2.56 +?+ +?+ 8.60E-07 1.09E-01 6.93E-04 3.73E-04 3.96E-04 EA_ALL_MAP 
262 rs78373079 3 21687409 t 0.94 1650 -0.52 7.99 -- ++ 8.68E-07 1.40E-04 7.30E-01 4.12E-02 3.70E-02 AA_ALL_PP 
263 rs7649309 3 55217829 a 0.34 1650 0.22 -2.87 +- -- 8.71E-07 3.23E-03 6.90E-01 1.16E-02 1.54E-02 AA_ALL_DBP 
264 rs114642658 19 46792651 t 0.06 1650 -6.63 3.70 -- ++ 8.72E-07 1.92E-01 1.08E-07 6.16E-07 1.04E-06 AA_ALL_PP 
265 rs258096 16 55762882 a 0.10 1650 -4.46 -2.68 -- -- 8.75E-07 2.70E-01 1.25E-03 1.13E-06 1.68E-06 AA_ALL_SBP 
266 rs9307319 4 109274125 t 0.15 1000 0.81 -9.62 ++ -- 8.77E-07 3.96E-04 5.56E-01 5.22E-02 8.05E-02 AA_WOD_SBP 
267 rs6494255 15 61595365 a 0.08 1800 1.94 -6.23 +?+ -?- 8.81E-07 1.84E-08 6.82E-03 3.02E-01 2.87E-01 EA_ALL_DBP 
268 rs5857499 4 36666783 d 0.20 1815 -1.30 -4.82 --- --- 8.82E-07 1.07E-03 8.11E-02 1.65E-03 1.28E-03 EA_WOD_PP 
269 rs111397655 7 38658037 t 0.09 1816 -2.87 -0.97 - - 8.84E-07 4.77E-01 7.64E-03 3.62E-07 2.29E-07 AS_WOD_SBP 
270 rs513891 13 72946718 c 0.66 1815 1.03 3.06 +++ +++ 8.90E-07 2.21E-03 3.38E-02 2.15E-04 2.67E-04 EA_WOD_MAP 
271 rs75458041 16 76851070 a 0.93 1650 -2.62 10.61 -- ++ 8.93E-07 5.73E-05 7.63E-02 5.13E-01 5.68E-01 AA_ALL_MAP 
272 rs2176167 2 203100918 t 0.59 1650 0.09 -3.97 -+ -- 8.96E-07 2.11E-05 8.64E-01 1.36E-02 1.41E-02 AA_ALL_DBP 
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273 rs74847356 1 247998148 a 0.10 1650 -2.10 -2.49 -- -- 8.98E-07 1.03E-01 3.39E-02 2.89E-05 1.89E-05 AA_ALL_MAP 
274 rs1149048 1 31198733 a 0.18 1650 -3.04 1.01 -- ++ 9.02E-07 3.87E-01 2.58E-06 2.42E-07 1.64E-07 AA_ALL_DBP 
275 rs1486201 6 120791750 a 0.06 1650 1.72 -11.82 ++ -- 9.06E-07 1.45E-05 3.71E-01 8.07E-02 7.46E-02 AA_ALL_SBP 
276 rs519377 13 72947336 a 0.66 1815 1.02 3.05 +++ +++ 9.10E-07 2.22E-03 3.50E-02 2.32E-04 2.89E-04 EA_WOD_MAP 
277 rs138939593 18 41930279 c 0.04 1816 2.28 3.60 + + 9.16E-07 4.63E-02 9.67E-02 1.95E-06 1.75E-06 AS_WOD_DBP 
278 rs4954158 2 135426618 t 0.22 1000 -4.24 5.67 -- ++ 9.22E-07 1.19E-03 4.95E-07 5.99E-03 2.51E-03 AA_WOD_PP 
279 rs16861034 1 168587942 t 0.87 1000 -4.20 5.44 -- ++ 9.25E-07 3.72E-04 2.21E-06 3.17E-02 3.66E-02 AA_WOD_DBP 
280 rs78428774 11 79790957 t 0.94 1650 1.91 10.04 ++ ++ 9.30E-07 4.72E-04 3.32E-01 3.70E-03 4.14E-03 AA_ALL_SBP 
281 rs6531476 4 36653541 t 0.80 1815 1.22 4.63 +++ +++ 9.40E-07 1.03E-03 8.79E-02 1.83E-03 1.42E-03 EA_WOD_PP 
282 rs2443496 8 22365788 a 0.59 1650 -2.49 3.79 -- ++ 9.41E-07 2.35E-05 2.61E-07 3.15E-03 3.50E-03 AA_ALL_DBP 
283 rs74045701 13 33749052 t 0.11 1650 -4.64 8.79 -- ++ 9.48E-07 2.64E-05 1.07E-06 3.68E-02 3.85E-02 AA_ALL_PP 
284 rs147340264 15 32318437 d 0.09 1650 0.09 6.50 +- ++ 9.55E-07 1.11E-05 9.17E-01 2.40E-02 2.24E-02 AA_ALL_DBP 
285 rs562136 13 72935310 a 0.68 1815 0.96 2.84 +++ +++ 9.60E-07 4.85E-03 5.39E-02 3.59E-04 4.08E-04 EA_WOD_MAP 
286 rs2000523 11 105632364 c 0.80 1000 1.00 4.08 -+ ++ 9.70E-07 9.47E-03 2.72E-01 9.36E-05 1.20E-04 AA_WOD_MAP 
287 rs57955811 9 37535368 d 0.92 1650 0.40 6.11 -+ ++ 9.72E-07 2.88E-04 7.28E-01 2.16E-02 2.24E-02 AA_ALL_MAP 
288 rs10791773 11 105631278 a 0.80 1000 1.01 4.06 -+ ++ 9.79E-07 9.83E-03 2.67E-01 9.13E-05 1.18E-04 AA_WOD_MAP 
289 rs1467194 2 135430621 a 0.20 1000 -4.36 5.82 -- ++ 9.81E-07 1.09E-03 8.99E-07 2.05E-03 1.48E-03 AA_WOD_PP 
290 rs61948170 13 34797815 a 0.03 1816 6.94 -2.21 + - 9.85E-07 3.18E-01 6.38E-05 2.23E-07 3.37E-07 AS_WOD_SBP 
 
1SNPs are duplicate if found from multiple analyses 
2Effect is in mmHg unit 
3Direction of effect in GENOA, FHS, and HyperGEN EA in European ancestry, respectively; Direction of effect in JHA and 
HyperGEN AA in African American ancestry, respectively; Question mark if cohort was not included in a meta-analysis 
Abbreviations: BP: blood pressure; SBP: systolic BP; DBP: diastolic BP; EA: effect allele; EAF: effect allele frequency; 1 DF 
Interaction P: P-value of the interaction test with 1 degree of freedom; 2 DF Joint P: P-value of the joint test with 2 degrees of freedom 
of genetic main and interaction effects; Model 2: P-value of SNP only model; Model 3: P-value of SNP in a model with SNP and E; 
EA: European ancestry; AA: African American ancestry; AS: Asian ancestry; G: Genetic Main; GxE: Interaction; ALL: All 
participants; WOD: Subject without diuretic use  
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Table 17 Replication of novel loci from Li et al. in European and African ancestry in Aim 3 
 
European ancestry 
rs ID CHR POS 
P Value 
ALL WOD 
SBP DBP MAP PP SBP DBP MAP PP 
rs11104632 12 86747816 0.69 0.44 0.55 0.49 0.58 0.28 0.36 0.93 
rs13211840 6 149153883 0.75 0.14 0.36 0.27 0.71 0.27 0.38 0.55 
rs2567241 4 141542612 0.87 0.27 0.50 0.94 0.70 0.29 0.42 0.76 
 
 
African ancestry 
rs ID CHR POS 
P Value 
ALL WOD 
SBP DBP MAP PP SBP DBP MAP PP 
rs11104632 12 86747816 0.55 0.90 0.87 0.30 0.26 1.00 0.60 0.19 
rs13211840 6 149153883 0.20 0.15 0.17 0.25 0.21 0.32 0.32 0.19 
rs2567241 4 141542612 0.40 0.10 0.20 0.75 0.65 0.35 0.59 0.27 
 
P-value < 0.1 bolded  
Abbreviations: P Value: P-value for the joint test with 2 degrees of freedom, testing genetic main and interaction effects; ALL: All 
participants; WOD: Participants without diuretic use   
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Table 18 Replication of known blood pressure loci using 2DF joint test in Aim 3 
Known blood pressure loci until June 2017 (M=239) 
FDR adjusted P-value < 0.1 bolded 
ALL: All participants; WOD: Participants without diuretic use 
“-” if a SNP did not exist in genotyping data 
 
European Americans 
 
rs ID CHR POS Gene / Locus Reference FDR adjusted P-value 
ALL WOD 
SBP DBP MAP PP SBP DBP MAP PP 
rs10059921 5 87514515 TMEM161B Warren, ture Genetics 2017 0.982 0.918 0.992 0.971 0.871 0.885 0.893 0.938 
rs10077885 5 114390121 TRIM36 Ehret, ture Genetics 2016 0.737 0.969 0.992 0.902 0.738 0.912 0.918 0.869 
rs10078021 5 75038431 POC5 Warren, ture Genetics 2017 0.991 0.922 0.992 0.902 0.871 0.914 0.962 0.869 
rs1008058 5 122435627 PRDM6 Surendran, ture Genetics 2016 0.730 0.953 0.659 0.902 0.731 0.888 0.836 0.869 
rs1011018 7 139463264 HIPK2 Warren, ture Genetics 2017 0.737 0.712 0.898 0.929 0.598 0.719 0.676 0.869 
rs10224002 7 151415041 PRKAG2 Tragante, AJHG 2014 0.991 0.999 0.992 0.983 0.950 0.940 0.962 0.973 
rs10260816 7 46010100 IGFBP3 Kato, ture Genetics 2015 0.884 0.712 0.659 0.950 0.783 0.843 0.585 0.925 
rs1036477 15 48914926 FBN1 Tragante, AJHG 2014 0.737 0.598 0.659 0.917 0.710 0.682 0.585 0.869 
rs10407022 19 2249477 AMH Surendran, ture Genetics 2016 0.991 0.970 0.992 0.971 0.856 0.711 0.676 0.938 
rs1060105 12 123806219 SBNO1 Surendran, ture Genetics 2016 0.884 0.910 0.982 0.969 0.738 0.811 0.676 0.925 
rs10760117 9 123586737 PSMD5 Ehret, ture Genetics 2016 0.737 0.983 0.982 0.902 0.858 0.940 0.918 0.869 
rs10826995 10 32082658 ARHGAP12 Warren, ture Genetics 2017 0.974 0.953 0.992 0.994 0.710 0.885 0.676 0.869 
rs10850411 12 115387796 TBX5-TBX3 Ehret, ture 2011 0.737 0.589 0.552 0.917 0.598 0.711 0.585 0.869 
rs10916082 1 227252626 CDC42BPA Warren, ture Genetics 2017 0.991 0.922 0.992 0.971 0.925 0.885 0.893 0.945 
rs10922502 1 89360158 GTF2B Warren, ture Genetics 2017 0.737 0.983 0.992 0.902 0.738 0.940 0.988 0.869 
rs10943605 6 79655477 PHIP Liu, ture Genetics 2016 0.940 0.970 0.992 0.902 0.925 0.922 0.962 0.869 
rs10948071 6 43280713 CRIP3 Ganesh, AJHG 2014 0.991 0.983 0.992 0.962 0.927 0.885 0.879 0.951 
rs10995311 10 64564934 ADO Surendran, ture Genetics 2016 0.737 0.848 0.659 0.902 0.710 0.711 0.585 0.869 
rs110419 11 8252853 LMO1 Surendran, ture Genetics 2016 0.991 0.791 0.992 0.971 0.925 0.876 0.960 0.979 
rs11066280 12 112817783 RPL6-ALDH1 Kato, ture Genetics 2011  - -  -  -  -  -  -   - 
rs111245230 9 113169775 SVEP1 Liu, ture Genetics 2016 0.619 0.918 0.630 0.902 0.710 0.888 0.809 0.869 
rs11128722 3 14958126 FGD5 Ehret, ture Genetics 2016 0.974 0.970 0.992 0.920 0.738 0.968 0.918 0.869 
rs11154027 6 121781390 GJA1 Warren, ture Genetics 2017 0.737 0.983 0.992 0.902 0.925 0.940 0.992 0.869 
rs11191548 10 104846178 CYP17A1-NT5C2 Newton-Cheh, ture Genetics 2009 0.884 0.983 0.992 0.950 0.842 0.942 0.960 0.869 
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rs112184198 10 102604514 PAX2 Warren, ture Genetics 2017 0.991 0.970 0.992 0.971 0.871 0.887 0.918 0.869 
rs11222084 11 130273230 ADAMTS8 Wain, ture Genetics 2011 0.940 0.910 0.992 0.902 0.836 0.711 0.962 0.417 
rs11229457 11 58207203 OR5B12 Surendran, ture Genetics 2016 0.892 0.970 0.982 0.917 0.925 0.913 0.988 0.869 
rs112557609 1 56576924 RP4-710M16.1-PPAP2B Warren, ture Genetics 2017 0.997 0.953 0.992 0.959 0.998 0.888 0.962 0.869 
rs1126464 16 89704365 DPEP1 Surendran, ture Genetics 2016 0.991 0.937 0.992 0.971 0.871 0.843 0.838 0.938 
rs11442819 11 45208141 PRDM11 Warren, ture Genetics 2017 0.730 0.514 0.530 0.917 0.925 0.843 0.893 0.966 
rs11537751 11 47587452 PTPMT1 Liu, ture Genetics 2016 0.954 0.970 0.992 0.902 0.925 0.968 0.992 0.930 
rs11556924 7 129663496 ZC3HC1 Ehret, ture Genetics 2016 0.737 0.970 0.982 0.902 0.710 0.930 0.893 0.869 
rs115795127 9 85993901 FRMD3 Liang, PLoS Genetics 2017  - -  -  -  -  -  -   - 
rs11639856 16 24788645 TNRC6A Liu, ture Genetics 2016 0.954 0.983 0.992 0.950 0.925 0.986 0.960 0.869 
rs11643209 16 75331044 CFDP1 Warren, ture Genetics 2017 0.619 0.953 0.630 0.902 0.396 0.843 0.585 0.732 
rs11689667 2 85491365 TCF7L1 Warren, ture Genetics 2017 0.929 0.918 0.992 0.902 0.921 0.703 0.913 0.869 
rs1173771 5 32815028 NPR3-C5orf23 Ehret, ture 2011 0.884 0.712 0.859 0.929 0.925 0.849 0.943 0.938 
rs11953630 5 157845402 EBF1 Ehret, ture 2011 0.884 0.922 0.992 0.902 0.783 0.828 0.879 0.938 
rs11977526 7 46008110 IGFBP1-IGFBP3 Zhu, AJHG 2015 0.737 0.605 0.552 0.929 0.710 0.843 0.585 0.869 
rs12374077 3 185317674 SENP2 Warren, ture Genetics 2017 0.846 0.970 0.992 0.920 0.921 0.914 0.940 0.938 
rs12408022 1 217718789 GPATCH2 Warren, ture Genetics 2017 0.974 0.943 0.992 0.902 0.871 0.888 0.960 0.869 
rs1250259 2 216300482 FN1 Warren, ture Genetics 2017 0.991 0.953 0.992 0.902 0.925 0.888 0.918 0.869 
rs12521868 5 131784393 C5orf56 Surendran, ture Genetics 2016 0.991 0.999 0.992 0.971 0.871 0.968 0.962 0.869 
rs12579720 12 20173764 PDE3A Kato, ture Genetics 2015 0.737 0.483 0.549 0.962 0.598 0.569 0.585 0.869 
rs12627651 21 44760603 CRYAA-SIK1 Ehret, ture Genetics 2016 0.974 0.978 0.992 0.927 0.842 0.888 0.960 0.789 
rs12628032 22 19967980 ARVCF Warren, ture Genetics 2017 0.730 0.712 0.552 0.902 0.871 0.888 0.893 0.938 
rs12731740 1 208024820 CD34 Warren, ture Genetics 2017 0.884 0.970 0.992 0.929 0.167 0.569 0.186 0.732 
rs1275988 2 26914364 KCNK3 Ganesh, AJHG 2014 0.737 0.598 0.552 0.902 0.710 0.777 0.585 0.732 
rs12921187 16 4943019 PPL Warren, ture Genetics 2017 0.991 0.910 0.992 0.971 0.925 0.888 0.960 0.872 
rs12940887 17 47402807 ZNF652 Ehret, ture 2011 0.999 0.970 0.992 0.971 0.871 0.888 0.918 0.869 
rs12941318 17 1333598 CRK Warren, ture Genetics 2017 0.991 0.999 0.992 0.971 0.871 0.942 0.940 0.869 
rs12946454 17 43208121 PLCD3 Newton-Cheh, ture Genetics 2009 0.759 0.970 0.992 0.902 0.836 0.843 0.838 0.925 
rs12958173 18 42141977 SETBP1 Ehret, ture Genetics 2016 0.972 0.983 0.992 0.962 0.710 0.843 0.785 0.869 
rs13002573 2 164915208 FIGN-GRB14 Wain, ture Genetics 2011 0.757 0.712 0.773 0.950 0.738 0.777 0.722 0.869 
rs13082711 3 27537909 SLC4A7 Ehret, ture 2011 0.884 0.969 0.992 0.929 0.871 0.885 0.893 0.938 
rs13107325 4 103188709 SLC39A8 Ehret, ture 2011 0.991 0.712 0.982 0.962 0.871 0.828 0.879 0.869 
rs13139571 4 156645513 GUCY1A3-GUCY1B3 Ehret, ture 2011 0.991 0.983 0.992 0.977 0.871 0.885 0.893 0.938 
rs13209747 6 127115454 RSPO3 Francescini, AJHG 2013 0.884 0.953 0.982 0.959 0.752 0.843 0.879 0.869 
rs13238550 7 131059056 MKLN1 Warren, ture Genetics 2017 0.646 0.623 0.552 0.902 0.738 0.711 0.676 0.938 
rs1327235 20 10969030 JAG1 Ehret, ture 2011 0.892 0.377 0.530 0.929 0.871 0.569 0.585 0.938 
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rs13333226 16 20365654 UMOD Padmabhan, PloS Genetics 2010 0.991 0.970 0.992 0.971 0.710 0.912 0.676 0.869 
rs13359291 5 122476457 PRDM6 Kato, ture Genetics 2015 0.730 0.794 0.659 0.902 0.710 0.912 0.879 0.869 
rs1344653 2 19730845 OSR1 Kato, ture Genetics 2015 0.619 0.377 0.468 0.902 0.598 0.569 0.585 0.732 
rs1378942 15 75077367 CYP1A1-ULK3 Newton-Cheh, ture Genetics 2009 0.737 0.712 0.552 0.902 0.738 0.682 0.676 0.869 
rs139236208 12 94880742 CCDC41 Warren, ture Genetics 2017 0.757 0.970 0.992 0.917 0.598 0.912 0.785 0.869 
rs139385870 1 1685921 DK-CPSF3L Warren, ture Genetics 2017 0.974 0.605 0.552 0.969 0.950 0.711 0.676 0.869 
rs1401454 11 16250183 SOX6 Francescini, AJHG 2013 0.759 0.910 0.992 0.929 0.783 0.885 0.918 0.938 
rs1421811 5 32714270 NPR3-C5orf23 Johnson, AJHG 2011 0.991 0.712 0.982 0.969 0.871 0.843 0.879 0.945 
rs143112823 3 154707967 RP11-439C8.2 Warren, ture Genetics 2017 0.991 0.970 0.992 0.977 0.858 0.967 0.957 0.869 
rs1438896 2 145646072 TEX41 Warren, ture Genetics 2017 0.991 0.953 0.992 0.971 0.975 0.888 0.918 0.938 
rs1446468 2 164963486 FIGN-GRB14 Wain, ture Genetics 2011 0.991 0.910 0.926 0.996 0.998 0.892 0.893 0.938 
rs1458038 4 81164723 FGF5 Ehret, ture 2011 0.884 0.712 0.982 0.983 0.710 0.719 0.676 0.869 
rs147212971 6 166178451 PDE10A Warren, ture Genetics 2017  - -  -  -  -  -  -   - 
rs1530440 10 63524591 C10orf107 Newton-Cheh, ture Genetics 2009 0.737 0.618 0.785 0.950 0.738 0.888 0.893 0.869 
rs1563788 6 43308363 TTBK1, SLC22A7, ZNF318 Kato, ture Genetics 2015 0.991 0.970 0.992 0.969 0.925 0.914 0.962 0.938 
rs1566497 4 169717148 PALLD Warren, ture Genetics 2017 0.990 0.839 0.982 0.971 0.998 0.940 0.960 0.951 
rs167479 19 11526765 RGL3 Surendran, ture Genetics 2016  - -  -  -  -  -  -   - 
rs16823124 2 183224127 PDE1A Tragante, AJHG 2014 0.972 0.918 0.982 0.990 0.925 0.888 0.918 0.938 
rs16833934 3 163737250 MIR1263 Simino, AJHG 2014 0.884 0.837 0.659 0.969 0.925 0.888 0.879 0.938 
rs16849225 2 164906820 FIGN-GRB14 Kato, ture Genetics 2011 0.737 0.598 0.630 0.950 0.710 0.682 0.585 0.869 
rs16851397 3 141134818 ZBTB38 Surendran, ture Genetics 2016  - -  -  -  -  -  -   - 
rs17030613 1 113190807 ST7L-CAPZA1-MOV10 Kato, ture Genetics 2011 0.991 0.970 0.992 0.971 0.871 0.942 0.893 0.869 
rs17059668 4 174584663 chr4mb174 Warren, ture Genetics 2017  - -  -  -  -  -  -   - 
rs17080102 6 151004770 PLEKHG1 Francescini, AJHG 2013 0.999 0.910 0.992 0.971 0.925 0.914 0.988 0.869 
rs17249754 12 90060586 ATP2B1 Levy, ture Genetics 2009 0.737 0.377 0.552 0.971 0.752 0.569 0.722 0.966 
rs17367504 1 11862778 MTHFR-NPPB Newton-Cheh, ture Genetics 2009 0.737 0.910 0.982 0.929 0.871 0.888 0.918 0.869 
rs17428471 7 27337867 EVX1-HOXA Francescini, AJHG 2013 0.884 0.970 0.992 0.902 0.710 0.970 0.906 0.732 
rs17477177 7 106411858 PIK3CG Wain, ture Genetics 2011 0.737 0.910 0.864 0.902 0.710 0.843 0.838 0.869 
rs17608766 17 45013271 GOSR2 Ehret, ture 2011 0.814 0.999 0.992 0.902 0.871 0.942 0.962 0.869 
rs17638167 19 11584818 ELAVL3 Ehret, ture Genetics 2016 0.991 0.970 0.992 0.969 0.871 0.968 0.962 0.869 
rs1799945 6 26091179 HFE Ehret, ture 2011 0.619 0.712 0.530 0.902 0.710 0.887 0.585 0.869 
rs1801253 10 115805056 ADRB1  Johnson, Hypertension 2011 0.737 0.970 0.992 0.902 0.925 0.935 0.962 0.869 
rs1813353 10 18707448 CACNB2 Ehret, ture 2011 0.974 0.999 0.992 0.950 0.783 0.885 0.676 0.938 
rs1925153 6 56102780 COL21A1 Liu, ture Genetics 2016 0.991 0.969 0.992 0.920 0.925 0.888 0.940 0.925 
rs1953126 9 123640500 PHF19 Liu, ture Genetics 2016 0.991 0.953 0.992 0.902 0.856 0.885 0.893 0.869 
rs1975487 2 55809054 PNPT1 Ehret, ture Genetics 2016 0.991 0.953 0.992 0.920 0.998 0.888 0.960 0.938 
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rs2004776 1 230848702 AGT Johnson, AJHG 2011 0.999 0.922 0.992 0.917 0.925 0.912 0.918 0.869 
rs2014408 11 16365282 SOX6 Johnson, AJHG 2011 0.619 0.589 0.552 0.902 0.598 0.711 0.676 0.930 
rs2014912 4 86715670 ARHGAP24 Kato, ture Genetics 2015 0.672 0.423 0.530 0.962 0.598 0.571 0.585 0.925 
rs2071518 8 120435812 NOV Wain, ture Genetics 2011 0.853 0.970 0.992 0.920 0.998 0.942 0.962 0.950 
rs2107595 7 19049388 HDAC9 Kato, ture Genetics 2015 0.884 0.589 0.992 0.589 0.925 0.733 0.918 0.869 
rs217727 11 2016908 H19 Tragante, AJHG 2014 0.759 0.970 0.992 0.902 0.710 0.682 0.585 0.869 
rs2188962 5 131770805 C5orf56 Liu, ture Genetics 2016 0.991 0.983 0.992 0.971 0.871 0.968 0.962 0.869 
rs2240736 17 59485393 C17orf82,TBX2 Kato, ture Genetics 2015 0.991 0.899 0.828 0.982 0.998 0.912 0.918 0.938 
rs2270860 6 43270151 SLC22A7 Liu, ture Genetics 2016 0.991 0.970 0.992 0.962 0.925 0.888 0.960 0.938 
rs2282978 7 92264410 CDK6 Tragante, AJHG 2014 0.771 0.969 0.992 0.902 0.871 0.968 0.988 0.869 
rs2289081 2 20881840 C2orf43 Warren, ture Genetics 2017 0.840 0.918 0.727 0.917 0.738 0.785 0.585 0.869 
rs2291435 4 38387395 TBC1D1-FLJ13197 Ehret, ture Genetics 2016 0.884 0.943 0.992 0.971 0.871 0.888 0.928 0.938 
rs2302061 19 2226772 DOT1L Liu, ture Genetics 2016 0.991 0.999 0.992 0.962 - -  -   - 
rs2304130 19 19789528 ZNF101 Surendran, ture Genetics 2016  - -  -  -  - -  -   - 
rs2306374 3 138119952 MRAS Warren, ture Genetics 2017 0.619 0.598 0.552 0.902 0.222 0.682 0.585 0.732 
rs2384550 12 115352731 TBX5-TBX3 Levy, ture Genetics 2009 0.913 0.970 0.992 0.929 0.738 0.885 0.879 0.869 
rs2467099 17 73949045 ACOX1 Warren, ture Genetics 2017 0.999 0.943 0.992 0.962 0.966 0.711 0.879 0.869 
rs2493292 1 3328659 PRDM16 Liu, ture Genetics 2016 0.999 0.970 0.992 0.971 - -  -   - 
rs2521501 15 91437388 FURIN-FES Ehret, ture 2011 0.901 0.953 0.992 0.902 0.958 0.914 0.962 0.938 
rs2579519 2 96675166 GPAT2-FAHD2CP Warren, ture Genetics 2017 0.991 0.910 0.992 0.971 0.871 0.888 0.893 0.938 
rs2760061 1 228191075 WNT3A Warren, ture Genetics 2017 0.901 0.655 0.630 0.971 0.925 0.843 0.879 0.869 
rs2782980 10 115781527 ADRB1 Wain, ture Genetics 2011 0.957 0.910 0.992 0.929 0.858 0.746 0.893 0.938 
rs2854275 6 32628428 HLA-DQB1 Tragante, AJHG 2014 0.991 0.943 0.992 0.971 - -  -   - 
rs2898290 8 11433909 BLK-GATA4 Ho, Jourl of Hypertension 2011 0.974 0.970 0.992 0.990 0.989 0.922 0.962 0.938 
rs2932538 1 113216543 ST7L-CAPZA1-MOV10 Ehret, ture 2011 0.884 0.918 0.630 0.929 0.871 0.912 0.893 0.869 
rs2969070 7 2512545 CHST12-LFNG Ehret, ture Genetics 2016 0.884 0.508 0.552 0.962 0.710 0.571 0.585 0.869 
rs2972146 2 227100698 2q36.3 Surendran, ture Genetics 2016 0.619 0.910 0.828 0.902 0.598 0.885 0.785 0.734 
rs2978098 8 101676675 SNX31 Warren, ture Genetics 2017 0.991 0.943 0.992 0.996 0.950 0.940 0.962 0.938 
rs2978456 8 42324765 SLC20A2 Warren, ture Genetics 2017 0.737 0.712 0.571 0.920 0.784 0.888 0.879 0.925 
rs3184504 12 111884608 SH2B3 Levy, ture Genetics 2009 0.759 0.712 0.659 0.917 0.710 0.571 0.585 0.869 
rs319690 3 47927484 MAP4 Wain, ture Genetics 2011 0.737 0.970 0.992 0.902 0.783 0.912 0.893 0.869 
rs33063 16 69640217 NFAT5 Tragante, AJHG 2014 0.737 0.714 0.915 0.902 0.710 0.843 0.676 0.869 
rs34591516 8 142367087 GPR20 Surendran, ture Genetics 2016 0.940 0.703 0.773 0.971 0.871 0.711 0.676 0.997 
rs347591 3 11290122 HRH1-ATG7 Ganesh, Human Molecular Genetics 2013 0.991 0.970 0.992 0.920 0.842 0.885 0.869 0.869 
rs35199222 15 81013037 ABHD17C Warren, ture Genetics 2017 0.888 0.953 0.992 0.950 0.925 0.887 0.940 0.938 
rs35444 12 115552437 TBX5-TBX3 Kato, ture Genetics 2011 0.737 0.910 0.992 0.917 0.710 0.942 0.975 0.841 
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rs36022378 3 49913705 CAMKV-ACTBP13 Warren, ture Genetics 2017 0.999 0.970 0.997 0.962 0.776 0.295 0.675 0.938 
rs36083386 6 152397912 ESR1 Warren, ture Genetics 2017 0.759 0.910 0.859 0.962 0.925 0.733 0.893 0.938 
rs3741378 11 65408937 SIPA1 Tragante, AJHG 2014 0.913 0.712 0.982 0.983 0.925 0.914 0.957 0.938 
rs3771371 2 71627539 ZNF638 Warren, ture Genetics 2017 0.737 0.983 0.992 0.902 0.738 0.888 0.960 0.732 
rs3774372 3 41877414 ULK4 Ehret, ture 2011 0.737 0.686 0.530 0.929 0.776 0.719 0.585 0.869 
rs381815 11 16902268 PLEKHA7 Levy, ture Genetics 2009 0.759 0.910 0.769 0.902 0.752 0.711 0.676 0.869 
rs3889199 1 59653742 FGGY Warren, ture Genetics 2017 0.913 0.970 0.992 0.902 0.858 0.968 0.998 0.869 
rs3918226 7 150690176 NOS3 Johnson, AJHG 2011 0.737 0.953 0.982 0.902 - -  -   - 
rs409558 6 31708147 MSH5-SAPCD1 Liu, ture Genetics 2016 0.884 0.759 0.659 0.929 0.871 0.780 0.676 0.869 
rs419076 3 169100886 MECOM Ehret, ture 2011 0.940 0.598 0.982 0.920 0.940 0.711 0.960 0.869 
rs4245739 1 204518842 MDM4 Ganesh, Human Molecular Genetics 2013 0.884 0.508 0.552 0.962 0.925 0.843 0.893 0.938 
rs4247374 19 7252756 INSR Ehret, ture Genetics 2016 - -  -   - - -  -   - 
rs4308 17 61559625 ACE Warren, ture Genetics 2017 0.884 0.970 0.992 0.920 0.783 0.888 0.943 0.869 
rs4360494 1 38455891 SF3A3 Warren, ture Genetics 2017 0.991 0.999 0.992 0.971 0.925 0.888 0.936 0.869 
rs4364717 9 21801530 MTAP Warren, ture Genetics 2017 0.619 0.508 0.530 0.902 0.434 0.280 0.384 0.869 
rs4373814 10 18419972 CACNB2 Ehret, ture 2011 0.960 0.969 0.992 0.969 0.871 0.888 0.893 0.869 
rs4387287 10 105677897 OBFC1 Surendran, ture Genetics 2016 0.814 0.712 0.982 0.917 0.871 0.912 0.962 0.869 
rs4454254 8 141060027 TRAPPC9 Warren, ture Genetics 2017 0.913 0.983 0.992 0.950 0.752 0.885 0.879 0.938 
rs4494250 10 96563757 CYP2C19 Liu, ture Genetics 2016 0.997 0.983 0.992 0.969 0.925 0.888 0.962 0.938 
rs449789 6 159699125 FNDC1 Warren, ture Genetics 2017 0.737 0.910 0.659 0.902 0.925 0.912 0.918 0.938 
rs452036 14 23865885 MYH6 Surendran, ture Genetics 2016 0.999 0.970 0.992 0.971 0.921 0.912 0.940 0.938 
rs4530754 5 122855416 CSNK1G3 Liu, ture Genetics 2016 0.974 0.918 0.982 0.971 0.783 0.840 0.838 0.973 
rs4590817 10 63467553 C10orf107 Ehret, ture 2011 0.782 0.618 0.982 0.971 0.871 0.843 0.879 0.951 
rs4601790 11 65353906 EHBP1L1 Simino, AJHG 2014 0.991 0.943 0.992 0.950 0.925 0.899 0.893 0.869 
rs4660293 1 40028180 PABPC4 Liu, ture Genetics 2016 0.884 0.970 0.992 0.929 0.925 0.888 0.960 0.938 
rs470113 22 40729614 TNRC6B Surendran, ture Genetics 2016 0.737 0.377 0.487 0.950 0.598 0.569 0.585 0.869 
rs4728142 7 128573967 7q32.1 Surendran, ture Genetics 2016 0.991 0.910 0.992 0.927 0.925 0.827 0.893 0.870 
rs4746172 10 75855842 VCL Tragante, AJHG 2014 0.619 0.427 0.530 0.902 0.710 0.623 0.676 0.869 
rs4823006 22 29451671 ZNRF3 Liu, ture Genetics 2016 0.884 0.717 0.982 0.969 0.598 0.569 0.675 0.869 
rs4841569 8 11452177 BLK-GATA4 Simino, AJHG 2014 0.884 0.970 0.992 0.927 0.856 0.968 0.962 0.869 
rs4846049 1 11850365 MTHFR-NPPB Johnson, AJHG 2011 0.737 0.910 0.982 0.950 0.710 0.711 0.676 0.925 
rs4952611 2 40567743 SLC8A1 Warren, ture Genetics 2017 0.884 0.956 0.982 0.917 0.598 0.746 0.585 0.869 
rs5068 1 11905974 MTHFR-NPPB Newton-Cheh, ture Genetics 2009 0.954 0.922 0.992 0.969 0.783 0.843 0.811 0.938 
rs5219 11 17409572 KCNJ11 Liu, ture Genetics 2016 0.991 0.970 0.992 0.929 0.783 0.892 0.893 0.869 
rs55701159 2 25139596 ADCY3 Warren, ture Genetics 2017 0.991 0.970 0.992 0.998 0.925 0.885 0.893 0.986 
rs55780018 2 208526140 METTL21A-AC079767.3 Warren, ture Genetics 2017 0.954 0.953 0.992 0.971 0.989 0.914 0.962 0.952 
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rs6015450 20 57751117 GS-EDN3 Ehret, ture 2011 0.737 0.712 0.552 0.929 0.760 0.569 0.585 0.938 
rs6081613 20 19465907 SLC24A3 Warren, ture Genetics 2017 0.954 0.922 0.992 0.902 0.738 0.914 0.960 0.869 
rs6095241 20 47308798 PREX1 Surendran, ture Genetics 2016 0.759 0.970 0.992 0.902 0.856 0.843 0.893 0.938 
rs6108168 20 8626271 PLCB1 Warren, ture Genetics 2017 0.991 0.970 0.992 0.969 0.856 0.711 0.585 0.938 
rs62012628 15 79070000 ADAMTS7 Warren, ture Genetics 2017 0.840 0.918 0.945 0.920 0.037 0.295 0.102 0.417 
rs62080325 17 42060631 PYY Warren, ture Genetics 2017 0.954 0.970 0.992 0.962 0.925 0.912 0.962 0.938 
rs62104477 19 30294991 CCNE1 Warren, ture Genetics 2017 0.913 0.983 0.992 0.917 0.921 0.738 0.676 0.938 
rs6271 9 136522274 DBH Ehret, ture Genetics 2016 0.737 0.712 0.630 0.929 0.388 0.569 0.290 0.869 
rs633185 11 100593538 FLJ32810-TMEM133 Ehret, ture 2011 0.737 0.969 0.659 0.902 0.731 0.888 0.601 0.869 
rs6487543 12 26438189 SSPN Warren, ture Genetics 2017 0.737 0.970 0.930 0.902 0.925 0.940 0.962 0.941 
rs661348 11 1905292 LSP1-TNNT3 Johnson, AJHG 2011 0.884 0.943 0.992 0.902 0.925 0.968 0.992 0.869 
rs6686889 1 25030470 chr1mb25 Warren, ture Genetics 2017 0.974 0.970 0.992 0.962 0.958 0.914 0.895 0.938 
rs6712094 2 165043460 FIGN-GRB14 Ganesh, AJHG 2014 0.814 0.953 0.982 0.917 0.856 0.922 0.957 0.869 
rs6722745 2 108875244 SULT1C3 Liu, ture Genetics 2016 0.991 0.970 0.992 0.971 0.738 0.843 0.893 0.732 
rs67330701 11 69079707 MYEOV Warren, ture Genetics 2017 - -  -   - - -  -   - 
rs6797587 3 48197614 CDC25A Simino, AJHG 2014 0.954 0.953 0.992 0.902 0.776 0.887 0.918 0.869 
rs6825911 4 111381638 ENPEP Kato, ture Genetics 2011 0.991 0.918 0.992 0.977 0.921 0.843 0.943 0.869 
rs687621 9 136137065 ABO Surendran, ture Genetics 2016 0.913 0.508 0.630 0.902 0.925 0.623 0.676 0.869 
rs6891344 5 123136656 CSNK1G3 Ehret, ture Genetics 2016 0.884 0.970 0.992 0.917 0.921 0.914 0.940 0.938 
rs6911827 6 22130601 CASC15 Warren, ture Genetics 2017 0.730 0.377 0.530 0.950 0.598 0.569 0.585 0.925 
rs6969780 7 27159136 HOXA3 Liu, ture Genetics 2016 0.991 0.859 0.926 0.929 0.871 0.682 0.676 0.938 
rs709209 1 6278414 RNF207 Surendran, ture Genetics 2016 0.991 0.970 0.992 0.917 0.710 0.295 0.548 0.869 
rs7103648 11 47461783 RAPSN, PSMC3, SLC39A13 Ehret, ture Genetics 2016 0.940 0.978 0.992 0.902 0.871 0.922 0.992 0.869 
rs7126805 11 828916 CRACR2B Warren, ture Genetics 2017 0.913 0.970 0.992 0.929 0.921 0.998 0.962 0.869 
rs7129220 11 10350538 ADM Ehret, ture 2011 0.935 0.970 0.992 0.902 0.710 0.888 0.838 0.869 
rs7178615 15 66869072 RP11-321F6.1 Warren, ture Genetics 2017 0.884 0.970 0.982 0.920 0.949 0.914 0.962 0.869 
rs7236548 18 43097750 SLC14A2 Warren, ture Genetics 2017 0.974 0.970 0.992 0.950 0.871 0.885 0.893 0.872 
rs7248104 19 7224431 INSR Liu, ture Genetics 2016 0.619 0.598 0.487 0.902 0.378 0.280 0.171 0.869 
rs72765298 9 127900996 SCAI Warren, ture Genetics 2017 0.737 0.983 0.992 0.902 0.925 0.940 0.992 0.869 
rs7297416 12 54443090 HOXC4 Tragante, AJHG 2014 0.913 0.999 0.992 0.920 0.598 0.888 0.838 0.789 
rs7302981 12 50537815 CERS5 Surendran, ture Genetics 2016 0.757 0.712 0.773 0.971 0.710 0.711 0.676 0.925 
rs740406 19 2232221 AMH Kato, ture Genetics 2015 - -  -   - - -  -   - 
rs7406910 17 46688256 HOXB7 Surendran, ture Genetics 2016 0.884 0.983 0.992 0.902 0.921 0.885 0.893 0.869 
rs740698 17 60767151 MRC2 Warren, ture Genetics 2017 0.999 0.863 0.992 0.969 0.949 0.968 0.962 0.870 
rs74181299 2 65283972 CEP68 Warren, ture Genetics 2017 0.737 0.717 0.659 0.902 0.738 0.885 0.820 0.869 
rs743757 3 50476378 CAC2D2 Warren, ture Genetics 2017 0.737 0.423 0.571 0.902 0.913 0.077 0.676 0.732 
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rs745821 18 48142854 MAPK4 Warren, ture Genetics 2017 0.991 0.943 0.992 0.917 0.937 0.885 0.893 0.869 
rs7515635 1 42408070 HIVEP3 Ehret, ture Genetics 2016 0.991 0.970 0.992 0.929 0.925 0.968 0.960 0.925 
rs751984 11 61278246 LRRC10B Kato, ture Genetics 2015 0.737 0.918 0.630 0.902 0.776 0.915 0.893 0.869 
rs7562 2 28635740 FOSL2 Warren, ture Genetics 2017 0.974 0.655 0.992 0.971 0.925 0.682 0.879 0.870 
rs757081 11 17351683 NUCB2 Tragante, AJHG 2014 0.888 0.970 0.992 0.917 0.871 0.922 0.957 0.925 
rs7592578 2 191439591 TMEM194B Warren, ture Genetics 2017 0.737 0.918 0.982 0.902 0.731 0.914 0.893 0.869 
rs76206723 7 40447971 SUGCT Warren, ture Genetics 2017 0.646 0.953 0.859 0.589 0.738 0.912 0.960 0.417 
rs76326501 2 43167878 AC016735.1 Warren, ture Genetics 2017 0.737 0.423 0.542 0.929 0.776 0.569 0.585 0.938 
rs76452347 9 35906471 HRCT1 Liu, ture Genetics 2016 0.730 0.970 0.859 0.902 0.921 0.942 0.947 0.938 
rs76987554 6 134080855 TARID/TCF21 Liang, PLoS Genetics 2017 - -  -   - - -  -   - 
rs78648104 6 50683009 TFAP2D Warren, ture Genetics 2017 0.997 0.970 0.992 0.989 0.925 0.888 0.940 0.870 
rs79089478 17 40317241 KCNH4-HSD17B1 Warren, ture Genetics 2017 0.958 0.623 0.769 0.989 0.925 0.682 0.814 0.789 
rs79146658 2 179786068 CCDC141 Warren, ture Genetics 2017 0.999 0.970 0.992 0.971 0.598 0.827 0.585 0.869 
rs8016306 14 63928546 PPP2R5E Warren, ture Genetics 2017 0.888 0.953 0.992 0.930 0.921 0.930 0.960 0.869 
rs8059962 16 81574197 CMIP Warren, ture Genetics 2017 0.913 0.983 0.992 0.902 0.783 0.843 0.838 0.938 
rs8068318 17 59483766 TBX2 Surendran, ture Genetics 2016 0.991 0.910 0.864 0.989 0.998 0.914 0.918 0.938 
rs8258 11 117283676 CEP164 Warren, ture Genetics 2017 0.737 0.729 0.926 0.962 0.784 0.843 0.879 0.938 
rs867186 20 33764554 PROCR Surendran, ture Genetics 2016 0.884 0.970 0.992 0.920 0.925 0.682 0.809 0.938 
rs871606 4 54799245 CHIC2 Wain, ture Genetics 2011 0.737 0.969 0.992 0.902 0.598 0.711 0.585 0.869 
rs880315 1 10796866 CASZ1 Takeuchi, Circulation 2010 0.730 0.712 0.552 0.902 0.598 0.719 0.585 0.869 
rs891511 7 150704843 NOS3 Liu, ture Genetics 2016 0.814 0.970 0.992 0.902 0.871 0.843 0.879 0.941 
rs894344 8 135612745 ZFAT Warren, ture Genetics 2017 0.730 0.589 0.659 0.929 0.738 0.885 0.879 0.869 
rs900145 11 13293905 ARNTL Liu, ture Genetics 2016 0.991 0.983 0.992 0.917 0.925 0.914 0.985 0.869 
rs918466 3 64710253 ADAMTS9 Ehret, ture Genetics 2016 0.884 0.943 0.992 0.950 0.598 0.914 0.676 0.732 
rs9306160 21 45107562 RRP1B Surendran, ture Genetics 2016 0.884 0.686 0.992 0.929 0.921 0.952 0.992 0.869 
rs9323988 14 98587630 RP11-61O1.1 Warren, ture Genetics 2017 0.730 0.712 0.785 0.902 0.858 0.914 0.960 0.869 
rs932764 10 95895940 PLCE1 Ehret, ture 2011 0.619 0.377 0.487 0.902 0.598 0.711 0.585 0.851 
rs9349379 6 12903957 PHACTR1 Surendran, ture Genetics 2016 0.991 0.970 0.992 0.977 0.925 0.914 0.918 0.938 
rs9372498 6 118572486 SLC35F1 Warren, ture Genetics 2017 0.737 0.970 0.859 0.902 0.738 0.888 0.838 0.869 
rs953492 1 243471192 SDCCAG8 Warren, ture Genetics 2017 0.892 0.970 0.992 0.902 0.598 0.885 0.676 0.732 
rs9549328 13 113636156 MCF2L Warren, ture Genetics 2017 0.884 0.970 0.997 0.902 0.958 0.888 0.893 0.938 
rs9687065 5 148391140 ABLIM3,SH3TC2 Kato, ture Genetics 2015 0.730 0.423 0.487 0.917 0.388 0.275 0.186 0.869 
rs9827472 3 56726646 FAM208A Warren, ture Genetics 2017 0.737 0.759 0.659 0.902 0.783 0.828 0.809 0.869 
rs9859176 3 134000025 RYK Warren, ture Genetics 2017 0.935 0.970 0.982 0.962 0.921 0.912 0.838 0.938 
rs9888615 14 53377540 FERMT2 Warren, ture Genetics 2017 0.737 0.943 0.992 0.902 0.752 0.843 0.879 0.869 
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rs ID CHR POS Gene / Locus Reference FDR adjusted P-value 
ALL WOD 
SBP DBP MAP PP SBP DBP MAP PP 
rs10059921 5 87514515 TMEM161B Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 - -  -   - 
rs10077885 5 114390121 TRIM36 Ehret, ture Genetics 2016 0.984 0.987 0.980 0.977 0.958 0.959 0.946 0.979 
rs10078021 5 75038431 POC5 Warren, ture Genetics 2017 0.984 0.964 0.959 0.977 0.958 0.959 0.972 0.979 
rs1008058 5 122435627 PRDM6 Surendran, ture Genetics 2016 0.984 0.964 0.980 0.977 0.966 0.956 0.975 0.979 
rs1011018 7 139463264 HIPK2 Warren, ture Genetics 2017 0.984 0.964 0.922 0.947 0.958 0.871 0.901 0.979 
rs10224002 7 151415041 PRKAG2 Tragante, AJHG 2014 0.984 0.767 0.922 0.977 0.958 0.700 0.784 0.979 
rs10260816 7 46010100 IGFBP3 Kato, ture Genetics 2015 0.996 0.998 0.993 0.977 0.958 0.833 0.901 0.979 
rs1036477 15 48914926 FBN1 Tragante, AJHG 2014 0.761 0.604 0.559 0.947 0.958 0.959 0.962 0.979 
rs10407022 19 2249477 AMH Surendran, ture Genetics 2016 0.984 0.964 0.980 0.977 0.958 0.959 0.946 0.979 
rs1060105 12 123806219 SBNO1 Surendran, ture Genetics 2016 0.727 0.499 0.559 0.947 0.958 0.717 0.866 0.979 
rs10760117 9 123586737 PSMD5 Ehret, ture Genetics 2016 0.996 0.987 0.993 0.977 0.958 0.952 0.962 0.979 
rs10826995 10 32082658 ARHGAP12 Warren, ture Genetics 2017 0.984 0.871 0.922 0.977 0.958 0.795 0.866 0.979 
rs10850411 12 115387796 TBX5-TBX3 Ehret, ture 2011 0.984 0.964 0.922 0.947 0.958 0.959 0.972 0.979 
rs10916082 1 227252626 CDC42BPA Warren, ture Genetics 2017 0.984 0.871 0.980 0.947 0.966 0.795 0.901 0.979 
rs10922502 1 89360158 GTF2B Warren, ture Genetics 2017 0.984 0.964 0.980 0.985 0.958 0.959 0.988 0.979 
rs10943605 6 79655477 PHIP Liu, ture Genetics 2016 0.984 0.770 0.922 0.977 0.958 0.717 0.843 0.979 
rs10948071 6 43280713 CRIP3 Ganesh, AJHG 2014 0.984 0.943 0.988 0.948 0.958 0.753 0.866 0.979 
rs10995311 10 64564934 ADO Surendran, ture Genetics 2016 0.984 0.918 0.958 0.977 0.958 0.867 0.946 0.979 
rs110419 11 8252853 LMO1 Surendran, ture Genetics 2016 0.984 0.871 0.922 0.977 0.958 0.959 0.996 0.979 
rs11066280 12 112817783 RPL6-ALDH1 Kato, ture Genetics 2011 - -  -   - - -  -   - 
rs111245230 9 113169775 SVEP1 Liu, ture Genetics 2016 - -  -   - - -  -   - 
rs11128722 3 14958126 FGD5 Ehret, ture Genetics 2016 0.984 0.964 0.980 0.977 0.958 0.959 0.972 0.979 
rs11154027 6 121781390 GJA1 Warren, ture Genetics 2017 0.996 0.943 0.980 0.977 0.958 0.952 0.946 0.979 
rs11191548 10 104846178 CYP17A1-NT5C2 Newton-Cheh, ture Genetics 2009 0.984 0.964 0.980 0.977 0.958 0.859 0.901 0.979 
rs112184198 10 102604514 PAX2 Warren, ture Genetics 2017 0.985 0.943 0.980 0.977 0.968 0.959 0.989 0.983 
rs11222084 11 130273230 ADAMTS8 Wain, ture Genetics 2011 0.984 0.964 0.980 0.977 0.958 0.959 0.975 0.979 
rs11229457 11 58207203 OR5B12 Surendran, ture Genetics 2016 0.984 0.767 0.914 0.977 0.958 0.867 0.901 0.979 
rs112557609 1 56576924 RP4-710M16.1-PPAP2B Warren, ture Genetics 2017 0.996 0.964 0.980 0.977 0.958 0.817 0.866 0.979 
rs1126464 16 89704365 DPEP1 Surendran, ture Genetics 2016 0.984 0.767 0.922 0.977 0.966 0.771 0.901 0.979 
rs11442819 11 45208141 PRDM11 Warren, ture Genetics 2017 0.984 0.987 0.980 0.977 0.958 0.899 0.901 0.979 
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rs11537751 11 47587452 PTPMT1 Liu, ture Genetics 2016 0.984 0.964 0.993 0.977 - -  -   - 
rs11556924 7 129663496 ZC3HC1 Ehret, ture Genetics 2016 0.984 0.499 0.588 0.977 0.958 0.447 0.858 0.979 
rs115795127 9 85993901 FRMD3 Liang, PLoS Genetics 2017 0.984 0.868 0.980 0.977 0.958 0.959 0.975 0.979 
rs11639856 16 24788645 TNRC6A Liu, ture Genetics 2016 0.984 0.918 0.980 0.977 0.958 0.959 0.946 0.979 
rs11643209 16 75331044 CFDP1 Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.959 0.913 0.979 
rs11689667 2 85491365 TCF7L1 Warren, ture Genetics 2017 0.984 0.767 0.922 0.977 0.958 0.817 0.901 0.979 
rs1173771 5 32815028 NPR3-C5orf23 Ehret, ture 2011 0.984 0.499 0.914 0.977 0.958 0.717 0.866 0.979 
rs11953630 5 157845402 EBF1 Ehret, ture 2011 0.984 0.943 0.922 0.977 0.958 0.840 0.901 0.979 
rs11977526 7 46008110 IGFBP1-IGFBP3 Zhu, AJHG 2015 0.984 0.964 0.980 0.977 0.958 0.867 0.901 0.979 
rs12374077 3 185317674 SENP2 Warren, ture Genetics 2017 0.984 0.918 0.980 0.977 0.958 0.867 0.901 0.992 
rs12408022 1 217718789 GPATCH2 Warren, ture Genetics 2017 0.996 0.964 0.980 0.977 0.958 0.795 0.901 0.979 
rs1250259 2 216300482 FN1 Warren, ture Genetics 2017 0.984 0.943 0.980 0.977 0.958 0.952 0.946 0.979 
rs12521868 5 131784393 C5orf56 Surendran, ture Genetics 2016 0.984 0.987 0.980 0.977 0.958 0.833 0.946 0.979 
rs12579720 12 20173764 PDE3A Kato, ture Genetics 2015 0.984 0.943 0.980 0.977 0.958 0.700 0.858 0.983 
rs12627651 21 44760603 CRYAA-SIK1 Ehret, ture Genetics 2016 0.984 0.499 0.559 0.977 0.949 0.447 0.759 0.979 
rs12628032 22 19967980 ARVCF Warren, ture Genetics 2017 0.665 0.515 0.559 0.845 0.958 0.700 0.784 0.979 
rs12731740 1 208024820 CD34 Warren, ture Genetics 2017 0.984 0.114 0.771 0.977 - -  -   - 
rs1275988 2 26914364 KCNK3 Ganesh, AJHG 2014 0.984 0.964 0.980 0.977 0.993 0.959 0.972 0.979 
rs12921187 16 4943019 PPL Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.993 0.959 0.975 0.983 
rs12940887 17 47402807 ZNF652 Ehret, ture 2011 0.984 0.987 0.980 0.977 0.958 0.959 0.972 0.979 
rs12941318 17 1333598 CRK Warren, ture Genetics 2017 0.984 0.443 0.559 0.977 0.958 0.447 0.759 0.983 
rs12946454 17 43208121 PLCD3 Newton-Cheh, ture Genetics 2009 0.984 0.987 0.980 0.977 0.949 0.700 0.784 0.979 
rs12958173 18 42141977 SETBP1 Ehret, ture Genetics 2016 0.984 0.919 0.980 0.977 0.958 0.859 0.913 0.983 
rs13002573 2 164915208 FIGN-GRB14 Wain, ture Genetics 2011 0.984 0.767 0.914 0.977 0.958 0.959 0.989 0.979 
rs13082711 3 27537909 SLC4A7 Ehret, ture 2011 0.984 0.767 0.922 0.977 0.966 0.899 0.972 0.979 
rs13107325 4 103188709 SLC39A8 Ehret, ture 2011 - -  -   - - -  -   - 
rs13139571 4 156645513 GUCY1A3-GUCY1B3 Ehret, ture 2011 0.069 0.830 0.559 0.059 0.394 0.959 0.866 0.021 
rs13209747 6 127115454 RSPO3 Francescini, AJHG 2013 0.966 0.499 0.559 0.977 0.958 0.795 0.866 0.979 
rs13238550 7 131059056 MKLN1 Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.959 0.962 0.979 
rs1327235 20 10969030 JAG1 Ehret, ture 2011 0.996 0.964 0.980 0.977 0.958 0.975 0.975 0.979 
rs13333226 16 20365654 UMOD Padmabhan, PloS Genetics 2010 0.984 0.871 0.914 0.977 0.958 0.717 0.866 0.979 
rs13359291 5 122476457 PRDM6 Kato, ture Genetics 2015 0.984 0.987 0.980 0.947 0.966 0.959 0.972 0.979 
rs1344653 2 19730845 OSR1 Kato, ture Genetics 2015 0.984 0.964 0.980 0.977 0.966 0.959 0.974 1.000 
rs1378942 15 75077367 CYP1A1-ULK3 Newton-Cheh, ture Genetics 2009 0.984 0.964 0.980 0.977 0.966 0.931 0.962 0.979 
rs139236208 12 94880742 CCDC41 Warren, ture Genetics 2017 0.984 1.000 0.988 0.977 - -  -   - 
rs139385870 1 1685921 DK-CPSF3L Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.949 0.795 0.843 0.979 
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rs1401454 11 16250183 SOX6 Francescini, AJHG 2013 0.984 0.499 0.559 0.977 0.958 0.700 0.866 0.979 
rs1421811 5 32714270 NPR3-C5orf23 Johnson, AJHG 2011 0.984 0.987 0.980 0.977 0.993 0.952 0.972 0.979 
rs143112823 3 154707967 RP11-439C8.2 Warren, ture Genetics 2017 0.416 0.499 0.559 0.845 0.886 0.717 0.784 0.893 
rs1438896 2 145646072 TEX41 Warren, ture Genetics 2017 0.985 0.964 0.980 0.977 0.958 0.952 0.946 0.979 
rs1446468 2 164963486 FIGN-GRB14 Wain, ture Genetics 2011 0.996 0.964 0.980 0.977 0.958 0.867 0.972 0.979 
rs1458038 4 81164723 FGF5 Ehret, ture 2011 0.984 0.964 0.988 0.977 0.958 0.959 0.946 0.979 
rs147212971 6 166178451 PDE10A Warren, ture Genetics 2017 0.984 0.604 0.922 0.977 0.958 0.717 0.866 0.979 
rs1530440 10 63524591 C10orf107 Newton-Cheh, ture Genetics 2009 0.984 0.964 0.980 0.977 0.958 0.901 0.972 0.979 
rs1563788 6 43308363 TTBK1,SLC22A7,ZNF318 Kato, ture Genetics 2015 0.984 0.767 0.922 0.977 0.958 0.795 0.866 0.979 
rs1566497 4 169717148 PALLD Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.959 0.962 0.979 
rs167479 19 11526765 RGL3 Surendran, ture Genetics 2016 0.984 0.964 0.978 0.845 0.958 0.901 0.996 0.893 
rs16823124 2 183224127 PDE1A Tragante, AJHG 2014 0.984 0.772 0.914 0.977 0.949 0.700 0.759 0.979 
rs16833934 3 163737250 MIR1263 Simino, AJHG 2014 0.984 0.767 0.922 0.977 0.959 0.833 0.946 0.979 
rs16849225 2 164906820 FIGN-GRB14 Kato, ture Genetics 2011 0.984 0.767 0.914 0.977 0.966 0.859 0.946 0.979 
rs16851397 3 141134818 ZBTB38 Surendran, ture Genetics 2016 0.984 0.964 0.980 0.845 0.958 0.952 0.975 0.979 
rs17030613 1 113190807 ST7L-CAPZA1-MOV10 Kato, ture Genetics 2011 0.984 0.964 0.980 0.977 0.958 0.717 0.843 0.979 
rs17059668 4 174584663 chr4mb174 Warren, ture Genetics 2017 0.727 0.499 0.559 0.947 0.958 0.867 0.866 0.979 
rs17080102 6 151004770 PLEKHG1 Francescini, AJHG 2013 0.984 0.964 0.980 0.977 0.958 0.833 0.903 0.979 
rs17249754 12 90060586 ATP2B1 Levy, ture Genetics 2009 0.984 0.964 0.993 0.977 0.958 0.997 0.975 0.979 
rs17367504 1 11862778 MTHFR-NPPB Newton-Cheh, ture Genetics 2009 0.984 0.964 0.980 0.977 0.958 0.867 0.866 0.979 
rs17428471 7 27337867 EVX1-HOXA Francescini, AJHG 2013 0.984 0.987 0.980 0.977 0.958 0.931 0.901 0.979 
rs17477177 7 106411858 PIK3CG Wain, ture Genetics 2011 0.984 0.998 0.980 0.947 0.958 0.931 0.977 0.979 
rs17608766 17 45013271 GOSR2 Ehret, ture 2011 0.984 0.943 0.980 0.977 0.993 0.959 0.975 1.000 
rs17638167 19 11584818 ELAVL3 Ehret, ture Genetics 2016 - -  -   - - -  -   - 
rs1799945 6 26091179 HFE Ehret, ture 2011 0.984 0.964 0.980 0.977 0.958 0.931 0.975 0.979 
rs1801253 10 115805056 ADRB1  Johnson, Hypertension 2011 0.727 0.499 0.559 0.947 0.958 0.952 0.920 0.979 
rs1813353 10 18707448 CACNB2 Ehret, ture 2011 0.984 1.000 0.993 0.977 0.958 0.871 0.901 0.979 
rs1925153 6 56102780 COL21A1 Liu, ture Genetics 2016 0.984 0.868 0.922 0.977 0.958 0.931 0.946 0.983 
rs1953126 9 123640500 PHF19 Liu, ture Genetics 2016 0.996 0.964 0.980 0.977 0.958 0.717 0.866 0.979 
rs1975487 2 55809054 PNPT1 Ehret, ture Genetics 2016 0.984 0.964 0.980 0.977 0.958 0.819 0.901 0.983 
rs2004776 1 230848702 AGT Johnson, AJHG 2011 0.996 0.964 0.980 0.977 0.958 0.956 0.962 0.979 
rs2014408 11 16365282 SOX6 Johnson, AJHG 2011 0.984 0.604 0.914 0.977 0.958 0.700 0.866 0.979 
rs2014912 4 86715670 ARHGAP24 Kato, ture Genetics 2015 0.996 0.964 0.980 0.977 0.958 0.931 0.901 0.979 
rs2071518 8 120435812 NOV Wain, ture Genetics 2011 0.984 0.745 0.922 0.977 0.958 0.714 0.901 0.979 
rs2107595 7 19049388 HDAC9 Kato, ture Genetics 2015 0.984 0.964 0.980 0.977 0.958 0.959 0.977 0.979 
rs217727 11 2016908 H19 Tragante, AJHG 2014 0.984 0.964 0.980 0.977 0.958 0.959 0.962 0.979 
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rs2188962 5 131770805 C5orf56 Liu, ture Genetics 2016 0.984 0.964 0.980 0.977 0.958 0.901 0.962 0.979 
rs2240736 17 59485393 C17orf82,TBX2 Kato, ture Genetics 2015 0.984 0.964 0.993 0.977 0.958 0.959 0.962 0.979 
rs2270860 6 43270151 SLC22A7 Liu, ture Genetics 2016 0.984 0.767 0.922 0.977 0.958 0.817 0.866 0.979 
rs2282978 7 92264410 CDK6 Tragante, AJHG 2014 0.984 0.964 0.980 0.845 0.958 0.959 0.946 0.893 
rs2289081 2 20881840 C2orf43 Warren, ture Genetics 2017 0.727 0.943 0.771 0.845 0.958 0.975 0.946 0.979 
rs2291435 4 38387395 TBC1D1-FLJ13197 Ehret, ture Genetics 2016 0.984 0.853 0.922 0.977 0.958 0.833 0.866 0.979 
rs2302061 19 2226772 DOT1L Liu, ture Genetics 2016 0.984 0.853 0.980 0.948 0.958 0.700 0.901 0.979 
rs2304130 19 19789528 ZNF101 Surendran, ture Genetics 2016 0.984 0.943 0.922 0.977 0.958 0.899 0.901 0.979 
rs2306374 3 138119952 MRAS Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.966 0.959 0.977 0.979 
rs2384550 12 115352731 TBX5-TBX3 Levy, ture Genetics 2009 0.984 0.964 0.980 0.977 0.958 0.959 0.972 0.979 
rs2467099 17 73949045 ACOX1 Warren, ture Genetics 2017 0.985 0.964 0.980 0.977 0.958 0.960 0.972 0.979 
rs2493292 1 3328659 PRDM16 Liu, ture Genetics 2016 0.987 0.772 0.980 0.977 0.966 0.700 0.901 0.979 
rs2521501 15 91437388 FURIN-FES Ehret, ture 2011 0.984 0.964 0.980 0.977 0.958 0.871 0.901 0.979 
rs2579519 2 96675166 GPAT2-FAHD2CP Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.959 0.962 0.979 
rs2760061 1 228191075 WNT3A Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.931 0.913 0.979 
rs2782980 10 115781527 ADRB1 Wain, ture Genetics 2011 0.996 0.964 0.980 0.977 0.958 0.931 0.903 0.979 
rs2854275 6 32628428 HLA-DQB1 Tragante, AJHG 2014 - -  -   - - -  -   - 
rs2898290 8 11433909 BLK-GATA4 Ho, Jourl of Hypertension 2011 0.984 0.918 0.980 0.845 0.958 0.952 0.975 0.979 
rs2932538 1 113216543 ST7L-CAPZA1-MOV10 Ehret, ture 2011 0.984 0.566 0.914 0.977 0.958 0.959 0.996 0.979 
rs2969070 7 2512545 CHST12-LFNG Ehret, ture Genetics 2016 0.984 0.964 0.993 0.977 0.966 0.887 0.972 0.979 
rs2972146 2 227100698 2q36.3 Surendran, ture Genetics 2016 0.984 0.987 0.980 0.977 0.958 0.952 0.901 0.979 
rs2978098 8 101676675 SNX31 Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.959 0.977 0.979 
rs2978456 8 42324765 SLC20A2 Warren, ture Genetics 2017 0.984 0.964 0.980 0.951 0.958 0.959 0.901 0.979 
rs3184504 12 111884608 SH2B3 Levy, ture Genetics 2009 0.984 0.964 0.980 0.948 0.958 0.771 0.901 0.979 
rs319690 3 47927484 MAP4 Wain, ture Genetics 2011 0.984 0.943 0.914 0.947 0.958 0.931 0.901 0.979 
rs33063 16 69640217 NFAT5 Tragante, AJHG 2014 0.984 0.964 0.980 0.977 0.958 0.952 0.962 0.979 
rs34591516 8 142367087 GPR20 Surendran, ture Genetics 2016 0.984 0.767 0.914 0.977 0.958 0.822 0.901 0.979 
rs347591 3 11290122 HRH1-ATG7 Ganesh, Human Molecular Genetics 2013 0.984 0.964 0.922 0.977 0.958 0.931 0.946 0.989 
rs35199222 15 81013037 ABHD17C Warren, ture Genetics 2017 0.984 0.964 0.993 0.977 0.976 0.959 0.977 0.979 
rs35444 12 115552437 TBX5-TBX3 Kato, ture Genetics 2011 0.984 0.964 0.980 0.977 0.958 0.960 0.975 0.979 
rs36022378 3 49913705 CAMKV-ACTBP13 Warren, ture Genetics 2017 0.984 0.987 0.980 0.977 0.958 0.819 0.866 0.979 
rs36083386 6 152397912 ESR1 Warren, ture Genetics 2017 0.966 0.767 0.725 0.947 0.958 0.959 0.903 0.979 
rs3741378 11 65408937 SIPA1 Tragante, AJHG 2014 0.984 0.566 0.559 0.977 0.958 0.840 0.901 0.983 
rs3771371 2 71627539 ZNF638 Warren, ture Genetics 2017 0.984 0.964 0.988 0.977 0.958 0.959 0.946 0.979 
rs3774372 3 41877414 ULK4 Ehret, ture 2011 0.984 0.964 0.980 0.947 0.958 0.977 0.946 0.979 
rs381815 11 16902268 PLEKHA7 Levy, ture Genetics 2009 0.727 0.395 0.559 0.977 0.958 0.700 0.866 0.979 
 
 
 
103 
rs3889199 1 59653742 FGGY Warren, ture Genetics 2017 0.984 0.964 0.993 0.977 0.958 0.977 0.975 0.979 
rs3918226 7 150690176 NOS3 Johnson, AJHG 2011 - -  -   - - -  -   - 
rs409558 6 31708147 MSH5-SAPCD1 Liu, ture Genetics 2016 0.984 0.964 0.980 0.977 0.958 0.959 0.975 0.979 
rs419076 3 169100886 MECOM Ehret, ture 2011 0.984 0.987 0.980 0.947 0.949 0.959 0.866 0.462 
rs4245739 1 204518842 MDM4 Ganesh, Human Molecular Genetics 2013 0.984 1.000 0.980 0.977 0.965 0.959 0.975 0.979 
rs4247374 19 7252756 INSR Ehret, ture Genetics 2016 0.985 0.964 0.980 0.977 - -  -   - 
rs4308 17 61559625 ACE Warren, ture Genetics 2017 0.984 0.964 0.922 0.947 0.993 0.959 0.975 0.984 
rs4360494 1 38455891 SF3A3 Warren, ture Genetics 2017 0.996 0.604 0.922 0.977 0.958 0.700 0.784 0.979 
rs4364717 9 21801530 MTAP Warren, ture Genetics 2017 0.984 0.499 0.707 0.977 0.958 0.700 0.787 0.979 
rs4373814 10 18419972 CACNB2 Ehret, ture 2011 0.727 0.747 0.559 0.947 0.394 0.700 0.759 0.893 
rs4387287 10 105677897 OBFC1 Surendran, ture Genetics 2016 0.984 0.853 0.980 0.977 0.958 0.840 0.946 0.979 
rs4454254 8 141060027 TRAPPC9 Warren, ture Genetics 2017 0.985 0.964 0.980 0.985 0.958 0.863 0.901 0.979 
rs4494250 10 96563757 CYP2C19 Liu, ture Genetics 2016 0.984 0.993 0.998 0.977 0.958 0.952 0.946 0.979 
rs449789 6 159699125 FNDC1 Warren, ture Genetics 2017 0.984 0.964 0.993 0.977 0.958 0.959 0.972 0.983 
rs452036 14 23865885 MYH6 Surendran, ture Genetics 2016 0.984 0.964 0.980 0.977 0.958 0.959 0.972 0.979 
rs4530754 5 122855416 CSNK1G3 Liu, ture Genetics 2016 0.984 0.998 0.980 0.947 0.958 0.867 0.901 0.979 
rs4590817 10 63467553 C10orf107 Ehret, ture 2011 0.966 0.566 0.559 0.977 0.949 0.447 0.759 0.979 
rs4601790 11 65353906 EHBP1L1 Simino, AJHG 2014 0.996 0.964 0.980 0.977 0.976 0.931 0.972 0.979 
rs4660293 1 40028180 PABPC4 Liu, ture Genetics 2016 0.984 0.964 0.980 0.845 0.958 0.959 0.962 0.979 
rs470113 22 40729614 TNRC6B Surendran, ture Genetics 2016 0.984 0.964 0.980 0.977 0.958 0.949 0.946 0.979 
rs4728142 7 128573967 7q32.1 Surendran, ture Genetics 2016 0.984 0.964 0.922 0.947 0.958 0.840 0.866 0.979 
rs4746172 10 75855842 VCL Tragante, AJHG 2014 0.996 0.964 0.988 0.977 0.958 0.819 0.866 0.979 
rs4823006 22 29451671 ZNRF3 Liu, ture Genetics 2016 0.984 0.918 0.978 0.977 0.958 0.717 0.866 0.979 
rs4841569 8 11452177 BLK-GATA4 Simino, AJHG 2014 0.984 0.570 0.559 0.977 0.886 0.700 0.759 0.979 
rs4846049 1 11850365 MTHFR-NPPB Johnson, AJHG 2011 0.984 0.853 0.924 0.977 0.966 0.819 0.903 0.979 
rs4952611 2 40567743 SLC8A1 Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.959 0.946 0.979 
rs5068 1 11905974 MTHFR-NPPB Newton-Cheh, ture Genetics 2009 0.984 0.565 0.559 0.977 - -  -   - 
rs5219 11 17409572 KCNJ11 Liu, ture Genetics 2016 0.984 0.918 0.980 0.977 0.958 0.931 0.972 0.979 
rs55701159 2 25139596 ADCY3 Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.833 0.901 0.983 
rs55780018 2 208526140 METTL21A-AC079767.3 Warren, ture Genetics 2017 0.984 0.767 0.922 0.977 0.966 0.819 0.946 0.979 
rs6015450 20 57751117 GS-EDN3 Ehret, ture 2011 0.984 0.499 0.593 0.977 0.958 0.833 0.901 0.979 
rs6081613 20 19465907 SLC24A3 Warren, ture Genetics 2017 0.984 0.499 0.559 0.977 0.993 0.959 0.975 0.979 
rs6095241 20 47308798 PREX1 Surendran, ture Genetics 2016 0.984 0.767 0.922 0.977 0.958 0.795 0.866 0.979 
rs6108168 20 8626271 PLCB1 Warren, ture Genetics 2017 0.984 0.964 0.993 0.977 0.958 0.817 0.901 0.979 
rs62012628 15 79070000 ADAMTS7 Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.966 0.959 0.996 0.979 
rs62080325 17 42060631 PYY Warren, ture Genetics 2017 0.984 0.964 0.993 0.977 0.958 0.840 0.913 0.979 
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rs62104477 19 30294991 CCNE1 Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.931 0.901 0.983 
rs6271 9 136522274 DBH Ehret, ture Genetics 2016 - -  -   - - -  -   - 
rs633185 11 100593538 FLJ32810-TMEM133 Ehret, ture 2011 0.984 0.964 0.980 0.845 0.958 0.795 0.946 0.979 
rs6487543 12 26438189 SSPN Warren, ture Genetics 2017 0.984 0.871 0.980 0.977 0.958 0.959 0.946 0.979 
rs661348 11 1905292 LSP1-TNNT3 Johnson, AJHG 2011 0.984 0.767 0.922 0.985 0.958 0.867 0.946 0.979 
rs6686889 1 25030470 chr1mb25 Warren, ture Genetics 2017 0.984 0.918 0.980 0.977 0.958 0.959 0.972 0.979 
rs6712094 2 165043460 FIGN-GRB14 Ganesh, AJHG 2014 0.984 0.964 0.980 0.947 0.958 0.959 0.972 0.979 
rs6722745 2 108875244 SULT1C3 Liu, ture Genetics 2016 0.984 0.964 0.980 0.977 0.958 0.952 0.989 0.979 
rs67330701 11 69079707 MYEOV Warren, ture Genetics 2017 - -  -   - - -  -   - 
rs6797587 3 48197614 CDC25A Simino, AJHG 2014 0.984 0.964 0.980 0.977 0.958 0.840 0.974 0.979 
rs6825911 4 111381638 ENPEP Kato, ture Genetics 2011 0.984 0.964 0.980 0.977 0.958 0.931 0.901 0.979 
rs687621 9 136137065 ABO Surendran, ture Genetics 2016 0.984 0.964 0.980 0.977 0.958 0.896 0.901 0.979 
rs6891344 5 123136656 CSNK1G3 Ehret, ture Genetics 2016 0.984 0.964 0.980 0.977 0.966 0.959 0.982 0.979 
rs6911827 6 22130601 CASC15 Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.867 0.901 0.979 
rs6969780 7 27159136 HOXA3 Liu, ture Genetics 2016 0.984 0.767 0.922 0.977 0.949 0.700 0.759 0.979 
rs709209 1 6278414 RNF207 Surendran, ture Genetics 2016 0.984 0.964 0.980 0.977 0.958 0.959 0.946 0.979 
rs7103648 11 47461783 RAPSN, PSMC3, SLC39A13 Ehret, ture Genetics 2016 0.984 0.767 0.980 0.977 0.958 0.819 0.901 1.000 
rs7126805 11 828916 CRACR2B Warren, ture Genetics 2017 0.984 0.499 0.559 0.977 0.949 0.700 0.784 0.979 
rs7129220 11 10350538 ADM Ehret, ture 2011 0.984 0.964 0.980 0.977 0.958 0.959 0.946 0.979 
rs7178615 15 66869072 RP11-321F6.1 Warren, ture Genetics 2017 0.984 0.918 0.978 0.977 0.958 0.752 0.866 0.979 
rs7236548 18 43097750 SLC14A2 Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.867 0.901 0.979 
rs7248104 19 7224431 INSR Liu, ture Genetics 2016 0.984 0.964 0.980 0.985 0.966 0.959 0.972 0.979 
rs72765298 9 127900996 SCAI Warren, ture Genetics 2017 0.984 0.871 0.938 0.977 - -  -   - 
rs7297416 12 54443090 HOXC4 Tragante, AJHG 2014 0.984 0.964 0.980 0.977 0.958 0.899 0.901 0.979 
rs7302981 12 50537815 CERS5 Surendran, ture Genetics 2016 0.984 0.964 0.980 0.951 0.958 0.952 0.866 0.979 
rs740406 19 2232221 AMH Kato, ture Genetics 2015 0.984 0.871 0.980 0.947 0.958 0.753 0.946 0.893 
rs7406910 17 46688256 HOXB7 Surendran, ture Genetics 2016 0.984 0.767 0.922 0.977 0.958 0.795 0.901 0.979 
rs740698 17 60767151 MRC2 Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.795 0.866 0.979 
rs74181299 2 65283972 CEP68 Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.959 0.972 0.979 
rs743757 3 50476378 CAC2D2 Warren, ture Genetics 2017 0.984 0.954 0.922 0.947 0.958 0.959 0.946 0.979 
rs745821 18 48142854 MAPK4 Warren, ture Genetics 2017 0.984 0.992 0.980 0.977 0.958 0.959 0.975 0.979 
rs7515635 1 42408070 HIVEP3 Ehret, ture Genetics 2016 0.996 0.964 0.980 0.977 0.958 0.931 0.946 0.979 
rs751984 11 61278246 LRRC10B Kato, ture Genetics 2015 0.984 0.499 0.559 0.977 0.958 0.952 0.946 0.979 
rs7562 2 28635740 FOSL2 Warren, ture Genetics 2017 0.984 0.918 0.943 0.977 0.958 0.959 0.972 0.979 
rs757081 11 17351683 NUCB2 Tragante, AJHG 2014 0.984 0.767 0.914 0.977 0.949 0.700 0.759 0.979 
rs7592578 2 191439591 TMEM194B Warren, ture Genetics 2017 0.966 0.964 0.922 0.845 0.958 0.939 0.972 0.979 
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rs76206723 7 40447971 SUGCT Warren, ture Genetics 2017 0.984 0.918 0.980 0.948 0.949 0.959 0.866 0.146 
rs76326501 2 43167878 AC016735.1 Warren, ture Genetics 2017 0.984 0.871 0.980 0.977 - -  -   - 
rs76452347 9 35906471 HRCT1 Liu, ture Genetics 2016 0.984 0.964 0.980 0.977 0.958 0.959 0.972 0.983 
rs76987554 6 134080855 TARID/TCF21 Liang, PLoS Genetics 2017 0.984 0.772 0.922 0.977 0.958 0.833 0.901 0.979 
rs78648104 6 50683009 TFAP2D Warren, ture Genetics 2017 - -  -   - - -  -   - 
rs79089478 17 40317241 KCNH4-HSD17B1 Warren, ture Genetics 2017 - -  -   - - -  -   - 
rs79146658 2 179786068 CCDC141 Warren, ture Genetics 2017 0.984 0.998 0.980 0.977 - -  -   - 
rs8016306 14 63928546 PPP2R5E Warren, ture Genetics 2017 0.984 0.987 0.993 0.977 0.958 0.871 0.901 0.979 
rs8059962 16 81574197 CMIP Warren, ture Genetics 2017 0.984 0.964 0.993 0.977 0.958 0.988 0.975 0.979 
rs8068318 17 59483766 TBX2 Surendran, ture Genetics 2016 0.984 0.964 0.980 0.951 0.958 0.959 0.946 0.979 
rs8258 11 117283676 CEP164 Warren, ture Genetics 2017 0.984 0.868 0.914 0.947 0.958 0.867 0.866 0.979 
rs867186 20 33764554 PROCR Surendran, ture Genetics 2016 0.984 0.964 0.988 0.977 0.958 0.717 0.843 0.979 
rs871606 4 54799245 CHIC2 Wain, ture Genetics 2011 0.984 0.767 0.978 0.977 0.958 0.700 0.866 0.979 
rs880315 1 10796866 CASZ1 Takeuchi, Circulation 2010 0.984 0.871 0.922 0.977 0.958 0.833 0.901 1.000 
rs891511 7 150704843 NOS3 Liu, ture Genetics 2016 0.984 0.964 0.922 0.947 0.958 0.959 0.946 0.979 
rs894344 8 135612745 ZFAT Warren, ture Genetics 2017 0.984 0.964 0.993 0.977 0.958 0.887 0.901 0.979 
rs900145 11 13293905 ARNTL Liu, ture Genetics 2016 0.984 0.964 0.988 0.947 0.958 0.931 0.962 0.983 
rs918466 3 64710253 ADAMTS9 Ehret, ture Genetics 2016 0.984 0.964 0.993 0.948 0.958 0.959 0.960 0.979 
rs9306160 21 45107562 RRP1B Surendran, ture Genetics 2016 0.984 0.964 0.980 0.977 0.958 0.959 0.996 0.979 
rs9323988 14 98587630 RP11-61O1.1 Warren, ture Genetics 2017 0.984 0.770 0.914 0.977 0.958 0.931 0.946 0.979 
rs932764 10 95895940 PLCE1 Ehret, ture 2011 0.984 0.964 0.980 0.977 0.965 0.959 0.975 0.979 
rs9349379 6 12903957 PHACTR1 Surendran, ture Genetics 2016 0.984 0.964 0.980 0.977 0.958 0.975 0.972 0.979 
rs9372498 6 118572486 SLC35F1 Warren, ture Genetics 2017 0.984 0.964 0.988 0.977 0.958 0.931 0.903 0.979 
rs953492 1 243471192 SDCCAG8 Warren, ture Genetics 2017 0.984 0.772 0.914 0.977 0.958 0.700 0.843 1.000 
rs9549328 13 113636156 MCF2L Warren, ture Genetics 2017 0.984 0.767 0.914 0.977 0.958 0.795 0.866 0.979 
rs9687065 5 148391140 ABLIM3,SH3TC2 Kato, ture Genetics 2015 0.984 0.943 0.980 0.977 0.958 0.931 0.946 0.992 
rs9827472 3 56726646 FAM208A Warren, ture Genetics 2017 0.984 0.964 0.980 0.977 0.958 0.819 0.866 0.979 
rs9859176 3 134000025 RYK Warren, ture Genetics 2017 0.984 0.964 0.980 0.845 0.958 0.959 0.901 0.979 
rs9888615 14 53377540 FERMT2 Warren, ture Genetics 2017 0.984 0.604 0.559 0.977 0.958 0.700 0.843 0.979 
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Asians 
 
rs ID CHR POS Gene / Locus Reference FDR adjusted P-value 
ALL WOD 
SBP DBP MAP PP SBP DBP MAP PP 
rs10059921 5 87514515 TMEM161B Warren, ture Genetics 2017 - -  -   - - -  -   - 
rs10077885 5 114390121 TRIM36 Ehret, ture Genetics 2016 0.924 0.976 0.972 0.915 0.898 0.974 0.968 0.904 
rs10078021 5 75038431 POC5 Warren, ture Genetics 2017 0.924 0.931 0.875 0.867 0.898 0.805 0.887 0.849 
rs1008058 5 122435627 PRDM6 Surendran, ture Genetics 2016 0.924 0.987 0.997 0.818 0.912 0.993 0.982 0.826 
rs1011018 7 139463264 HIPK2 Warren, ture Genetics 2017 0.924 0.981 0.994 0.818 0.912 0.993 0.982 0.821 
rs10224002 7 151415041 PRKAG2 Tragante, AJHG 2014 0.709 0.833 0.873 0.867 0.552 0.805 0.682 0.849 
rs10260816 7 46010100 IGFBP3 Kato, ture Genetics 2015 0.924 0.976 0.985 0.818 0.898 0.974 0.968 0.847 
rs1036477 15 48914926 FBN1 Tragante, AJHG 2014 0.998 0.981 0.994 0.891 0.997 0.988 0.982 0.896 
rs10407022 19 2249477 AMH Surendran, ture Genetics 2016 0.924 0.965 0.875 0.840 0.898 0.922 0.909 0.849 
rs1060105 12 123806219 SBNO1 Surendran, ture Genetics 2016 - -  -   - - -  -   - 
rs10760117 9 123586737 PSMD5 Ehret, ture Genetics 2016 0.924 0.981 0.985 0.960 0.912 0.993 0.980 0.975 
rs10826995 10 32082658 ARHGAP12 Warren, ture Genetics 2017 - -  -   - - -  -   - 
rs10850411 12 115387796 TBX5-TBX3 Ehret, ture 2011 0.924 0.981 0.985 0.818 0.898 0.974 0.968 0.822 
rs10916082 1 227252626 CDC42BPA Warren, ture Genetics 2017 0.924 0.981 0.994 0.867 0.912 0.993 0.982 0.849 
rs10922502 1 89360158 GTF2B Warren, ture Genetics 2017 0.927 0.981 0.994 0.891 0.900 0.993 0.980 0.896 
rs10943605 6 79655477 PHIP Liu, ture Genetics 2016 0.948 0.976 0.985 0.818 0.952 0.974 0.982 0.821 
rs10948071 6 43280713 CRIP3 Ganesh, AJHG 2014 0.924 0.981 0.985 0.818 0.898 0.993 0.968 0.821 
rs10995311 10 64564934 ADO Surendran, ture Genetics 2016 0.948 0.984 0.994 0.980 0.952 0.993 0.982 0.976 
rs110419 11 8252853 LMO1 Surendran, ture Genetics 2016 0.948 0.984 0.997 0.891 0.952 0.993 0.982 0.896 
rs11066280 12 112817783 RPL6-ALDH1 Kato, ture Genetics 2011 0.907 0.833 0.873 0.867 0.898 0.805 0.887 0.849 
rs111245230 9 113169775 SVEP1 Liu, ture Genetics 2016 - -  -   - - -  -   - 
rs11128722 3 14958126 FGD5 Ehret, ture Genetics 2016 0.927 0.981 0.997 0.818 0.912 0.993 0.982 0.821 
rs11154027 6 121781390 GJA1 Warren, ture Genetics 2017 0.924 0.872 0.972 0.891 0.912 0.843 0.968 0.896 
rs11191548 10 104846178 CYP17A1-NT5C2 Newton-Cheh, ture Genetics 2009 0.924 0.981 0.985 0.818 0.912 0.974 0.968 0.847 
rs112184198 10 102604514 PAX2 Warren, ture Genetics 2017 - -  -   - - -  -   - 
rs11222084 11 130273230 ADAMTS8 Wain, ture Genetics 2011 0.834 0.965 0.875 0.818 0.552 0.805 0.887 0.821 
rs11229457 11 58207203 OR5B12 Surendran, ture Genetics 2016 0.924 0.965 0.972 0.891 0.898 0.843 0.968 0.896 
rs112557609 1 56576924 RP4-710M16.1-PPAP2B Warren, ture Genetics 2017 0.924 0.981 0.989 0.818 0.912 0.993 0.982 0.840 
rs1126464 16 89704365 DPEP1 Surendran, ture Genetics 2016 - -  -   - - -  -   - 
rs11442819 11 45208141 PRDM11 Warren, ture Genetics 2017 - -  -   - - -  -   - 
rs11537751 11 47587452 PTPMT1 Liu, ture Genetics 2016 - -  -   - - -  -   - 
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rs11556924 7 129663496 ZC3HC1 Ehret, ture Genetics 2016 0.924 0.976 0.972 0.891 0.898 0.974 0.968 0.896 
rs115795127 9 85993901 FRMD3 Liang, PLoS Genetics 2017 - -  -   - - -  -   - 
rs11639856 16 24788645 TNRC6A Liu, ture Genetics 2016 0.948 0.981 0.994 0.980 0.952 0.993 0.982 0.976 
rs11643209 16 75331044 CFDP1 Warren, ture Genetics 2017 0.924 0.981 0.996 0.650 0.898 0.993 0.982 0.771 
rs11689667 2 85491365 TCF7L1 Warren, ture Genetics 2017 0.924 0.981 0.985 0.891 0.912 0.993 0.980 0.896 
rs1173771 5 32815028 NPR3-C5orf23 Ehret, ture 2011 0.924 0.833 0.875 0.915 0.898 0.805 0.887 0.896 
rs11953630 5 157845402 EBF1 Ehret, ture 2011 0.924 0.981 0.985 0.818 0.898 0.993 0.968 0.826 
rs11977526 7 46008110 IGFBP1-IGFBP3 Zhu, AJHG 2015 0.985 0.965 0.985 0.818 0.952 0.922 0.968 0.826 
rs12374077 3 185317674 SENP2 Warren, ture Genetics 2017 0.924 0.833 0.873 0.912 0.898 0.805 0.887 0.896 
rs12408022 1 217718789 GPATCH2 Warren, ture Genetics 2017 0.985 0.965 0.985 0.818 0.980 0.922 0.968 0.847 
rs1250259 2 216300482 FN1 Warren, ture Genetics 2017 0.924 0.981 0.972 0.818 0.898 0.974 0.968 0.821 
rs12521868 5 131784393 C5orf56 Surendran, ture Genetics 2016 - -  -   - - -  -   - 
rs12579720 12 20173764 PDE3A Kato, ture Genetics 2015 0.948 0.872 0.972 0.891 0.952 0.805 0.968 0.865 
rs12627651 21 44760603 CRYAA-SIK1 Ehret, ture Genetics 2016 0.924 0.981 0.985 0.818 0.898 0.993 0.982 0.826 
rs12628032 22 19967980 ARVCF Warren, ture Genetics 2017 0.985 0.981 0.996 0.980 0.952 0.993 0.982 0.976 
rs12731740 1 208024820 CD34 Warren, ture Genetics 2017 0.924 0.981 0.994 0.650 0.898 0.993 0.982 0.780 
rs1275988 2 26914364 KCNK3 Ganesh, AJHG 2014 0.924 0.981 0.985 0.867 0.898 0.974 0.968 0.849 
rs12921187 16 4943019 PPL Warren, ture Genetics 2017 0.924 0.965 0.972 0.980 0.898 0.805 0.925 0.979 
rs12940887 17 47402807 ZNF652 Ehret, ture 2011 0.924 0.976 0.972 0.818 0.898 0.974 0.968 0.847 
rs12941318 17 1333598 CRK Warren, ture Genetics 2017 0.924 0.981 0.985 0.891 0.898 0.974 0.968 0.865 
rs12946454 17 43208121 PLCD3 Newton-Cheh, ture Genetics 2009 0.924 0.981 0.985 0.818 0.898 0.974 0.968 0.823 
rs12958173 18 42141977 SETBP1 Ehret, ture Genetics 2016 0.949 0.981 0.996 0.891 0.952 0.993 0.982 0.896 
rs13002573 2 164915208 FIGN-GRB14 Wain, ture Genetics 2011 0.924 0.976 0.985 0.918 0.898 0.974 0.968 0.904 
rs13082711 3 27537909 SLC4A7 Ehret, ture 2011 0.924 0.833 0.873 0.818 0.898 0.805 0.887 0.821 
rs13107325 4 103188709 SLC39A8 Ehret, ture 2011 - -  -   - - -  -   - 
rs13139571 4 156645513 GUCY1A3-GUCY1B3 Ehret, ture 2011 0.924 0.981 0.985 0.818 0.898 0.993 0.968 0.847 
rs13209747 6 127115454 RSPO3 Francescini, AJHG 2013 0.948 0.981 0.985 0.891 0.952 0.988 0.982 0.896 
rs13238550 7 131059056 MKLN1 Warren, ture Genetics 2017 0.924 0.981 0.985 0.891 0.898 0.993 0.968 0.865 
rs1327235 20 10969030 JAG1 Ehret, ture 2011 0.948 0.981 0.994 0.918 0.912 0.993 0.982 0.896 
rs13333226 16 20365654 UMOD Padmabhan, PloS Genetics 2010 0.948 0.976 0.985 0.980 0.932 0.974 0.968 0.979 
rs13359291 5 122476457 PRDM6 Kato, ture Genetics 2015 0.924 0.981 0.972 0.818 0.898 0.974 0.968 0.840 
rs1344653 2 19730845 OSR1 Kato, ture Genetics 2015 0.924 0.873 0.972 0.891 0.912 0.805 0.968 0.896 
rs1378942 15 75077367 CYP1A1-ULK3 Newton-Cheh, ture Genetics 2009 0.924 0.981 0.972 0.818 0.898 0.983 0.968 0.826 
rs139236208 12 94880742 CCDC41 Warren, ture Genetics 2017 - -  -   - - -  -   - 
rs139385870 1 1685921 DK-CPSF3L Warren, ture Genetics 2017 0.924 0.981 0.985 0.818 0.898 0.993 0.968 0.822 
rs1401454 11 16250183 SOX6 Francescini, AJHG 2013 0.948 0.981 0.985 0.980 0.952 0.974 0.968 0.979 
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rs1421811 5 32714270 NPR3-C5orf23 Johnson, AJHG 2011 0.998 0.981 0.994 0.980 0.997 0.993 0.982 0.976 
rs143112823 3 154707967 RP11-439C8.2 Warren, ture Genetics 2017 - -  -   - - -  -   - 
rs1438896 2 145646072 TEX41 Warren, ture Genetics 2017 0.951 0.976 0.994 0.818 0.952 0.974 0.982 0.821 
rs1446468 2 164963486 FIGN-GRB14 Wain, ture Genetics 2011 0.927 0.981 0.985 0.980 0.912 0.993 0.968 0.975 
rs1458038 4 81164723 FGF5 Ehret, ture 2011 0.751 0.981 0.972 0.650 0.552 0.993 0.968 0.771 
rs147212971 6 166178451 PDE10A Warren, ture Genetics 2017 0.924 0.981 0.994 0.818 0.900 0.993 0.982 0.821 
rs1530440 10 63524591 C10orf107 Newton-Cheh, ture Genetics 2009 0.927 0.872 0.972 0.891 0.912 0.805 0.937 0.896 
rs1563788 6 43308363 TTBK1,SLC22A7,ZNF318 Kato, ture Genetics 2015 0.924 0.981 0.985 0.818 0.898 0.993 0.968 0.821 
rs1566497 4 169717148 PALLD Warren, ture Genetics 2017 0.924 0.981 0.985 0.867 0.898 0.993 0.980 0.849 
rs167479 19 11526765 RGL3 Surendran, ture Genetics 2016 - -  -   - - -  -   - 
rs16823124 2 183224127 PDE1A Tragante, AJHG 2014 0.924 0.833 0.875 0.980 0.898 0.805 0.887 0.979 
rs16833934 3 163737250 MIR1263 Simino, AJHG 2014 0.924 0.931 0.972 0.891 0.898 0.805 0.887 0.865 
rs16849225 2 164906820 FIGN-GRB14 Kato, ture Genetics 2011 0.924 0.976 0.972 0.891 0.898 0.974 0.968 0.896 
rs16851397 3 141134818 ZBTB38 Surendran, ture Genetics 2016 - -  -   - - -  -   - 
rs17030613 1 113190807 ST7L-CAPZA1-MOV10 Kato, ture Genetics 2011 0.924 0.965 0.960 0.980 0.898 0.843 0.909 0.975 
rs17059668 4 174584663 chr4mb174 Warren, ture Genetics 2017 0.985 0.981 0.994 0.980 0.979 0.993 0.982 0.976 
rs17080102 6 151004770 PLEKHG1 Francescini, AJHG 2013 0.709 0.833 0.549 0.891 0.552 0.805 0.682 0.896 
rs17249754 12 90060586 ATP2B1 Levy, ture Genetics 2009 - -  -   - - -  -   - 
rs17367504 1 11862778 MTHFR-NPPB Newton-Cheh, ture Genetics 2009 0.948 0.981 0.985 0.980 0.952 0.993 0.980 0.976 
rs17428471 7 27337867 EVX1-HOXA Francescini, AJHG 2013 0.948 0.981 0.985 0.867 0.952 0.974 0.980 0.849 
rs17477177 7 106411858 PIK3CG Wain, ture Genetics 2011 0.948 0.981 0.997 0.818 0.952 0.993 0.982 0.826 
rs17608766 17 45013271 GOSR2 Ehret, ture 2011 - -  -   - - -  -   - 
rs17638167 19 11584818 ELAVL3 Ehret, ture Genetics 2016 0.924 0.976 0.972 0.891 0.898 0.974 0.968 0.865 
rs1799945 6 26091179 HFE Ehret, ture 2011 0.924 0.984 0.996 0.818 0.900 0.993 0.982 0.821 
rs1801253 10 115805056 ADRB1  Johnson, Hypertension 2011 0.709 0.833 0.873 0.818 0.552 0.805 0.887 0.847 
rs1813353 10 18707448 CACNB2 Ehret, ture 2011 0.924 0.976 0.985 0.918 0.912 0.974 0.968 0.943 
rs1925153 6 56102780 COL21A1 Liu, ture Genetics 2016 - -  -   - - -  -   - 
rs1953126 9 123640500 PHF19 Liu, ture Genetics 2016 0.924 0.833 0.875 0.891 0.898 0.805 0.925 0.849 
rs1975487 2 55809054 PNPT1 Ehret, ture Genetics 2016 0.998 0.981 0.985 0.891 0.997 0.974 0.980 0.885 
rs2004776 1 230848702 AGT Johnson, AJHG 2011 0.924 0.872 0.972 0.818 0.912 0.805 0.968 0.821 
rs2014408 11 16365282 SOX6 Johnson, AJHG 2011 0.924 0.965 0.875 0.832 0.898 0.974 0.937 0.847 
rs2014912 4 86715670 ARHGAP24 Kato, ture Genetics 2015 0.907 0.965 0.875 0.818 0.898 0.922 0.909 0.821 
rs2071518 8 120435812 NOV Wain, ture Genetics 2011 0.948 0.981 0.994 0.980 0.952 0.993 0.982 0.976 
rs2107595 7 19049388 HDAC9 Kato, ture Genetics 2015 0.924 0.976 0.985 0.818 0.898 0.974 0.968 0.826 
rs217727 11 2016908 H19 Tragante, AJHG 2014 0.998 0.965 0.985 0.818 0.997 0.922 0.968 0.821 
rs2188962 5 131770805 C5orf56 Liu, ture Genetics 2016 - -  -   - - -  -   - 
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rs2240736 17 59485393 C17orf82,TBX2 Kato, ture Genetics 2015 0.948 0.965 0.985 0.818 0.952 0.805 0.968 0.821 
rs2270860 6 43270151 SLC22A7 Liu, ture Genetics 2016 0.924 0.981 0.985 0.818 0.898 0.993 0.968 0.821 
rs2282978 7 92264410 CDK6 Tragante, AJHG 2014 0.924 0.981 0.985 0.818 0.898 0.993 0.980 0.821 
rs2289081 2 20881840 C2orf43 Warren, ture Genetics 2017 0.998 0.981 0.997 0.914 0.997 0.993 0.982 0.896 
rs2291435 4 38387395 TBC1D1-FLJ13197 Ehret, ture Genetics 2016 0.924 0.976 0.985 0.891 0.898 0.981 0.968 0.896 
rs2302061 19 2226772 DOT1L Liu, ture Genetics 2016 0.985 0.981 0.994 0.840 0.994 0.988 0.982 0.849 
rs2304130 19 19789528 ZNF101 Surendran, ture Genetics 2016 - -  -   - - -  -   - 
rs2306374 3 138119952 MRAS Warren, ture Genetics 2017 - -  -   - - -  -   - 
rs2384550 12 115352731 TBX5-TBX3 Levy, ture Genetics 2009 0.948 0.987 0.997 0.912 0.952 1.000 0.982 0.896 
rs2467099 17 73949045 ACOX1 Warren, ture Genetics 2017 0.998 0.987 0.997 0.980 0.997 0.993 0.982 0.979 
rs2493292 1 3328659 PRDM16 Liu, ture Genetics 2016 0.924 0.965 0.875 0.818 0.898 0.843 0.889 0.826 
rs2521501 15 91437388 FURIN-FES Ehret, ture 2011 0.948 0.981 0.985 0.980 0.952 0.974 0.968 0.976 
rs2579519 2 96675166 GPAT2-FAHD2CP Warren, ture Genetics 2017 0.924 0.981 0.985 0.927 0.898 0.988 0.968 0.906 
rs2760061 1 228191075 WNT3A Warren, ture Genetics 2017 0.998 0.973 0.985 0.818 0.997 0.974 0.968 0.847 
rs2782980 10 115781527 ADRB1 Wain, ture Genetics 2011 0.924 0.981 0.985 0.650 0.898 0.974 0.968 0.771 
rs2854275 6 32628428 HLA-DQB1 Tragante, AJHG 2014 - -   -  -  - -  -  -  
rs2898290 8 11433909 BLK-GATA4 Ho, Jourl of Hypertension 2011 0.924 0.981 0.985 0.980 0.912 0.988 0.968 0.975 
rs2932538 1 113216543 ST7L-CAPZA1-MOV10 Ehret, ture 2011 0.948 0.987 0.997 0.891 0.952 0.994 0.982 0.896 
rs2969070 7 2512545 CHST12-LFNG Ehret, ture Genetics 2016 0.998 0.981 0.996 0.980 0.997 0.993 0.982 0.979 
rs2972146 2 227100698 2q36.3 Surendran, ture Genetics 2016 0.924 0.981 0.997 0.818 0.912 0.993 0.982 0.821 
rs2978098 8 101676675 SNX31 Warren, ture Genetics 2017 0.778 0.833 0.873 0.891 0.898 0.805 0.887 0.896 
rs2978456 8 42324765 SLC20A2 Warren, ture Genetics 2017 0.924 0.981 0.985 0.840 0.898 0.993 0.968 0.849 
rs3184504 12 111884608 SH2B3 Levy, ture Genetics 2009 - -   -  -  - -  -  -  
rs319690 3 47927484 MAP4 Wain, ture Genetics 2011 0.948 0.981 0.994 0.818 0.952 0.974 0.982 0.847 
rs33063 16 69640217 NFAT5 Tragante, AJHG 2014 0.924 0.981 0.985 0.846 0.898 0.993 0.968 0.849 
rs34591516 8 142367087 GPR20 Surendran, ture Genetics 2016 - -   -  -  - -  -  -  
rs347591 3 11290122 HRH1-ATG7 Ganesh, Human Molecular Genetics 2013 0.998 0.976 0.985 0.912 0.952 0.974 0.968 0.896 
rs35199222 15 81013037 ABHD17C Warren, ture Genetics 2017 0.949 0.984 0.997 0.891 0.952 0.994 0.982 0.890 
rs35444 12 115552437 TBX5-TBX3 Kato, ture Genetics 2011 0.924 0.976 0.972 0.650 0.898 0.974 0.968 0.780 
rs36022378 3 49913705 CAMKV-ACTBP13 Warren, ture Genetics 2017 0.959 0.976 0.985 0.891 0.952 0.974 0.968 0.896 
rs36083386 6 152397912 ESR1 Warren, ture Genetics 2017 0.924 0.872 0.875 0.892 0.898 0.843 0.968 0.896 
rs3741378 11 65408937 SIPA1 Tragante, AJHG 2014 0.924 0.981 0.985 0.980 0.929 0.993 0.980 0.979 
rs3771371 2 71627539 ZNF638 Warren, ture Genetics 2017 0.948 0.981 0.985 0.891 0.952 0.974 0.968 0.896 
rs3774372 3 41877414 ULK4 Ehret, ture 2011 0.948 0.976 0.985 0.934 0.952 0.974 0.968 0.943 
rs381815 11 16902268 PLEKHA7 Levy, ture Genetics 2009 0.998 0.981 0.994 0.818 0.952 0.974 0.982 0.847 
rs3889199 1 59653742 FGGY Warren, ture Genetics 2017 0.924 0.981 0.997 0.650 0.898 0.993 0.982 0.771 
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rs3918226 7 150690176 NOS3 Johnson, AJHG 2011 - -   -  -  - -  -  -  
rs409558 6 31708147 MSH5-SAPCD1 Liu, ture Genetics 2016 0.924 0.981 0.985 0.818 0.898 0.993 0.968 0.821 
rs419076 3 169100886 MECOM Ehret, ture 2011 0.924 0.833 0.875 0.818 0.898 0.805 0.889 0.823 
rs4245739 1 204518842 MDM4 Ganesh, Human Molecular Genetics 2013 0.924 0.976 0.972 0.891 0.898 0.922 0.968 0.865 
rs4247374 19 7252756 INSR Ehret, ture Genetics 2016 - -   -  -  - -  -  -  
rs4308 17 61559625 ACE Warren, ture Genetics 2017 0.948 0.981 0.985 0.980 0.952 0.993 0.980 0.979 
rs4360494 1 38455891 SF3A3 Warren, ture Genetics 2017 - -   -  -  - -  -  -  
rs4364717 9 21801530 MTAP Warren, ture Genetics 2017 0.924 0.981 0.997 0.818 0.898 0.993 0.982 0.821 
rs4373814 10 18419972 CACNB2 Ehret, ture 2011 0.924 0.872 0.960 0.980 0.912 0.843 0.968 0.976 
rs4387287 10 105677897 OBFC1 Surendran, ture Genetics 2016 0.924 0.981 0.985 0.867 0.898 0.988 0.968 0.849 
rs4454254 8 141060027 TRAPPC9 Warren, ture Genetics 2017 0.948 0.976 0.985 0.962 0.952 0.974 0.968 0.920 
rs4494250 10 96563757 CYP2C19 Liu, ture Genetics 2016 0.924 0.833 0.873 0.918 0.898 0.805 0.887 0.896 
rs449789 6 159699125 FNDC1 Warren, ture Genetics 2017 0.709 0.833 0.873 0.818 0.552 0.805 0.682 0.821 
rs452036 14 23865885 MYH6 Surendran, ture Genetics 2016 0.924 0.976 0.972 0.915 0.912 0.974 0.968 0.920 
rs4530754 5 122855416 CSNK1G3 Liu, ture Genetics 2016 0.924 0.981 0.985 0.818 0.912 0.993 0.982 0.826 
rs4590817 10 63467553 C10orf107 Ehret, ture 2011 - -   -  -  - -  -  -  
rs4601790 11 65353906 EHBP1L1 Simino, AJHG 2014 0.924 0.976 0.985 0.818 0.912 0.974 0.968 0.821 
rs4660293 1 40028180 PABPC4 Liu, ture Genetics 2016 0.927 0.981 0.985 0.891 0.912 0.981 0.968 0.896 
rs470113 22 40729614 TNRC6B Surendran, ture Genetics 2016 0.948 0.976 0.985 0.818 0.952 0.974 0.980 0.847 
rs4728142 7 128573967 7q32.1 Surendran, ture Genetics 2016 0.924 0.981 0.994 0.818 0.898 0.993 0.982 0.821 
rs4746172 10 75855842 VCL Tragante, AJHG 2014 0.924 0.976 0.972 0.980 0.900 0.974 0.968 0.976 
rs4823006 22 29451671 ZNRF3 Liu, ture Genetics 2016 0.927 0.976 0.985 0.980 0.912 0.974 0.968 0.979 
rs4841569 8 11452177 BLK-GATA4 Simino, AJHG 2014 - -   -  -  - -  -  -  
rs4846049 1 11850365 MTHFR-NPPB Johnson, AJHG 2011 0.948 0.981 0.997 0.818 0.952 0.993 0.982 0.821 
rs4952611 2 40567743 SLC8A1 Warren, ture Genetics 2017 0.998 0.981 0.994 0.927 0.997 0.993 0.982 0.975 
rs5068 1 11905974 MTHFR-NPPB Newton-Cheh, ture Genetics 2009 - -   -  -  - -  -  -  
rs5219 11 17409572 KCNJ11 Liu, ture Genetics 2016 0.924 0.872 0.875 0.937 0.898 0.805 0.887 0.922 
rs55701159 2 25139596 ADCY3 Warren, ture Genetics 2017 - -   -  -  - -  -  -  
rs55780018 2 208526140 METTL21A-AC079767.3 Warren, ture Genetics 2017 - -   -  -  - -  -  -  
rs6015450 20 57751117 GS-EDN3 Ehret, ture 2011 - -   -  -  - -  -  -  
rs6081613 20 19465907 SLC24A3 Warren, ture Genetics 2017 0.948 0.981 0.994 0.950 0.932 0.993 0.982 0.957 
rs6095241 20 47308798 PREX1 Surendran, ture Genetics 2016 0.924 0.833 0.875 0.891 0.912 0.805 0.909 0.896 
rs6108168 20 8626271 PLCB1 Warren, ture Genetics 2017 0.924 0.931 0.972 0.986 0.912 0.874 0.968 0.979 
rs62012628 15 79070000 ADAMTS7 Warren, ture Genetics 2017 - -   -  -  - -  -  -  
rs62080325 17 42060631 PYY Warren, ture Genetics 2017 - -   -  -  - -  -  -  
rs62104477 19 30294991 CCNE1 Warren, ture Genetics 2017 0.948 0.981 0.985 0.867 0.952 0.974 0.980 0.849 
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rs6271 9 136522274 DBH Ehret, ture Genetics 2016 - -   -  -  - -  -  -  
rs633185 11 100593538 FLJ32810-TMEM133 Ehret, ture 2011 0.948 0.981 0.985 0.822 0.952 0.974 0.980 0.847 
rs6487543 12 26438189 SSPN Warren, ture Genetics 2017 0.998 0.984 0.997 0.980 0.997 0.993 0.982 0.979 
rs661348 11 1905292 LSP1-TNNT3 Johnson, AJHG 2011 0.924 0.981 0.985 0.891 0.898 0.993 0.968 0.849 
rs6686889 1 25030470 chr1mb25 Warren, ture Genetics 2017 0.924 0.833 0.875 0.980 0.898 0.805 0.887 0.979 
rs6712094 2 165043460 FIGN-GRB14 Ganesh, AJHG 2014 0.948 0.981 0.991 0.915 0.952 0.993 0.982 0.904 
rs6722745 2 108875244 SULT1C3 Liu, ture Genetics 2016 0.948 0.976 0.985 0.980 0.952 0.974 0.968 0.976 
rs67330701 11 69079707 MYEOV Warren, ture Genetics 2017 0.924 0.981 0.985 0.818 0.898 0.993 0.968 0.826 
rs6797587 3 48197614 CDC25A Simino, AJHG 2014 0.924 0.981 0.985 0.818 0.898 0.993 0.980 0.847 
rs6825911 4 111381638 ENPEP Kato, ture Genetics 2011 0.751 0.965 0.875 0.818 0.647 0.883 0.887 0.821 
rs687621 9 136137065 ABO Surendran, ture Genetics 2016 0.924 0.931 0.875 0.891 0.898 0.805 0.887 0.896 
rs6891344 5 123136656 CSNK1G3 Ehret, ture Genetics 2016 0.924 0.833 0.875 0.912 0.898 0.805 0.909 0.896 
rs6911827 6 22130601 CASC15 Warren, ture Genetics 2017 0.924 0.981 0.985 0.891 0.898 0.993 0.968 0.896 
rs6969780 7 27159136 HOXA3 Liu, ture Genetics 2016 0.948 0.981 0.994 0.980 0.952 0.993 0.982 0.975 
rs709209 1 6278414 RNF207 Surendran, ture Genetics 2016 0.948 0.987 0.997 0.891 0.952 1.000 0.982 0.896 
rs7103648 11 47461783 RAPSN, PSMC3, SLC39A13 Ehret, ture Genetics 2016 0.924 0.976 0.972 0.818 0.898 0.974 0.968 0.847 
rs7126805 11 828916 CRACR2B Warren, ture Genetics 2017 - -   -  -  - -  -  -  
rs7129220 11 10350538 ADM Ehret, ture 2011 - -   -  -  - -  -  -  
rs7178615 15 66869072 RP11-321F6.1 Warren, ture Genetics 2017 0.924 0.981 0.994 0.650 0.900 0.974 0.982 0.771 
rs7236548 18 43097750 SLC14A2 Warren, ture Genetics 2017 0.924 0.981 0.994 0.818 0.898 0.993 0.982 0.847 
rs7248104 19 7224431 INSR Liu, ture Genetics 2016 0.907 0.965 0.875 0.818 0.898 0.922 0.889 0.826 
rs72765298 9 127900996 SCAI Warren, ture Genetics 2017 - -   -  -  - -  -  -  
rs7297416 12 54443090 HOXC4 Tragante, AJHG 2014 - -   -  -  - -  -  -  
rs7302981 12 50537815 CERS5 Surendran, ture Genetics 2016 - -   -  -  - -  -  -  
rs740406 19 2232221 AMH Kato, ture Genetics 2015 0.998 0.981 0.997 0.818 0.997 0.993 0.982 0.847 
rs7406910 17 46688256 HOXB7 Surendran, ture Genetics 2016 0.732 0.872 0.873 0.818 0.552 0.805 0.887 0.821 
rs740698 17 60767151 MRC2 Warren, ture Genetics 2017 0.948 0.981 0.997 0.818 0.932 0.993 0.982 0.847 
rs74181299 2 65283972 CEP68 Warren, ture Genetics 2017 0.948 0.984 0.994 0.912 0.952 0.993 0.982 0.896 
rs743757 3 50476378 CAC2D2 Warren, ture Genetics 2017 0.924 0.981 0.994 0.818 0.912 0.993 0.982 0.847 
rs745821 18 48142854 MAPK4 Warren, ture Genetics 2017 0.927 0.976 0.985 0.891 0.912 0.974 0.968 0.849 
rs7515635 1 42408070 HIVEP3 Ehret, ture Genetics 2016 0.924 0.833 0.873 0.980 0.898 0.805 0.887 0.979 
rs751984 11 61278246 LRRC10B Kato, ture Genetics 2015 0.751 0.872 0.873 0.818 0.898 0.805 0.887 0.847 
rs7562 2 28635740 FOSL2 Warren, ture Genetics 2017 0.948 0.976 0.985 0.912 0.932 0.974 0.968 0.896 
rs757081 11 17351683 NUCB2 Tragante, AJHG 2014 0.924 0.981 0.985 0.903 0.898 0.974 0.968 0.896 
rs7592578 2 191439591 TMEM194B Warren, ture Genetics 2017 0.998 0.981 0.997 0.980 0.997 0.993 0.982 0.979 
rs76206723 7 40447971 SUGCT Warren, ture Genetics 2017 0.948 0.984 0.994 0.891 0.952 0.993 0.982 0.896 
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rs76326501 2 43167878 AC016735.1 Warren, ture Genetics 2017 - -   -  -  - -  -  -  
rs76452347 9 35906471 HRCT1 Liu, ture Genetics 2016 - -   -  -  - -  -  -  
rs76987554 6 134080855 TARID/TCF21 Liang, PLoS Genetics 2017 - -   -  -  - -  -  -  
rs78648104 6 50683009 TFAP2D Warren, ture Genetics 2017 0.924 0.976 0.985 0.891 0.898 0.974 0.968 0.896 
rs79089478 17 40317241 KCNH4-HSD17B1 Warren, ture Genetics 2017 - -   -  -  - -  -  -  
rs79146658 2 179786068 CCDC141 Warren, ture Genetics 2017 - -   -  -  - -  -  -  
rs8016306 14 63928546 PPP2R5E Warren, ture Genetics 2017 0.907 0.973 0.875 0.818 0.898 0.922 0.887 0.826 
rs8059962 16 81574197 CMIP Warren, ture Genetics 2017 0.948 0.981 0.994 0.945 0.952 0.993 0.982 0.943 
rs8068318 17 59483766 TBX2 Surendran, ture Genetics 2016 0.948 0.872 0.972 0.818 0.912 0.805 0.968 0.821 
rs8258 11 117283676 CEP164 Warren, ture Genetics 2017 0.927 0.981 0.994 0.818 0.932 0.993 0.982 0.847 
rs867186 20 33764554 PROCR Surendran, ture Genetics 2016 0.998 0.976 0.985 0.867 0.997 0.974 0.982 0.849 
rs871606 4 54799245 CHIC2 Wain, ture Genetics 2011 0.924 0.976 0.972 0.891 0.898 0.974 0.968 0.896 
rs880315 1 10796866 CASZ1 Takeuchi, Circulation 2010 - -   -  -  - -  -  -  
rs891511 7 150704843 NOS3 Liu, ture Genetics 2016 - -   -  -  - -  -  -  
rs894344 8 135612745 ZFAT Warren, ture Genetics 2017 0.964 0.981 0.994 0.980 0.997 0.994 0.982 0.979 
rs900145 11 13293905 ARNTL Liu, ture Genetics 2016 0.907 0.833 0.873 0.927 0.898 0.805 0.887 0.906 
rs918466 3 64710253 ADAMTS9 Ehret, ture Genetics 2016 0.924 0.981 0.994 0.818 0.912 0.993 0.982 0.847 
rs9306160 21 45107562 RRP1B Surendran, ture Genetics 2016 0.924 0.981 0.985 0.912 0.912 0.993 0.968 0.904 
rs9323988 14 98587630 RP11-61O1.1 Warren, ture Genetics 2017 0.948 0.981 0.994 0.980 0.952 0.993 0.982 0.976 
rs932764 10 95895940 PLCE1 Ehret, ture 2011 0.924 0.918 0.875 0.897 0.898 0.805 0.889 0.901 
rs9349379 6 12903957 PHACTR1 Surendran, ture Genetics 2016 - -   -  -  - -  -  -  
rs9372498 6 118572486 SLC35F1 Warren, ture Genetics 2017 0.924 0.976 0.985 0.650 0.898 0.974 0.980 0.771 
rs953492 1 243471192 SDCCAG8 Warren, ture Genetics 2017 0.998 0.981 0.994 0.867 0.997 0.993 0.982 0.849 
rs9549328 13 113636156 MCF2L Warren, ture Genetics 2017 0.924 0.981 0.985 0.818 0.898 0.993 0.968 0.821 
rs9687065 5 148391140 ABLIM3,SH3TC2 Kato, ture Genetics 2015 0.924 0.976 0.972 0.891 0.898 0.974 0.968 0.896 
rs9827472 3 56726646 FAM208A Warren, ture Genetics 2017 0.985 0.833 0.972 0.818 0.997 0.805 0.968 0.821 
rs9859176 3 134000025 RYK Warren, ture Genetics 2017 0.998 0.981 0.997 0.891 0.997 0.993 0.982 0.896 
rs9888615 14 53377540 FERMT2 Warren, ture Genetics 2017 0.924 0.965 0.960 0.867 0.898 0.805 0.887 0.849 
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Figure 9 QQ plots of meta-analyses using the 2DF joint test in European ancestry in Aim 3  
 
Blue line represents the results using all participants and red line represents the results from 
participants without diuretics 
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Asians (Chinese) 
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Figure 10 Miami plots for SBP, DBP, MAP, and PP using the 2 DF joint test in European 
ancestry in Aim 3 
 
Above Manhattan plots represent the results using all participants and below Manhattan plots 
represent the results from participants without diuretics 
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Figure 11 Miami plots for SBP, DBP, MAP, and PP using the 2 DF joint test in African ancestry 
in Aim 3 
 
Above Manhattan plots represent the results using all participants and below Manhattan plots 
represent the results from participants without diuretics 
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Figure 12 Miami plots for SBP, DBP, MAP, and PP using the 2 DF joint test in Asians in Aim 3 
 
Above Manhattan plots represent the results using all participants and below Manhattan plots 
represent the results from participants without diuretics 
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Figure 13 Regional plots for significant loci using LocusZoom in Aim 3 
 
EA: European American; AA: African Americans; AS: Asians (Chinese) 
ALL: All Participants; WOD: Participants without diuretics 
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Locus 3 with DBP in WOD AS Locus 4 with PP in ALL AA 
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Locus 5 with DBP in ALL AA Locus 6 with SBP in ALL EA 
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Locus 7 with MAP in ALL AA Locus 8 with SBP in ALL EA 
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Locus 9 with SBP in ALL AA Locus 10 with MAP in ALL AA 
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Locus 11 with DBP in ALL EA Locus 12 with MAP in ALL EA 
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CHAPTER V: Conclusion 
 
5.1 Review of main findings 
Blood pressure has long been known to be associated with high sodium intake, low 
potassium intake, and a high sodium-potassium ratio. In this dissertation, the rich combination of 
high-quality measurements of sodium and potassium intake and genotype data from multiethnic 
cohort studies of participants from European, African, and Asian ancestries have enabled the 
identification of genomic regions and genetic variants associated with sodium and potassium 
intake. To examine the association and interaction among sodium intake, potassium intake, 
genetics, and blood pressure, this dissertation has used a range of approaches: single-variant and 
gene-based approaches; effect modification by demographic factors (age, sex, and education); 
and gene-by-sodium interactions on blood pressure traits. 
In Aim 1, we conducted the largest genome-wide association investigation of 24-hour 
urinary sodium excretion, 24-hour urinary potassium excretion, and sodium-to-potassium ratio 
with and without adjustment for BMI and height using five European ancestry cohorts 
(N=7,363), followed by replication in an African (N=1,246) ancestry and an Asian cohort 
(N=2,475). A total of 52, 75, and 27 SNPs were significant (P <5 X 10-8) or suggestive SNPs (P 
<5 X 10-6) with 24-hour sodium excretion, 24-hour potassium excretion, and their ratio from the 
meta-analysis in European ancestry populations, respectively; three of those SNPs were 
replicated either in African ancestry or Asian populations (P<0.05). The genes near identified 
SNPs from the 24-hour sodium excretion GWAS include the Fc fragment of IgG receptor genes 
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(FCGR2B-FCGR2C- FCGR3A) that are associated with the human immune system [75] and 
genes associated with the activity of GTPases (GTPBP1 on chromosome 22 and CDC42SE1 on 
chromosome 1). GTPases have been suggestively associated with blood pressure regulation, 
hypertension, kidney function, and other traits that are related to the cardiovascular system and 
disease [78] [79]. From the 24-hour potassium excretion GWAS, several SNPs were found near 
genes DLEU2, CUL3, and ABO, which are suggestively associated with the regulation of blood 
pressure and CVD through the renin-angiotensin system or resistance to aldosterone [83] [85] 
[86]. From the sodium-to-potassium ratio GWAS, we found SNPs near KIRREL3, which has an 
important role involving renal filtration in the kidney [91]. 
In Aim 2, we employed state-of-the-art gene-based approaches to confirm the 
associations from Aim 1, using SKAT with both common and rare genetic variants in two 
European cohorts (GENOA and FHS). In GENOA, we found a total of 6 gene regions that had 
P-value < 0.05, and 3 gene regions (24-hour sodium excretion: SETD7 and ASH1L; 24-hour 
potassium excretion: RP11-431M7.2) were significant after FDR correction (FDR adjusted P 
value < 0.1). In FHS, 3 out of 5 gene regions (24-hour potassium excretion: BRO3BP and 
LINC00672; sodium-to-potassium ratio: RP11-433C9.2) had FDR adjusted P-value less than 0.1. 
We also evaluated the interaction between genes and three demographic variables (age ≥ 65 
years, sex, and college education completion) on 24-hour urinary sodium excretion, 24-hour 
urinary potassium excretion, and sodium-to-potassium ratio using iSKAT, and found five 
interactions in TAPSAR1, CTC-228N24, RP11-433C9.2, and RP11-483H11.1 that had an FDR 
adjusted P value less than 0.1 in GENOA. 
In Aim 3, the meta-analysis of a genome-wide gene-by-sodium interaction study on 
blood pressure measures (SBP, DBP, MAP, and PP) was conducted using 6 cohorts comprising 
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more than 6,000 participants of European, African, and Asian ancestry, and identified 12 
independent genome-wide significant genetic loci (P < 5 × 10-8). The genes near the top signal 
include NKAIN2 on chromosome 6, which is associated with the regulation of sodium and 
potassium ion transporting within or between cells [127]. We identified genes near significant 
SNPs that included ZDHHC19, which encodes a protein that may interact with other proteins 
including endothelial nitric oxide synthase (eNOS), which is important for cardiovascular 
homeostasis [128] as well as RUSC2, which is associated with the activity of GTPases and 
regulation of blood pressure [80, 131] [132]. 
 
5.2 Significance and implications 
This dissertation has used high-quality measurement in multiethnic studies to improve the 
understanding of 1) the role of genomic regions and genetic variations in sodium intake, 
potassium intake, and sodium-to-potassium ratio , 2) the impact of interactions between genetic 
factors and demographic factors (age, sex, and education level) on sodium and potassium intake, 
and 3) the effect of gene-by-sodium intake interaction on blood pressure traits using both 
traditional and state-of-the-art methods in genetic epidemiology. 
After the completion of the 1000 Genomes Project, advances in genomics and other 
‘omics’ technologies have accelerated the focus on developing personalized and precision health 
approaches where individual genetics and other sources of variability in disease treatment and 
prevention are considered [138]. While personalized and precision medicine mostly focuses on 
prevention and treatment of an individual’s disease, there has also been a significant growth in 
the interest of precision public health, which extends the personalized medicine approach into a 
public health context [139]. For example, Evangelatos et al. claim that “directing preventive 
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efforts to populations most at risk for certain diseases could be more effective if guided by 
stratification based on genetic information” [139].  While personalized and precision medicine 
could help to heal people who are already sick and have disease, precision public health may 
help to prevent disease by targeting subsets of the population based on their traditional risk 
factors as well as genetic or omic markers.  Khoury et al. outlines the idea that precision public 
health is simply ensuring that the right intervention is made available to the right population at 
the right time [140]. However, genomic information does not add significantly more information 
to risk prediction above and beyond traditional epidemiologic risk factors because the identified 
genetic markers on disease are acting through those risk factors or only have small main effects 
on disease [141]. More studies are needed to provide a sufficiently extensive and robust evidence 
for prevention recommendations using individual genetic profiles for any of the chronic diseases. 
In this context, the initial discoveries from Aim 1 may help shed an initial light on the 
importance of the genetic architecture of sodium and potassium intake. In addition, in Aim 2, we 
identified preliminary evidence of effect modification of those genetic effects on sodium and/or 
potassium intake by traditional epidemiological factors such as age, sex, and education. This 
finding raises the important long-range question about how to tailor messaging about dietary 
behaviors to be more precise in order to have the desired health benefits for different, already 
known, subsets of the population with different dietary intakes.  This same issue is important for 
our findings in Aim 3, which suggest that genetic variations may modify the relationship 
between sodium intake and blood pressure. If replication supports this finding, it could have a 
major effect on stratifying treatment and prevention recommendations for millions of adults who 
have high blood pressure or hypertension, since it would indicate which subgroups of the 
population had an increased risk of elevated blood pressure through sodium consumption.   
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5.3 Strengths 
This dissertation has many strengths that reflect the decades of work it takes to create 
high-quality genetic epidemiology cohort studies. The genome-wide association analyses in Aim 
1 and 3 were conducted in multiethnic cohort studies, which is a valuable strength. Since sodium 
and potassium intake vary greatly across culture and race/ethnicity, the genetic effects on sodium 
and potassium intake and/or gene-by-sodium intake interactions could also differ across 
populations. This dissertation includes populations with both higher and lower mean sodium and 
potassium intake, which allowed us to generalize these results across a variety of populations. In 
addition, the variability of sodium and potassium intake within and across populations likely 
increased our power to detect effects.  
In Aim 1, we used multiple dietary phenotypes as outcomes (sodium intake, potassium 
intake, and sodium-to-potassium ratio) that are mostly associated with blood pressure regulation 
to contribute to the comprehensive understanding of genetic architecture of three phenotypes. In 
addition, each of the participating cohorts in this dissertation has high-quality measurements of 
sodium and potassium intake from urinary samples, enabling us to initiate an international 
collaboration of multiethnic genome-wide meta-analysis in Aim 1 and 3. Throughout the 
dissertation, we assumed that 24-hour urinary sodium and potassium excretion levels were 
measures of recent intake because they are regarded as the gold standard for sodium and 
potassium intake assessment. For the genotyping data in Aim 1 and 3, we used 1000 Genomes 
Project imputed genotypes that passed a strict QC assessment in each cohort, and we further 
excluded SNPs based on their allele frequency, imputation quality, and their match with the 1000 
Genomes reference panel data through the study-level and meta-level QC steps. 
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In Aim 2, we used rare genetic variants in addition to common variants in the analysis, 
which allowed us to investigate the effect of both common and rare variants on sodium and 
potassium intake. 
Regarding the methods of statistical analysis, the dissertation covers both traditional and 
state-of-the-art approaches in genetic epidemiology, which allow a comprehensive understanding 
of the results. In Aim 1, we employed a traditional genetic analysis method (GWAS meta-
analysis) to investigate the genetic determinants of sodium and potassium intake. Secondly, an 
advanced gene-based approach was utilized to confirm the associations from Aim 1 and evaluate 
effect modification by demographic factors. Lastly, genome-wide gene-by-sodium intake 
interactions were evaluated across the genome using a powerful statistical approach, joint meta-
analysis of SNP and SNP by environment (SNP × E) regression coefficients (2DF joint test) 
[124]. 
 
5.4 Limitations  
Although the analyses in this dissertation were conducted in the largest collection of 
multiethnic cohorts for each Aim, the total sample size was still insufficient to have the power to 
detect many significant results from the genome-wide SNP and gene-by-environment interaction 
analyses. In addition, since collecting 24-hour or half-day urine samples is time consuming and 
costly, not many cohorts have both 24-hour/half-day urine samples and genotyping data. In 
addition, as there was only one cohort of African and Asian ancestry in Aim 1, we could not 
conduct the meta-analysis in those race/ethnicity populations.  In Aim 2, the gene-based 
association analysis and gene-by-environment interaction analysis were conducted in only two 
small European ancestry cohorts, and based on the sample size in each cohort we could not 
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evaluate the association and interactions if the number of genetic markers in a region was higher 
than the recommended value by SKAT. In Aim 3, since we only one Asian ancestry cohort, we 
could not conduct the meta-analysis in that ancestry group. 
Generally, 24-hour urinary sodium and potassium excretion is regarded as the gold 
standard for assessment of sodium and potassium intake and is more accurate than those from 
self-reported dietary questionnaires [20-22]. Since collecting 24-hour urinary samples is very 
challenging, sodium and potassium excretions from half-day and spot urine samples are often 
measured instead. In Aims 1 and 3, sodium and potassium intake were measured from half-day 
and spot urine samples in some of the participating cohorts, which might decrease the accuracy 
of the measurement. However, the estimated 24-hour sodium and potassium excretion measured 
from half-day and spot-urine samples using a special formula (simple volume-time linear 
extrapolation and Kawasaki formula) have reasonably high correlation coefficients with those 
from 24-hour urine samples (0.837 and 0.53-0.82, respectively) [11, 25]. In a future study, we 
plan to conduct sensitivity analyses to assess the effect of suboptimal urine quality measurements 
by excluding samples in which sodium and potassium intake was measured from spot urine and 
compare the results to the larger meta-analysis [142]. 
The low rate of replication of significant or suggestive genetic loci from European 
discovery set in the African and Asian cohorts in Aim 1 may be due to different genetic linkage 
disequilibrium structures in each ancestry. In addition, the genetic effects may only manifest in 
certain environmental contexts (gene-by-environment interaction) [143]. As a result, a SNP 
found in a specific race/ethnicity group may not replicat in another group. Thus, we need other 
European ancestry cohorts as replication sets or to employ gene-based approaches to replicate 
our findings in populations of different race/ancestry groups. 
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In Aim 2, we evaluated the association between sodium and potassium intake and genes 
near significant or suggestive genetic loci that were identified in Aim 1. However, the regions 
evaluated in Aim 2 only included the gene regions near identified genetic loci, and excluded the 
regions near genetic loci in non-gene regions from Aim 1. To expand the regions that were tested 
in Aim 2, we plan to include non-gene regions in the analysis of association and interactions by 
defining regions as the location of the index SNP ± 20kb. 
 
5.5 Future work 
In Aims 1 and 3, we identified genome-wide significant or suggestive genetic loci 
associated with sodium and potassium intake as well as gene-by-sodium intake interactions. 
However, we need large and independent multiethnic cohorts to confirm the associations from 
Aim 1. In Aim 1, potential replication cohorts include 1) Genetic epidemiology network of salt 
sensitivity (GenSalt) study (N=1,823) [144], 2) UK Biobank (N=500,000) [136], 3) Jackson 
Heart Study (JHS, N=633), and 4) Nurses' Health Study and Health Professionals Follow-up 
Study (NHS & HPFS, N=1,650) [145-147]. To expand on the results in Aim 3, we are currently 
suggesting collaborations with additional cohorts to confirm suggestive or significant loci found 
from the discovery stage. Potential cohorts include 1) 24-hour urine sample: Prevention of REnal 
and Vascular ENd-stage Disease (PREVEND) (N=3,649) [61]; 2) Spot urine sample: Heredity 
and Phenotype Intervention (HAPI) Heart Study (N=844) [70], Multiethnic Study of 
Atherosclerosis (MESA) cohort (N=2,462) [135] and UK Biobank (N=500,000) [136]; and 3) 
FFQ: Health and Retirement Study (N=8,035) [137]. In addition, we plan to explore the gene-by-
potassium intake interactions, which would expand our understanding of dietary effects on 
genetics of blood pressure. 
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The strength of the gene-based approach is that we can evaluate associations or 
interactions across race/ethnicity groups because the gene is a functional unit that does not vary 
by race/ethnicity group. Since we only used two European ancestry cohorts in Aim 2, we plan to 
include larger cohorts across multiple race/ethnicities to conduct a meta-analysis of the results as 
well as replicate the results in larger cohorts. In addition, gene-based approaches using only 
functional genetic variants could be employed in Aim 2. Functional polymorphisms include the 
genetic variants that have been proven or predicted to influence gene expression or protein 
functions. It is important to know if a polymorphism is functional to better understand the 
mechanistic basis by which a polymorphism is associated with a specific health outcome [148]. 
Using weighting based on bioinformatic evaluation of each variant’s potential to have a 
functional effect would be an important next step in gene-based analysis [149]. 
Blood pressure traits, as well as its risk factors -- intakes of sodium and potassium -- are complex 
phenotypes. To have better insight into the genetics of complex traits and their mechanisms in 
disease risk, integrating the information from the genome, and epigenome, environmental 
exposures, as well as their interactions are needed. We plan to expand our initial findings using 
gene expression data, epigenetic data, and other related environmental factors to evaluate the 
underlying evidence for personalized and precision approaches to reduce the burden of disease in 
populations.
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APPENDICES 
 
Appendix 1 Descriptions of participating cohorts  
 
Genetic Epidemiology Network of Arteriopathy (GENOA), USA: GENOA is one of four 
networks in the NHLBI Family-Blood Pressure Program (FBPP). [The FBPP Investigators. 
Multi-center genetic study of hypertension: The Family Blood Pressure Program (FBPP). 
Hypertension 2002;39:3-9.; Daniels PR, Kardia SL, Hanis CL, Brown CA, Hutchinson R, 
Boerwinkle E, Turner ST; Genetic Epidemiology Network of Arteriopathy study. Familial 
aggregation of hypertension treatment and control in the Genetic Epidemiology Network of 
Arteriopathy (GENOA) study. Am J Med. 2004 May 15;116(10):676-81. PubMed PMID: 
15121494.] GENOA's long-term objective is to elucidate the genetics of target organ 
complications of hypertension, including both atherosclerotic and arteriolosclerotic 
complications involving the heart, brain, kidneys, and peripheral arteries. The longitudinal 
GENOA Study recruited European-American and African-American sibships with at least 2 
individuals with clinically diagnosed essential hypertension before age 60 years. All other 
members of the sibship were invited to participate regardless of their hypertension status. 
Participants were diagnosed with hypertension if they had either 1) a previous clinical diagnosis 
of hypertension by a physician with current anti-hypertensive treatment, or 2) an average systolic 
blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg based on the second and 
third readings at the time of their clinic visit. Exclusion criteria were secondary hypertension, 
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alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. 
During the first exam (1995-2000), 1,583 European Americans from Rochester, MN and 1,854 
African Americans from Jackson, MS were examined. Between 2000 and 2005, 1,241 of the 
European Americans and 1,482 of the African Americans returned for a second examination. 
Because African-American probands for GENOA were recruited through the Atherosclerosis 
Risk in Communities (ARIC) Jackson field center participants, we excluded ARIC participants 
from analyses. 
 
FBPP Investigators. Multi-center genetic study of hypertension: The Family Blood Pressure 
Program (FBPP). Hypertension. 2002 Jan; 39(1):3-9. 
Daniels PR, Kardia SL, Hanis CL, Brown CA, Hutchinson R, Boerwinkle E, Turner ST, Genetic 
Epidemiology Network of Arteriopathy study.  
Familial aggregation of hypertension treatment and control in the Genetic Epidemiology 
Network of Arteriopathy (GENOA) study. Am J Med. 2004 May 15; 116(10):676-81. 
 
Prevention of REnal and Vascular ENd-stage Disease (PREVEND), Netherland: 
PREVEND is an ongoing prospective study investigating the natural course of increased levels 
of urinary albumin excretion and its relation to renal and cardiovascular disease. Details of the 
protocol have been described elsewhere (www.prevend.org). PREVEND genetics is supported 
by the Dutch Kidney Foundation (Grant E033), the EU project grant GENECURE (FP-6 LSHM 
CT 2006 037697), the National Institutes of Health (grant 2R01LM010098), The Netherlands 
organisation for health research and development (NWO-Groot grant 175.010.2007.006, NWO 
VENI grant 916.761.70, ZonMw grant 90.700.441), and the Dutch Inter University Cardiology 
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Institute Netherlands (ICIN). N. Verweij is supported by Marie Sklodowska-Curie GF (call: 
H2020-MSCA-IF-2014, Project ID: 661395) and an NWO VENI grant (016.186.125). We would 
like to thank the Center for Information Technology of the University of Groningen for their 
support and for providing access to the Peregrine high-performance computing cluster. 
 
Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, 
Janssen WM, Grobbee DE, de Jong PE. Urinary albumin excretion predicts cardiovascular and 
noncardiovascular mortality in general population. Circulation. 2002 Oct 1;106(14):1777-82. 
 
Framingham Heart Study (FHS), USA: FHS began in 1948 with the recruitment of an original 
cohort of 5,209 men and women (mean age 44 years; 55 percent women). In 1971 a second 
generation of study participants was enrolled; this cohort (mean age 37 years; 52% women) 
consisted of 5,124 children and spouses of children of the original cohort. A third-generation 
cohort of 4,095 children of offspring cohort participants (mean age 40 years; 53 percent women) 
was enrolled in 2002-2005 and are seen every 4 to 8 years. Details of study designs for the three 
cohorts are summarized elsewhere. At each clinic visit, a medical history was obtained with a 
focus on cardiovascular content, and participants underwent a physical examination including 
measurement of height and weight from which BMI was calculated. Systolic and diastolic blood 
pressures were measured twice by a physician on the left arm of the resting and seated 
participant using a mercury column sphygmomanometer. Blood pressures were recorded to the 
nearest even number. The means of two separate systolic and diastolic blood pressure readings at 
each clinic examination were used for statistical analyses. 
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Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the 
Framingham Study. Ann N Y Acad Sci. 1963;107:539-556.  PMID 14025561 
Feinleib m, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring 
Study. Design and preliminary data. Prev Med. 1975;4:518-525. PMID 1208363 
Splansky GL, Corey D, Yang Q et al. The Third Generation Cohort of the National Heart, Lung, 
and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am 
J Epidemiol. 2007;165:1328-1335. PMID 17372189 
 
Heredity and Phenotype Intervention (HAPI) Heart, USA: The Heredity and Phenotype 
Intervention (HAPI) Heart Study was initiated in 2002 to measure the cardiovascular response to 
4 short-term interventions affecting cardiovascular risk factors and to identify the genetic and 
environmental determinants of these responses.  The interventions were carried out in 868 
relatively healthy Amish adults aged 20 years and older who were recruited between 2003 and 
2006.  Fasting blood samples were collected for measurement of blood chemistries and isolation 
of DNA for genetic analysis.   
The Heredity and Phenotype Intervention (HAPI) Heart Study was supported by NIH grant U01 
HL72515, and by grants from the University of Maryland General Clinical Research Center 
(GCRC, M01 RR 16500), the Johns Hopkins University GCRC (M01 RR 000052), National 
Center for Research Resources, the Mid-Atlantic Nutrition and Obesity Research Center (P30 
DK072488), and the Paul Beeson Physician Faculty Scholars in Aging Program of the American 
Federation of Aging Research.  The HAPI Heart researchers acknowledge the Amish liaisons, 
field workers, and the cooperation and support of the Amish community. 
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Mitchell BD, McArdle PF, Shen H, Rampersaud E, Pollin TI, Bielak LF, Jaquish C, Douglas JA, 
Roy-Gagnon MH, Sack P, Naglieri R. The genetic response to short-term interventions affecting 
cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) 
Heart Study. American heart journal. 2008 May 1;155(5):823-8. 
 
Hypertension Genetic Epidemiology Network (HyperGEN), USA: HyperGEN is 1 of 4 
NHLBI “Networks,” coordinated under the family blood pressure program aimed to characterize 
genes promoting hypertension and related conditions. Participants were recruited from 
hypertensive sibships ascertained through population-based cohorts or from the community-at-
large and were later extended to include other siblings and offspring of the original sibpair. 
Information on race, demographics, height, weight, current medications (via self-report) and co-
morbid conditions as well as clinical measures (fasting serum chemistries, fasting lipids, and 
urine chemistries) was collected. Participants with type 1 diabetes or advanced renal disease 
(defined as serum creatinine level > 2 mg/dL) were excluded from the original study since these 
two conditions can cause secondary hypertension and the goal of HyperGEN was to identify 
novel essential hypertension loci. 
 
Williams RR, Rao DC, Ellison RC, Arnett DK, Heiss G, Oberman A, Eckfeldt JH, Leppert MF, 
Province MA, Mockrin SC and Hunt SC. NHLBI family blood pressure program: methodology 
and recruitment in the HyperGEN network. Hypertension genetic epidemiology network. Ann 
Epidemiol 2000;10:389-400. 
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Jackson Heart Study (JHS), USA: The Jackson Heart Study is a longitudinal, community-
based observational cohort study investigating the role of environmental and genetic factors in 
the development of cardiovascular disease in African Americans.  Between 2000 and 2004, a 
total of 5301 participants were recruited from a tri-county area (Hinds, Madison, and Rankin 
Counties) that encompasses Jackson, MS. Details of the design and recruitment for the Jackson 
Heart Study cohort has been previously published.1-3   Briefly, approximately 30% of 
participants were former members of the Atherosclerosis Risk in Communities (ARIC) 
study.  The remainder were recruited by either 1) random selection from the Accudata list, 2) 
commercial listing, 3) a constrained volunteer sample, in which recruitment was distributed 
among defined demographic cells in proportions designed to mirror those in the overall 
population, or through the Jackson Heart Study Family Study. 
 
Wyatt SB, Diekelmann N, Henderson F, Andrew ME, Billingsley G, Felder SH et al. A 
community-driven model of research participation: the Jackson Heart Study Participant 
Recruitment and Retention Study. Ethn Dis 2003; 13(4):438-455. 
Taylor HA, Jr., Wilson JG, Jones DW, et al. Toward resolution of cardiovascular health 
disparities in African Americans: design and methods of the Jackson Heart Study. Ethn Dis 
2005; 15:S6-17. 
Fuqua SR, Wyatt SB, Andrew ME, et al. Recruiting African-American research participation in 
the Jackson Heart Study: methods, response rates, and sample description. Ethn Dis 2005; 15:S6-
29. 
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Genetic Epidemiology Network of Salt Sensitivity (GenSalt): GenSalt is a multi-center, 
family based study designed to identify, through dietary sodium and potassium intervention, salt-
sensitivitivity susceptibility genes which may underlie essential hypertension in rural Han 
Chinese families. Approximately 629 families with at least one ‘proband’ with high blood 
pressure were recruited and tested for a wide variety of physiological, metabolic and biochemical 
measures at baseline and at multiple times during the 3-week intervention. The intervention 
consisted of one week on a low sodium diet, followed by one week on a high sodium diet, and 
finally one week on a high sodium diet with a potassium supplement. 
 
GenSalt Collaborative Research Group. GenSalt: rationale, design, methods and baseline 
characteristics of study participants. J Hum Hypertens. 2007 Aug; 21(8):639-46. 
 
Healthy Twin Study, Korea (HTS), South Korea: The Healthy Twin Study is a cohort of adult 
like-sex twin pairs aged 30 years or over and their first-degree family members who have been 
recruited since 2005. The participants underwent comprehensive health examinations and 
completed an extensive questionnaire survey. The initial recruitment process was done through 
mail, based on the National Twin and Family Registry, independent of their health status. The 
zygosity of twins was screened by a zygosity questionnaire that had a predictive power of 97.5% 
and was further validated by 16 short tandem repeat markers (for more than two thirds of the 
subjects). One of the inclusion criteria of the Healthy Twin Study was like-sex twins; thus, the 
number of dizygotic twins was relatively small in this study. Siblings, adjusted for age and sex, 
were combined with dizygotic twins as necessary. Self-reported family relationships were further 
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examined by genome-wide single nucleotide polymorphism data by using Affymetrix GeneChip 
version 6.0. Any dubious family relation conflicting with the genetic information was deleted. 
 
Sung J, Cho SI, Lee K, Ha M, Choi EY, Choi JS, Kim H, Kim J, Hong KS, Kim Y, et al. Healthy 
Twin: a twin-family study of Korea—protocols and current status. Twin Res Hum Genet 
2006;9:844–8. The Healthy Twin Study Website. Available from: http://www.twinkorea. org/ 
(cited 1 June 2013).
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